<?xml version="1.0"?>
<!--The content contained herein (“Content") is a publication of N-of-One. N-of-One does not provide medical services, nor is any N-of-One employee engaged in the practice of medicine for or on behalf of N-of-One. Some tests, drugs and biomarkers identified in this report may not be approved by the FDA for a particular use or validated for that use. The Content is compiled from sources believed to be reliable. Extensive efforts have been made to make the Content as accurate and as up-to-date as possible. The Content may contain typographical errors and omissions. The Content is for research, professional medical and scientific use only. Copyright N-of-One, Inc. 2011-2017: Not for Distribution, Publication or Re-publication.
Copyright N-of-One, Inc. 2011-2017: Not for Distribution, Publication or Re-publication.--><!--This file is intended for technical syntax validation only. 
Any scientific or clinical information included in these files is provided solely as placeholder content for technical validation, and may not be used for scientific research or clinical application.--><report disease="Acute myelocytic leukemia (AML)" report-id="AMP demo-AML" snomed-disease-concept-id="91861009" snomed-disease-name="Acute myeloid leukemia, disease (disorder)"><summary><positives><positive-result Ab5b7eacd-8c31-40c6-b154-fa26ee3cee2b="Ab1df9a1a-4bc6-4e6e-bdb2-d39f8c9de989" available-trials="Yes" biomarker="FLT3" diagnostic-level-of-evidence="None found" pathway="Tyrosine kinase" prognostic-level-of-evidence="A" result-type="MUTN (seq)" result-value="D593_L610dup" tier="1" user-alteration-name="D593_L610dup" variant-curated="Yes"><A995f416a-c908-447b-800d-5c4883e35954>Ad3ecf38e-50e0-4c93-a9ad-1ba90f3b0858</A995f416a-c908-447b-800d-5c4883e35954><summary-therapies><summary-therapy approval="This indication approved" drug-name="Midostaurin" effect="Sensitive" therapeutic-level-of-evidence="A"/><summary-therapy approval="Other indication approved" drug-name="Sorafenib" effect="Sensitive" therapeutic-level-of-evidence="B/C"/><summary-therapy approval="Other indication approved" drug-name="Ponatinib" effect="Sensitive" therapeutic-level-of-evidence="C"/><summary-therapy approval="Other indication approved" drug-name="Sunitinib" effect="Sensitive" therapeutic-level-of-evidence="C/D"/><summary-therapy approval="Other indication approved" drug-name="Cabozantinib" effect="Sensitive" therapeutic-level-of-evidence="D"/><summary-therapy approval="Other indication approved" drug-name="Nintedanib" effect="Sensitive" therapeutic-level-of-evidence="D"/><summary-therapy approval="Experimental" drug-name="Crenolanib" effect="Sensitive" therapeutic-level-of-evidence="C"/><summary-therapy approval="Experimental" drug-name="Quizartinib" effect="Sensitive" therapeutic-level-of-evidence="C"/><summary-therapy approval="Experimental" drug-name="PLX3397" effect="Sensitive" therapeutic-level-of-evidence="D"/></summary-therapies></positive-result><positive-result A645a3df6-7d1a-46a6-93d5-e3233a231c06="A2c15e94a-37d3-4090-806a-2209db7ca8d9" available-trials="No" biomarker="NPM1" diagnostic-level-of-evidence="A" pathway="Ribosome biogenesis" prognostic-level-of-evidence="A" result-type="MUTN (seq)" result-value="W288fs" tier="1" user-alteration-name="W288fs" variant-curated="Yes"><A950968e3-63e9-4617-a78c-ce1ac1f27699>A6e460440-ad9a-4020-b513-71c5bd18966c</A950968e3-63e9-4617-a78c-ce1ac1f27699><summary-therapies/></positive-result><positive-result Aab0eb1c4-5923-4e9f-9ffa-91457b70cc57="A8cbbd587-3927-4026-a98e-7cde3fe363da" available-trials="Yes" biomarker="TET2" diagnostic-level-of-evidence="None found" pathway="Tumor suppressor" prognostic-level-of-evidence="C" result-type="MUTN (seq)" result-value="R1214W" tier="2" user-alteration-name="R1214W" variant-curated="Yes"><A54930db7-824e-4900-ad5e-b876ae734de7>A9ae65ac8-b617-4339-a0fc-5b745c81a312</A54930db7-824e-4900-ad5e-b876ae734de7><summary-therapies><summary-therapy approval="Other indication approved" drug-name="Azacitidine" effect="Sensitive" therapeutic-level-of-evidence="C/D"/><summary-therapy approval="Other indication approved" drug-name="Decitabine" effect="Sensitive" therapeutic-level-of-evidence="C/D"/><summary-therapy approval="Experimental" drug-name="FdCyd+THU" effect="Sensitive" therapeutic-level-of-evidence="E"/><summary-therapy approval="Experimental" drug-name="Guadecitabine" effect="Sensitive" therapeutic-level-of-evidence="E"/></summary-therapies></positive-result><positive-result Abda271b2-1ea4-4358-853a-06258f03a9da="A0b51bcec-28df-4015-b952-c9f1225c1b30" biomarker="ASXL1" pathway="Epigenetic regulation" result-type="MUTN (seq)" result-value="K564E" user-alteration-name="K564E" variant-curated="No"><A5f40e747-4751-4c44-a08b-7ad53d0a1329>A69817300-2ef6-4357-be5a-7cc8c9ca1504</A5f40e747-4751-4c44-a08b-7ad53d0a1329></positive-result><positive-result A7e3ade21-ccde-4d6f-a42f-3cd8a6f4608c="A0aefe8a0-3d6c-4511-aa74-8e7c9e2f4def" available-trials="No" biomarker="NPM1" diagnostic-level-of-evidence="None found" pathway="Ribosome biogenesis" prognostic-level-of-evidence="None found" result-type="MUTN (seq)" result-value="K292_S293insI" tier="3" user-alteration-name="K292_S293insI" variant-curated="Yes"><Ac43e508b-2df0-4cbd-a732-262dd19360d5>Ab69ad311-f5f4-4ee0-8e19-02bba2be894c</Ac43e508b-2df0-4cbd-a732-262dd19360d5><summary-therapies/><notes>The functional consequences of NPM1-K292_S293insI are unknown. Therefore, the relevance of any available therapies and clinical trials targeting this alteration is uncertain.</notes></positive-result><positive-result A7542c0b2-2a6e-400b-91f8-6794c355ebdd="Aeb4c6678-7ba0-4bcb-a4c3-270b81aee30d" available-trials="No" biomarker="CEBPA" diagnostic-level-of-evidence="None found" pathway="Transcription factor" prognostic-level-of-evidence="None found" result-type="MUTN (seq)" result-value="H195_P196dup" tier="4" user-alteration-name="H195_P196dup" variant-curated="Yes"><A9814cda8-fa17-4b67-b73e-18bfb6c10818>A6b4697c2-7230-406e-bcfb-7aadc66cf219</A9814cda8-fa17-4b67-b73e-18bfb6c10818><summary-therapies/><notes>CEBPA-H195_P196dup is likely a germline polymorphism. Therefore, the relevance of any available therapies and clinical trials targeting this alteration is uncertain.</notes></positive-result></positives><pertinent-negatives><pertinent-negative biomarker="IGH-IGH-CCND1 fusion" result-type="FISH" result-value="No reportable mutation detected" user-alteration-name="IGH-CCND1 fusion"><notes/></pertinent-negative></pertinent-negatives><indeterminates><indeterminate biomarker="KRAS"><notes>The sequencing test was unable to determine the status of the KRAS gene in this tumor. Although no mutations were detected, it is possible that mutations are present.</notes></indeterminate></indeterminates></summary><guidelines><guideline><content><item><text>The NCCN Guidelines (v.3.2017) state that molecular analyses to detect KIT, FLT3-internal tandem duplication (ITD), NPM1, and CEBPA alterations may be useful for risk assessment, prognostication, and treatment when evaluating patients for acute myelocytic leukemia (AML).</text><references/></item><item><text>The NCCN Guidelines (v.3.2017) place AML patients harboring ITD alterations in FLT3, but with an otherwise normal karyotype, in the category of poor risk and state that these patients should be considered for appropriate clinical trials or early allogeneic hematopoietic cell transplantation (HCT).</text><references/></item><item><text>The NCCN Guidelines (v.3.2017) additionally state that midostaurin plus standard chemotherapy may be considered for both induction and maintenance therapy in FLT3-mutant AML patients, while sorafenib plus hypomethylating agents may be considered as a therapeutic option in the relapse setting for poor risk AML patients, depending on the physician's evaluation of the individual patient.</text><references/></item></content><references/><biomarkers><biomarker alteration="D593_L610dup" marker="FLT3"/></biomarkers></guideline><guideline><content><item><text>The NCCN Guidelines (v.1.2017) state that molecular analyses to detect KIT, FLT3-internal tandem duplication (ITD), NPM1, and CEBPA alteration may be useful for risk assessment, prognostication, and treatment when evaluating patients for acute myelocytic leukemia (AML).</text><references/></item><item><text>The NCCN Guidelines (v.1.2017) place normal-karyotype AML patients harboring NPM1 mutation in the absence of FLT-ITD in the category of favorable risk; multiple cycles of high dose araC (HiDAC) consolidation is listed as a category 1 therapeutic option for these patients, depending on the physician's evaluation of the individual patient.</text><references/></item></content><references/><biomarkers><biomarker alteration="W288fs" marker="NPM1"/></biomarkers></guideline><guideline><content><item empty-type="Unknown"><text>Although NCCN guidelines are defined for CEBPA in Acute myelocytic leukemia (AML), the CEBPA variant in this case is a Variant of Uncertain Clinical Significance, and the relevance of the NCCN guidelines is therefore unknown</text><references/></item></content><references/><biomarkers><biomarker alteration="H195_P196dup" marker="CEBPA"/></biomarkers></guideline></guidelines><interactions><interaction diagnostic-level-of-evidence="None found" prognostic-level-of-evidence="A"><interaction-biomarkers><biomarker alteration="D593_L610dup" marker="FLT3"/><biomarker alteration="W288fs" marker="NPM1"/></interaction-biomarkers><interaction-summary>NPM1 mutations in the absence of FLT3-ITD have been associated with favorable outcomes in AML, especially in cytogenetically normal AML (CN-AML), while NPM1 mutations in the presence of FLT3-ITD have been associated with an intermediate prognosis (Schnittger et al., 2005; 16076867, Schlenk et al., 2008; 18450602, Thiede et al., 2006; 16455956, Metzeler et al., 2016; 27288520, Tsai et al., 2016; 27055875).</interaction-summary><references><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references><resistant-therapies/><synergistic-therapies/></interaction></interactions><detailed-biomarker-information><biomarker-content A67cf7f19-ed88-4562-b257-ff764d58194e="A19ed90d8-b16e-4703-9486-af309304cef0" alteration-name="D593_L610dup" marker="FLT3" test-type="MUTN (seq)" user-alteration-name="D593_L610dup"><Af244d19d-70e3-4dab-a10f-eb17ddfa5458>A2bc62dd3-5fbe-4240-9877-672e5a01a13e</Af244d19d-70e3-4dab-a10f-eb17ddfa5458><biomarker-summary><content><item><text>FLT3-D593_L610dup is predicted to be an activating mutation.</text><references/></item></content><references/></biomarker-summary><biomarker-summary content-type="clinical-relevance"><content><item><text>Activating FLT3 alterations have been reported to promote proliferation, inhibit apoptosis, and result in oncogenic transformation.</text><references><reference><reference-id>10698507</reference-id><title>Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.</title><authors>Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T</authors><journal>Oncogene</journal><issue>5</issue><year>2000</year><page>624-31</page></reference><reference><reference-id>16116483</reference-id><title>FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.</title><authors>Lee B, Williams I, Anastasiadou E, Boulton C, Joseph S, Amaral S, Curley D, Duclos N, Huntly B, Fabbro D, Griffin J, Gilliland D</authors><journal>Oncogene</journal><issue>53</issue><year>2005</year><page>7882-92</page></reference><reference><reference-id>11290608</reference-id><title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.</title><authors>Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2001</year><page>2434-9</page></reference><reference><reference-id>17936561</reference-id><title>FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.</title><authors>Lee B, Tothova Z, Levine R, Anderson K, Buza-Vidas N, Cullen D, McDowell E, Adelsperger J, Fröhling S, Huntly B, Beran M, Jacobsen S, Gilliland D</authors><journal>Cancer cell</journal><issue>4</issue><year>2007</year><page>367-80</page></reference><reference><reference-id>11090077</reference-id><title>Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.</title><authors>Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel W, Serve H</authors><journal>Blood</journal><issue>12</issue><year>2000</year><page>3907-14</page></reference></references></item><item><text>Activating alterations in FLT3 may predict sensitivity to small molecule multi-tyrosine kinase inhibitors, several of which have been approved by the FDA in certain indications.</text><references><reference><reference-id>16990784</reference-id><title>FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).</title><authors>Schittenhelm M, Yee K, Tyner J, McGreevey L, Haley A, Town A, Griffith D, Bainbridge T, Braziel R, O'Farrell A, Cherrington J, Heinrich M</authors><journal>Leukemia</journal><issue>11</issue><year>2006</year><page>2008-14</page></reference><reference><reference-id>20212254</reference-id><title>Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.</title><authors>Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Byrd A, Bekele B, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian H</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>11</issue><year>2010</year><page>1856-62</page></reference><reference><reference-id>19318574</reference-id><title>FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.</title><authors>von Bubnoff N, Engh R, Aberg E, Sänger J, Peschel C, Duyster J</authors><journal>Cancer research</journal><issue>7</issue><year>2009</year><page>3032-41</page></reference><reference><reference-id>27060207</reference-id><title>Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).</title><authors>Lu J, Wang A, Liao H, Chen C, Hou H, Hu C, Tien H, Ou D, Lin L</authors><journal>Cancer letters</journal><issue>2</issue><year>2016</year><page>218-25</page></reference><reference><reference-id>ASCO 2011, Abstract 6518</reference-id><title>Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.</title><authors>Talpaz M, Shah NP, Deininger MW et al.</authors><journal>J Clin Oncol</journal><year>2011</year><page>Abstract 6518</page></reference></references></item><item><text>Second generation Flt3 inhibitors with greater specificity for Flt3, such as quizartinib (AC-220), crenolanib (CP-868596), and PLX3397, are also in clinical development.</text><references><reference><reference-id>24883179</reference-id><title>The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.</title><authors>Wander S, Levis M, Fathi A</authors><journal>Therapeutic advances in hematology</journal><issue>3</issue><year>2014</year><page>65-77</page></reference><reference><reference-id>24002496</reference-id><title>Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.</title><authors>Cortes J, Kantarjian H, Foran J, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong R, James J, Levis M</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>29</issue><year>2013</year><page>3681-7</page></reference><reference><reference-id>24227820</reference-id><title>Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.</title><authors>Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M</authors><journal>Blood</journal><issue>1</issue><year>2014</year><page>94-100</page></reference><reference><reference-id>ASH 2011, Abstract 764</reference-id><title>764 PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro</title><authors>Smith CC, Perl AE, Lasater E et al.</authors><journal>Blood</journal><year>2011</year><page>Abstract 764</page></reference></references></item></content><references><reference><reference-id>10698507</reference-id><title>Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.</title><authors>Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T</authors><journal>Oncogene</journal><issue>5</issue><year>2000</year><page>624-31</page></reference><reference><reference-id>16116483</reference-id><title>FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.</title><authors>Lee B, Williams I, Anastasiadou E, Boulton C, Joseph S, Amaral S, Curley D, Duclos N, Huntly B, Fabbro D, Griffin J, Gilliland D</authors><journal>Oncogene</journal><issue>53</issue><year>2005</year><page>7882-92</page></reference><reference><reference-id>11290608</reference-id><title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.</title><authors>Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2001</year><page>2434-9</page></reference><reference><reference-id>17936561</reference-id><title>FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.</title><authors>Lee B, Tothova Z, Levine R, Anderson K, Buza-Vidas N, Cullen D, McDowell E, Adelsperger J, Fröhling S, Huntly B, Beran M, Jacobsen S, Gilliland D</authors><journal>Cancer cell</journal><issue>4</issue><year>2007</year><page>367-80</page></reference><reference><reference-id>11090077</reference-id><title>Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.</title><authors>Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel W, Serve H</authors><journal>Blood</journal><issue>12</issue><year>2000</year><page>3907-14</page></reference><reference><reference-id>16990784</reference-id><title>FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).</title><authors>Schittenhelm M, Yee K, Tyner J, McGreevey L, Haley A, Town A, Griffith D, Bainbridge T, Braziel R, O'Farrell A, Cherrington J, Heinrich M</authors><journal>Leukemia</journal><issue>11</issue><year>2006</year><page>2008-14</page></reference><reference><reference-id>20212254</reference-id><title>Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.</title><authors>Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Byrd A, Bekele B, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian H</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>11</issue><year>2010</year><page>1856-62</page></reference><reference><reference-id>19318574</reference-id><title>FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.</title><authors>von Bubnoff N, Engh R, Aberg E, Sänger J, Peschel C, Duyster J</authors><journal>Cancer research</journal><issue>7</issue><year>2009</year><page>3032-41</page></reference><reference><reference-id>27060207</reference-id><title>Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).</title><authors>Lu J, Wang A, Liao H, Chen C, Hou H, Hu C, Tien H, Ou D, Lin L</authors><journal>Cancer letters</journal><issue>2</issue><year>2016</year><page>218-25</page></reference><reference><reference-id>ASCO 2011, Abstract 6518</reference-id><title>Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.</title><authors>Talpaz M, Shah NP, Deininger MW et al.</authors><journal>J Clin Oncol</journal><year>2011</year><page>Abstract 6518</page></reference><reference><reference-id>24883179</reference-id><title>The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.</title><authors>Wander S, Levis M, Fathi A</authors><journal>Therapeutic advances in hematology</journal><issue>3</issue><year>2014</year><page>65-77</page></reference><reference><reference-id>24002496</reference-id><title>Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.</title><authors>Cortes J, Kantarjian H, Foran J, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong R, James J, Levis M</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>29</issue><year>2013</year><page>3681-7</page></reference><reference><reference-id>24227820</reference-id><title>Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.</title><authors>Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M</authors><journal>Blood</journal><issue>1</issue><year>2014</year><page>94-100</page></reference><reference><reference-id>ASH 2011, Abstract 764</reference-id><title>764 PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro</title><authors>Smith CC, Perl AE, Lasater E et al.</authors><journal>Blood</journal><year>2011</year><page>Abstract 764</page></reference></references></biomarker-summary><biomarker-summary content-type="disease-summary"><content><item><text>Constitutive activation of Flt3 by ITD or TKD mutations has been reported to lead to activation of several signaling pathways, including those of Akt and Stat5, and has been reported to promote proliferation, survival, and the induction of a myeloproliferative neoplasm (MPN).</text><references><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>11756186</reference-id><title>FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.</title><authors>Kelly L, Liu Q, Kutok J, Williams I, Boulton C, Gilliland D</authors><journal>Blood</journal><issue>1</issue><year>2002</year><page>310-8</page></reference><reference><reference-id>17268528</reference-id><title>Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.</title><authors>Baldwin B, Li L, Tse K, Small S, Collector M, Whartenby K, Sharkis S, Racke F, Huso D, Small D</authors><journal>Leukemia</journal><issue>4</issue><year>2007</year><page>764-71</page></reference><reference><reference-id>27636998</reference-id><title>Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.</title><authors>Poitras J, Heiser D, Li L, Nguyen B, Nagai K, Duffield A, Gamper C, Small D</authors><journal>Oncotarget</journal><issue>43</issue><year>2016</year><page>69124-69135</page></reference></references></item><item><text>In addition, several studies have reported transformation from MPN to AML when FLT3 mutations are combined with other alterations, including Hedgehog signaling, TET2 mutations, and loss of Cbl function.</text><references><reference><reference-id>26062848</reference-id><title>Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.</title><authors>Lim Y, Gondek L, Li L, Wang Q, Ma H, Ma H, Chang E, Huso D, Foerster S, Marchionni L, McGovern K, Watkins D, Peacock C, Levis M, Smith B, Merchant A, Small D, Matsui W</authors><journal>Science translational medicine</journal><issue>291</issue><year>2015</year><page>291ra96</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25534201</reference-id><title>Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.</title><authors>Taylor S, Thien C, Dagger S, Duyvestyn J, Grove C, Lee B, Gilliland D, Langdon W</authors><journal>Experimental hematology</journal><issue>3</issue><year>2015</year><page>191-206.e1</page></reference><reference><reference-id>27636998</reference-id><title>Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.</title><authors>Poitras J, Heiser D, Li L, Nguyen B, Nagai K, Duffield A, Gamper C, Small D</authors><journal>Oncotarget</journal><issue>43</issue><year>2016</year><page>69124-69135</page></reference></references></item><item><text>FLT3-ITD mutations in AML have been associated with poor prognosis in numerous scientific studies, and with an increased risk of relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT).</text><references><reference><reference-id>24801015</reference-id><title>Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.</title><authors>Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1279-86</page></reference><reference><reference-id>26234722</reference-id><title>DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Jung S, Yang D, Lee J, Kim N, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim D</authors><journal>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</journal><issue>1</issue><year>2016</year><page>61-70</page></reference><reference><reference-id>26191952</reference-id><title>FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.</title><authors>Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer D, Chughtai K, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi S</authors><journal>Bone marrow transplantation</journal><issue>4</issue><year>2016</year><page>511-520</page></reference><reference><reference-id>25912052</reference-id><title>Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.</title><authors>Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak W, Kyrcz-Krzemien S, Komarnicki M, Warzocha K</authors><journal>European journal of haematology</journal><issue>3</issue><year>2016</year><page>236-44</page></reference><reference><reference-id>21242187</reference-id><title>FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.</title><authors>Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, Schäfer I, Schlegelberger B, Heil G, Ganser A, Krauter J</authors><journal>Haematologica</journal><issue>5</issue><year>2011</year><page>681-6</page></reference></references></item></content><references><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>11756186</reference-id><title>FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.</title><authors>Kelly L, Liu Q, Kutok J, Williams I, Boulton C, Gilliland D</authors><journal>Blood</journal><issue>1</issue><year>2002</year><page>310-8</page></reference><reference><reference-id>17268528</reference-id><title>Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.</title><authors>Baldwin B, Li L, Tse K, Small S, Collector M, Whartenby K, Sharkis S, Racke F, Huso D, Small D</authors><journal>Leukemia</journal><issue>4</issue><year>2007</year><page>764-71</page></reference><reference><reference-id>27636998</reference-id><title>Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.</title><authors>Poitras J, Heiser D, Li L, Nguyen B, Nagai K, Duffield A, Gamper C, Small D</authors><journal>Oncotarget</journal><issue>43</issue><year>2016</year><page>69124-69135</page></reference><reference><reference-id>26062848</reference-id><title>Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.</title><authors>Lim Y, Gondek L, Li L, Wang Q, Ma H, Ma H, Chang E, Huso D, Foerster S, Marchionni L, McGovern K, Watkins D, Peacock C, Levis M, Smith B, Merchant A, Small D, Matsui W</authors><journal>Science translational medicine</journal><issue>291</issue><year>2015</year><page>291ra96</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25534201</reference-id><title>Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.</title><authors>Taylor S, Thien C, Dagger S, Duyvestyn J, Grove C, Lee B, Gilliland D, Langdon W</authors><journal>Experimental hematology</journal><issue>3</issue><year>2015</year><page>191-206.e1</page></reference><reference><reference-id>24801015</reference-id><title>Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.</title><authors>Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1279-86</page></reference><reference><reference-id>26234722</reference-id><title>DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Jung S, Yang D, Lee J, Kim N, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim D</authors><journal>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</journal><issue>1</issue><year>2016</year><page>61-70</page></reference><reference><reference-id>26191952</reference-id><title>FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.</title><authors>Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer D, Chughtai K, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi S</authors><journal>Bone marrow transplantation</journal><issue>4</issue><year>2016</year><page>511-520</page></reference><reference><reference-id>25912052</reference-id><title>Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.</title><authors>Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak W, Kyrcz-Krzemien S, Komarnicki M, Warzocha K</authors><journal>European journal of haematology</journal><issue>3</issue><year>2016</year><page>236-44</page></reference><reference><reference-id>21242187</reference-id><title>FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.</title><authors>Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, Schäfer I, Schlegelberger B, Heil G, Ganser A, Krauter J</authors><journal>Haematologica</journal><issue>5</issue><year>2011</year><page>681-6</page></reference></references></biomarker-summary><molecular-function><content><item><text>The alteration reported here results in a duplication within exon 14, within the juxtamembrane domain of the Flt3 protein (Integrative Genomics Viewer, v.2.3).</text><references><reference><reference-id>19549778</reference-id><title>Structural and functional alterations of FLT3 in acute myeloid leukemia.</title><authors>Meshinchi S, Appelbaum F</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>13</issue><year>2009</year><page>4263-9</page></reference></references></item><item><text>FLT3 internal tandem duplications (ITD) occurring within the juxtamembrane domain of the Flt3 protein have been reported to result in ligand-independent dimerization and constitutive activation of Flt3.</text><references><reference><reference-id>19549778</reference-id><title>Structural and functional alterations of FLT3 in acute myeloid leukemia.</title><authors>Meshinchi S, Appelbaum F</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>13</issue><year>2009</year><page>4263-9</page></reference><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference></references></item><item><text>FLT3-ITD alterations have also been shown to lead to activation of several signaling pathways, including those of Akt and Stat5, and have oncogenic effects.</text><references><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>11756186</reference-id><title>FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.</title><authors>Kelly L, Liu Q, Kutok J, Williams I, Boulton C, Gilliland D</authors><journal>Blood</journal><issue>1</issue><year>2002</year><page>310-8</page></reference></references></item></content><references><reference><reference-id>19549778</reference-id><title>Structural and functional alterations of FLT3 in acute myeloid leukemia.</title><authors>Meshinchi S, Appelbaum F</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>13</issue><year>2009</year><page>4263-9</page></reference><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>11756186</reference-id><title>FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.</title><authors>Kelly L, Liu Q, Kutok J, Williams I, Boulton C, Gilliland D</authors><journal>Blood</journal><issue>1</issue><year>2002</year><page>310-8</page></reference></references></molecular-function><incidence><content><item><text>FLT3 mutations have been reported in 23% (15993/68514) of Acute myelocytic leukemia (AML) samples analyzed in COSMIC (Apr 2017).</text><references/></item><item><text>FLT3 mutations have been reported in 28% of Acute myelocytic leukemia (AML) samples (cBioPortal for Cancer Genomics, Apr 2017).</text><references/></item><item><text>FLT3 mutations have been reported as the most common alteration in AML, with FLT3 internal tandem duplication (FLT3-ITD) and tyrosine kinase domain (FLT3-TKD) mutations cited in 20-35% and 3.7-10% of cases, respectively, and found to occur more frequently in AML with a normal karyotype.</text><references><reference><reference-id>25912052</reference-id><title>Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.</title><authors>Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak W, Kyrcz-Krzemien S, Komarnicki M, Warzocha K</authors><journal>European journal of haematology</journal><issue>3</issue><year>2016</year><page>236-44</page></reference><reference><reference-id>12036858</reference-id><title>Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.</title><authors>Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T</authors><journal>Blood</journal><issue>12</issue><year>2002</year><page>4326-35</page></reference><reference><reference-id>17965322</reference-id><title>Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.</title><authors>Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S</authors><journal>Blood</journal><issue>5</issue><year>2008</year><page>2527-37</page></reference><reference><reference-id>16266897</reference-id><title>Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.</title><authors>Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C</authors><journal>Haematologica</journal><issue>11</issue><year>2005</year><page>1502-10</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>27315441</reference-id><title>Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.</title><authors>Deol A, Sengsayadeth S, Ahn K, Wang H, Aljurf M, Antin J, Battiwalla M, Bornhauser M, Cahn J, Camitta B, Chen Y, Cutler C, Gale R, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus H, Liesveld J, Litzow M, Marks D, Nishihori T, Olsson R, Reshef R, Rowe J, Saad A, Sabloff M, Schouten H, Shea T, Soiffer R, Uy G, Waller E, Wiernik P, Wirk B, Woolfrey A, Bunjes D, Devine S, de Lima M, Sandmaier B, Weisdorf D, Khoury H, Saber W</authors><journal>Cancer</journal><issue>19</issue><year>2016</year><page>3005-3014</page></reference></references></item></content><references><reference><reference-id>25912052</reference-id><title>Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.</title><authors>Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak W, Kyrcz-Krzemien S, Komarnicki M, Warzocha K</authors><journal>European journal of haematology</journal><issue>3</issue><year>2016</year><page>236-44</page></reference><reference><reference-id>12036858</reference-id><title>Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.</title><authors>Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T</authors><journal>Blood</journal><issue>12</issue><year>2002</year><page>4326-35</page></reference><reference><reference-id>17965322</reference-id><title>Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.</title><authors>Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S</authors><journal>Blood</journal><issue>5</issue><year>2008</year><page>2527-37</page></reference><reference><reference-id>16266897</reference-id><title>Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.</title><authors>Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C</authors><journal>Haematologica</journal><issue>11</issue><year>2005</year><page>1502-10</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>27315441</reference-id><title>Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.</title><authors>Deol A, Sengsayadeth S, Ahn K, Wang H, Aljurf M, Antin J, Battiwalla M, Bornhauser M, Cahn J, Camitta B, Chen Y, Cutler C, Gale R, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus H, Liesveld J, Litzow M, Marks D, Nishihori T, Olsson R, Reshef R, Rowe J, Saad A, Sabloff M, Schouten H, Shea T, Soiffer R, Uy G, Waller E, Wiernik P, Wirk B, Woolfrey A, Bunjes D, Devine S, de Lima M, Sandmaier B, Weisdorf D, Khoury H, Saber W</authors><journal>Cancer</journal><issue>19</issue><year>2016</year><page>3005-3014</page></reference></references></incidence><role-in-disease><content><item><text>FLT3 has been reported to function as an oncogene, with activating mutations resulting in increased proliferation, decreased apoptosis, and cellular transformation.</text><references><reference><reference-id>11090077</reference-id><title>Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.</title><authors>Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel W, Serve H</authors><journal>Blood</journal><issue>12</issue><year>2000</year><page>3907-14</page></reference><reference><reference-id>10698507</reference-id><title>Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.</title><authors>Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T</authors><journal>Oncogene</journal><issue>5</issue><year>2000</year><page>624-31</page></reference><reference><reference-id>16116483</reference-id><title>FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.</title><authors>Lee B, Williams I, Anastasiadou E, Boulton C, Joseph S, Amaral S, Curley D, Duclos N, Huntly B, Fabbro D, Griffin J, Gilliland D</authors><journal>Oncogene</journal><issue>53</issue><year>2005</year><page>7882-92</page></reference><reference><reference-id>11290608</reference-id><title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.</title><authors>Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2001</year><page>2434-9</page></reference><reference><reference-id>17936561</reference-id><title>FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.</title><authors>Lee B, Tothova Z, Levine R, Anderson K, Buza-Vidas N, Cullen D, McDowell E, Adelsperger J, Fröhling S, Huntly B, Beran M, Jacobsen S, Gilliland D</authors><journal>Cancer cell</journal><issue>4</issue><year>2007</year><page>367-80</page></reference></references></item><item><text>Constitutive activation of Flt3 by ITD or TKD mutations has been reported to lead to activation of several signaling pathways, including those of Akt and Stat5, and has been reported to promote proliferation, survival, and the induction of a myeloproliferative neoplasm (MPN).</text><references><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>11756186</reference-id><title>FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.</title><authors>Kelly L, Liu Q, Kutok J, Williams I, Boulton C, Gilliland D</authors><journal>Blood</journal><issue>1</issue><year>2002</year><page>310-8</page></reference><reference><reference-id>17268528</reference-id><title>Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.</title><authors>Baldwin B, Li L, Tse K, Small S, Collector M, Whartenby K, Sharkis S, Racke F, Huso D, Small D</authors><journal>Leukemia</journal><issue>4</issue><year>2007</year><page>764-71</page></reference><reference><reference-id>27636998</reference-id><title>Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.</title><authors>Poitras J, Heiser D, Li L, Nguyen B, Nagai K, Duffield A, Gamper C, Small D</authors><journal>Oncotarget</journal><issue>43</issue><year>2016</year><page>69124-69135</page></reference></references></item><item><text>In addition, several studies have reported transformation from MPN to AML when FLT3 mutations are combined with other alterations, including Hedgehog signaling, TET2 mutations, and loss of Cbl function.</text><references><reference><reference-id>26062848</reference-id><title>Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.</title><authors>Lim Y, Gondek L, Li L, Wang Q, Ma H, Ma H, Chang E, Huso D, Foerster S, Marchionni L, McGovern K, Watkins D, Peacock C, Levis M, Smith B, Merchant A, Small D, Matsui W</authors><journal>Science translational medicine</journal><issue>291</issue><year>2015</year><page>291ra96</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25534201</reference-id><title>Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.</title><authors>Taylor S, Thien C, Dagger S, Duyvestyn J, Grove C, Lee B, Gilliland D, Langdon W</authors><journal>Experimental hematology</journal><issue>3</issue><year>2015</year><page>191-206.e1</page></reference><reference><reference-id>27636998</reference-id><title>Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.</title><authors>Poitras J, Heiser D, Li L, Nguyen B, Nagai K, Duffield A, Gamper C, Small D</authors><journal>Oncotarget</journal><issue>43</issue><year>2016</year><page>69124-69135</page></reference></references></item></content><references><reference><reference-id>11090077</reference-id><title>Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.</title><authors>Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel W, Serve H</authors><journal>Blood</journal><issue>12</issue><year>2000</year><page>3907-14</page></reference><reference><reference-id>10698507</reference-id><title>Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.</title><authors>Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T</authors><journal>Oncogene</journal><issue>5</issue><year>2000</year><page>624-31</page></reference><reference><reference-id>16116483</reference-id><title>FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.</title><authors>Lee B, Williams I, Anastasiadou E, Boulton C, Joseph S, Amaral S, Curley D, Duclos N, Huntly B, Fabbro D, Griffin J, Gilliland D</authors><journal>Oncogene</journal><issue>53</issue><year>2005</year><page>7882-92</page></reference><reference><reference-id>11290608</reference-id><title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.</title><authors>Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2001</year><page>2434-9</page></reference><reference><reference-id>17936561</reference-id><title>FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.</title><authors>Lee B, Tothova Z, Levine R, Anderson K, Buza-Vidas N, Cullen D, McDowell E, Adelsperger J, Fröhling S, Huntly B, Beran M, Jacobsen S, Gilliland D</authors><journal>Cancer cell</journal><issue>4</issue><year>2007</year><page>367-80</page></reference><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>11756186</reference-id><title>FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.</title><authors>Kelly L, Liu Q, Kutok J, Williams I, Boulton C, Gilliland D</authors><journal>Blood</journal><issue>1</issue><year>2002</year><page>310-8</page></reference><reference><reference-id>17268528</reference-id><title>Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.</title><authors>Baldwin B, Li L, Tse K, Small S, Collector M, Whartenby K, Sharkis S, Racke F, Huso D, Small D</authors><journal>Leukemia</journal><issue>4</issue><year>2007</year><page>764-71</page></reference><reference><reference-id>27636998</reference-id><title>Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.</title><authors>Poitras J, Heiser D, Li L, Nguyen B, Nagai K, Duffield A, Gamper C, Small D</authors><journal>Oncotarget</journal><issue>43</issue><year>2016</year><page>69124-69135</page></reference><reference><reference-id>26062848</reference-id><title>Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.</title><authors>Lim Y, Gondek L, Li L, Wang Q, Ma H, Ma H, Chang E, Huso D, Foerster S, Marchionni L, McGovern K, Watkins D, Peacock C, Levis M, Smith B, Merchant A, Small D, Matsui W</authors><journal>Science translational medicine</journal><issue>291</issue><year>2015</year><page>291ra96</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25534201</reference-id><title>Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.</title><authors>Taylor S, Thien C, Dagger S, Duyvestyn J, Grove C, Lee B, Gilliland D, Langdon W</authors><journal>Experimental hematology</journal><issue>3</issue><year>2015</year><page>191-206.e1</page></reference></references></role-in-disease><diagnostic-significance><variant diagnostic-level-of-evidence="None found"><content><item empty-type="Unknown"><text>Unknown.</text><references/></item></content><references/></variant></diagnostic-significance><prognostic-significance><variant prognostic-level-of-evidence="A"><content><item><text>FLT3-ITD mutations in AML have been associated with poor prognosis in numerous scientific studies, and with an increased risk of relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT).</text><references><reference><reference-id>24801015</reference-id><title>Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.</title><authors>Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1279-86</page></reference><reference><reference-id>26234722</reference-id><title>DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Jung S, Yang D, Lee J, Kim N, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim D</authors><journal>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</journal><issue>1</issue><year>2016</year><page>61-70</page></reference><reference><reference-id>26191952</reference-id><title>FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.</title><authors>Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer D, Chughtai K, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi S</authors><journal>Bone marrow transplantation</journal><issue>4</issue><year>2016</year><page>511-520</page></reference><reference><reference-id>25912052</reference-id><title>Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.</title><authors>Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak W, Kyrcz-Krzemien S, Komarnicki M, Warzocha K</authors><journal>European journal of haematology</journal><issue>3</issue><year>2016</year><page>236-44</page></reference><reference><reference-id>21242187</reference-id><title>FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.</title><authors>Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, Schäfer I, Schlegelberger B, Heil G, Ganser A, Krauter J</authors><journal>Haematologica</journal><issue>5</issue><year>2011</year><page>681-6</page></reference></references></item></content><references><reference><reference-id>24801015</reference-id><title>Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.</title><authors>Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1279-86</page></reference><reference><reference-id>26234722</reference-id><title>DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Jung S, Yang D, Lee J, Kim N, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim D</authors><journal>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</journal><issue>1</issue><year>2016</year><page>61-70</page></reference><reference><reference-id>26191952</reference-id><title>FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.</title><authors>Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer D, Chughtai K, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi S</authors><journal>Bone marrow transplantation</journal><issue>4</issue><year>2016</year><page>511-520</page></reference><reference><reference-id>25912052</reference-id><title>Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.</title><authors>Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak W, Kyrcz-Krzemien S, Komarnicki M, Warzocha K</authors><journal>European journal of haematology</journal><issue>3</issue><year>2016</year><page>236-44</page></reference><reference><reference-id>21242187</reference-id><title>FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.</title><authors>Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, Schäfer I, Schlegelberger B, Heil G, Ganser A, Krauter J</authors><journal>Haematologica</journal><issue>5</issue><year>2011</year><page>681-6</page></reference></references></variant></prognostic-significance><drug-sensitivity><content><item><text>Activating alterations in FLT3 may predict sensitivity to tyrosine kinase inhibitors, including both FLT3-specific and multi-kinase inhibitors.</text><references><reference><reference-id>24749672</reference-id><title>Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.</title><authors>Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F</authors><journal>Expert opinion on investigational drugs</journal><issue>7</issue><year>2014</year><page>943-54</page></reference><reference><reference-id>25231999</reference-id><title>Targeting FLT3 to treat leukemia.</title><authors>Konig H, Levis M</authors><journal>Expert opinion on therapeutic targets</journal><issue>1</issue><year>2015</year><page>37-54</page></reference></references></item><item><text>Sunitinib, sorafenib, cabozantinib, and ponatinib are inhibitors that target multiple kinases, including Flt3, and have been approved by the FDA for use in some indications; these and other inhibitors are under clinical investigation in several cancer types.</text><references><reference><reference-id>20212254</reference-id><title>Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.</title><authors>Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Byrd A, Bekele B, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian H</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>11</issue><year>2010</year><page>1856-62</page></reference><reference><reference-id>16990784</reference-id><title>FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).</title><authors>Schittenhelm M, Yee K, Tyner J, McGreevey L, Haley A, Town A, Griffith D, Bainbridge T, Braziel R, O'Farrell A, Cherrington J, Heinrich M</authors><journal>Leukemia</journal><issue>11</issue><year>2006</year><page>2008-14</page></reference><reference><reference-id>27060207</reference-id><title>Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).</title><authors>Lu J, Wang A, Liao H, Chen C, Hou H, Hu C, Tien H, Ou D, Lin L</authors><journal>Cancer letters</journal><issue>2</issue><year>2016</year><page>218-25</page></reference><reference><reference-id>ASCO 2011, Abstract 6518</reference-id><title>Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.</title><authors>Talpaz M, Shah NP, Deininger MW et al.</authors><journal>J Clin Oncol</journal><year>2011</year><page>Abstract 6518</page></reference></references></item><item><text>Second generation Flt3 inhibitors with greater specificity for Flt3, such as quizartinib (AC-220), crenolanib (CP-868596), and PLX3397, are also in clinical development.</text><references><reference><reference-id>24883179</reference-id><title>The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.</title><authors>Wander S, Levis M, Fathi A</authors><journal>Therapeutic advances in hematology</journal><issue>3</issue><year>2014</year><page>65-77</page></reference><reference><reference-id>24002496</reference-id><title>Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.</title><authors>Cortes J, Kantarjian H, Foran J, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong R, James J, Levis M</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>29</issue><year>2013</year><page>3681-7</page></reference><reference><reference-id>24227820</reference-id><title>Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.</title><authors>Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M</authors><journal>Blood</journal><issue>1</issue><year>2014</year><page>94-100</page></reference><reference><reference-id>ASH 2011, Abstract 764</reference-id><title>764 PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro</title><authors>Smith CC, Perl AE, Lasater E et al.</authors><journal>Blood</journal><year>2011</year><page>Abstract 764</page></reference></references></item><item><text>Midostaurin has been FDA-approved in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation therapy for adult newly-diagnosed AML patients harboring FLT3 internal tandem duplication (IDT) or tyrosine kinase domain (TKD) mutation.</text><references><reference><reference-id>ASH 2015, Abstract 6</reference-id><title>The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand)�P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])</title><authors>Stone RM, Mandrekar S, Sanford BL, et al. </authors><journal>Blood</journal><year>2015</year><page>Abstract 6</page></reference><reference><reference-id>28644114</reference-id><title>Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.</title><authors>Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C, Thiede C, Prior T, Döhner K, Marcucci G, Lo-Coco F, Klisovic R, Wei A, Sierra J, Sanz M, Brandwein J, de Witte T, Niederwieser D, Appelbaum F, Medeiros B, Tallman M, Krauter J, Schlenk R, Ganser A, Serve H, Ehninger G, Amadori S, Larson R, Döhner H</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2017</year><page>454-464</page></reference></references></item></content><references><reference><reference-id>24749672</reference-id><title>Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.</title><authors>Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F</authors><journal>Expert opinion on investigational drugs</journal><issue>7</issue><year>2014</year><page>943-54</page></reference><reference><reference-id>25231999</reference-id><title>Targeting FLT3 to treat leukemia.</title><authors>Konig H, Levis M</authors><journal>Expert opinion on therapeutic targets</journal><issue>1</issue><year>2015</year><page>37-54</page></reference><reference><reference-id>20212254</reference-id><title>Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.</title><authors>Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Byrd A, Bekele B, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian H</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>11</issue><year>2010</year><page>1856-62</page></reference><reference><reference-id>16990784</reference-id><title>FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).</title><authors>Schittenhelm M, Yee K, Tyner J, McGreevey L, Haley A, Town A, Griffith D, Bainbridge T, Braziel R, O'Farrell A, Cherrington J, Heinrich M</authors><journal>Leukemia</journal><issue>11</issue><year>2006</year><page>2008-14</page></reference><reference><reference-id>27060207</reference-id><title>Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).</title><authors>Lu J, Wang A, Liao H, Chen C, Hou H, Hu C, Tien H, Ou D, Lin L</authors><journal>Cancer letters</journal><issue>2</issue><year>2016</year><page>218-25</page></reference><reference><reference-id>ASCO 2011, Abstract 6518</reference-id><title>Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.</title><authors>Talpaz M, Shah NP, Deininger MW et al.</authors><journal>J Clin Oncol</journal><year>2011</year><page>Abstract 6518</page></reference><reference><reference-id>24883179</reference-id><title>The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.</title><authors>Wander S, Levis M, Fathi A</authors><journal>Therapeutic advances in hematology</journal><issue>3</issue><year>2014</year><page>65-77</page></reference><reference><reference-id>24002496</reference-id><title>Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.</title><authors>Cortes J, Kantarjian H, Foran J, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong R, James J, Levis M</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>29</issue><year>2013</year><page>3681-7</page></reference><reference><reference-id>24227820</reference-id><title>Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.</title><authors>Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M</authors><journal>Blood</journal><issue>1</issue><year>2014</year><page>94-100</page></reference><reference><reference-id>ASH 2011, Abstract 764</reference-id><title>764 PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro</title><authors>Smith CC, Perl AE, Lasater E et al.</authors><journal>Blood</journal><year>2011</year><page>Abstract 764</page></reference><reference><reference-id>ASH 2015, Abstract 6</reference-id><title>The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand)�P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])</title><authors>Stone RM, Mandrekar S, Sanford BL, et al. </authors><journal>Blood</journal><year>2015</year><page>Abstract 6</page></reference><reference><reference-id>28644114</reference-id><title>Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.</title><authors>Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C, Thiede C, Prior T, Döhner K, Marcucci G, Lo-Coco F, Klisovic R, Wei A, Sierra J, Sanz M, Brandwein J, de Witte T, Niederwieser D, Appelbaum F, Medeiros B, Tallman M, Krauter J, Schlenk R, Ganser A, Serve H, Ehninger G, Amadori S, Larson R, Döhner H</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2017</year><page>454-464</page></reference></references></drug-sensitivity><drug-resistance><content/><references/></drug-resistance><fda-approved><content><item><text>Midostaurin.</text><references/></item></content><references/></fda-approved><phase-3><content><item><text>The Phase 3 RATIFY trial in 717 FLT3-mutant AML patients has reported that the addition of midostaurin, as compared with placebo, to induction and consolidation therapy followed by one year of maintenance therapy was associated with an improved median overall survival (74.7 months versus 26.0 months) and event-free survival (eight months versus three months). The FLT3 mutation type (ITD or TKD) and allelic fraction were not associated with clinical outcome in the study.</text><references><reference><reference-id>ASH 2015, Abstract 6</reference-id><title>The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand)�P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])</title><authors>Stone RM, Mandrekar S, Sanford BL, et al. </authors><journal>Blood</journal><year>2015</year><page>Abstract 6</page></reference><reference><reference-id>28644114</reference-id><title>Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.</title><authors>Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C, Thiede C, Prior T, Döhner K, Marcucci G, Lo-Coco F, Klisovic R, Wei A, Sierra J, Sanz M, Brandwein J, de Witte T, Niederwieser D, Appelbaum F, Medeiros B, Tallman M, Krauter J, Schlenk R, Ganser A, Serve H, Ehninger G, Amadori S, Larson R, Döhner H</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2017</year><page>454-464</page></reference></references></item></content><references><reference><reference-id>ASH 2015, Abstract 6</reference-id><title>The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand)�P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])</title><authors>Stone RM, Mandrekar S, Sanford BL, et al. </authors><journal>Blood</journal><year>2015</year><page>Abstract 6</page></reference><reference><reference-id>28644114</reference-id><title>Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.</title><authors>Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C, Thiede C, Prior T, Döhner K, Marcucci G, Lo-Coco F, Klisovic R, Wei A, Sierra J, Sanz M, Brandwein J, de Witte T, Niederwieser D, Appelbaum F, Medeiros B, Tallman M, Krauter J, Schlenk R, Ganser A, Serve H, Ehninger G, Amadori S, Larson R, Döhner H</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2017</year><page>454-464</page></reference></references></phase-3><phase-2><content><item><text>A Phase 2 study in 54 FLT3-mutant AML patients of at least 60 years of age treated with sorafenib in combination with induction and post-remission therapy has reported an improved one year overall survival rate after a median follow up of 28.3 months in patients harboring FLT3-ITD mutations as compared with historical data (62% versus 30%, respectively); additionally, a one year survival rate of 71% was reported for patients harboring FLT3-TKD mutations. The two year overall survival was 28% and the disease-free survival was 27% for all evaluable patients.</text><references><reference><reference-id>ASH 2015, Abstract 319</reference-id><title>Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)</title><authors>Uy GL, Mandrekar S, Laumann K et al. </authors><year>2015</year><page>Abstract 319</page></reference></references></item><item><text>A Phase 1/2 study of sunitinib treatment and chemotherapy in elderly AML patients (median age of 70) with FLT3 mutations has reported that 59% (13/22) of patients achieved complete remission, with 53% (8/15) and 71% (5/7) of patients harboring FLT3-ITD and FLT3-TKD mutations, respectively. In addition, partial remission was reported in one patient (4.5%), refractory disease in five patients (23%), and death occurred in three patients (13.5%). Twelve patients achieving complete remission subsequently died, resulting in a median relapse-free survival time of 11 months, a median survival time of 18.8 months, and a two year survival of 36%.</text><references><reference><reference-id>25818407</reference-id><title>A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.</title><authors>Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk R</authors><journal>British journal of haematology</journal><issue>5</issue><year>2015</year><page>694-700</page></reference></references></item><item><text>A Phase 2 study assessed crenolanib in relapsed or refractory AML patients harboring FLT3-ITD, FLT3-D835, or FLT3-ITD+D835 mutations, including patients who had either not received prior Flt3 inhibitors (cohort A; n=18), or had progressed following prior tyrosine kinase inhibitor therapy (cohort B; n=36), or who had progressed to AML following MDS or other hematologic malignancies (cohort C; n=11). In cohort A, the rates of complete remission with incomplete platelet recovery and partial remission were 39% and 11%, respectively, and in cohort B, the rates were 17% and 14%, respectively. Only transient benefit was reported in cohort C.</text><references><reference><reference-id>ASCO 2016, Abstract 7008</reference-id><title>Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.</title><authors>Cortes JE, Kantarjian HM, Kadia TM, et al. </authors><journal>J Clin Oncol</journal><year>2016</year><page>Abstract 7008</page></reference></references></item><item><text>A preliminary analysis from a Phase 2 study of crenolanib in combination with standard induction chemotherapy in 25 evaluable newly diagnosed AML patients harboring FLT3-ITD and/or FLT3-TKD mutation has reported complete remission after one cycle of induction in 88% (22/25) of patients. At a median follow up of six months, relapses were observed in three patients.</text><references><reference><reference-id>ASH 2016, Abstract 1071</reference-id><title>Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)</title><authors>Wang ES, Stone RM, Tallman MS, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 2071</page></reference></references></item><item><text>Preliminary results of a Phase 1/2 trial of quizartinib in combination with either azacitidine or low-dose cytarabine in relapsed/refractory high-risk MDS, CMML, or AML patients reported an overall response rate of 69% (18/26); the overall response rate in FLT3-ITD positive patients was 82% (18/22), with nine patients showing a greater than 50% reduction of FLT3-ITD allelic burden, and two patients showing no detectable FLT3-ITD at the time of response.</text><references><reference><reference-id>ASH 2014, Abstract 388</reference-id><title>388 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
</title><authors>Borthakur G, Kantarjian HM, O'Brien S et al.</authors><journal>Blood</journal><year>2014</year></reference></references></item><item><text>The Phase 2 SORAML trial in 276 newly diagnosed AML patients ages 18-60 years assessed the efficacy of sorafenib following induction and consolidation therapy with daunorubicin and cytarabine. In 267 evaluable patients, the complete response rate was 59% in the placebo arm and 59% in the sorafenib arm, three year event-free survival rates were 22% and 40%, and the three year relapse-free survival rates were 38% and 56%, respectively. Three year overall survival rates were 56% and 63% in the placebo and sorafenib arms, respectively, and a nonsignificant trend for prolonged relapse-free and overall survival was observed in those harboring FLT3-ITD.</text><references><reference><reference-id>ASH 2014, Abstract 6</reference-id><title>Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial</title><authors>Rollig C, Muller-Tidow C, Huttmann A et al.</authors><journal>Blood</journal><year>2014</year><page>Abstract 6</page></reference><reference><reference-id>26549589</reference-id><title>Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.</title><authors>Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus C, Brandts C, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause S, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut I, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel W, Ehninger G</authors><journal>The Lancet. Oncology</journal><issue>16</issue><year>2015</year><page>1691-9</page></reference></references></item><item><text>A Phase 2 randomized, placebo-controlled study of 201 elderly AML patients has reported that addition of sorafenib to intensive chemotherapy did not improve the overall response rate (57% of 102 patients) compared to chemotherapy alone (64% of 975 patients). Therefore, the addition of sorafenib to standard induction and consolidation therapy was concluded to be not beneficial for elderly patients with AML.</text><references><reference><reference-id>23897964</reference-id><title>Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.</title><authors>Serve H, Krug U, Wagner R, Sauerland M, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer K, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel W</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>25</issue><year>2013</year><page>3110-8</page></reference></references></item><item><text>A Phase 2 study of quizartinib in patients older than 70 years with relapsed or refractory AML (n=83) has reported a composite-complete remission rate of 53.3% (32/60) in FLT3-ITD positive patients with a median duration of 13.9 weeks and 43.5% (10/23) of FLT3-ITD negative patients with a median duration of 8.3 weeks; common grade 3/4 toxicities included febrile neutropenia, anemia, transient QT-interval prolongation, and thrombocytopenia.</text><references><reference><reference-id>ASCO 2013, Abstract 7023</reference-id><title>Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).</title><authors>Perl AE, Dohner H, Rousselot PH, et al. </authors><journal>J Clin Onc</journal><year>2013</year><page>Abstract 7023</page></reference></references></item><item><text>An interim report has analyzed a Phase 1/2 study of quizartinib in combination with either azacitidine or low-dose cytarabine (LDAC) in relapsed or refractory high-risk MDS, CMML, or AML patients irrespective of FLT3 mutation and salvage status (Phase 1) or in MDS/CMML/AML patients with a FLT3-ITD mutation who were greater than 60 years of age with no prior therapies or any age with relapsed disease (Phase 2). An overall response rate of 67% (35/52) has been reported, including eight responses in the LDAC arm and 27 in the azacitidine arm. All responses were reported to occur in patients with a FLT3-ITD mutation and without a D835 mutation. Accrual to the study was continuing at the time of publication.</text><references><reference><reference-id>ASH 2016, Abstract 1642</reference-id><title>The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial</title><authors>Abdelall W, Kantarjian HM, Borthakur G, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 1642</page></reference></references></item></content><references><reference><reference-id>ASH 2015, Abstract 319</reference-id><title>Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)</title><authors>Uy GL, Mandrekar S, Laumann K et al. </authors><year>2015</year><page>Abstract 319</page></reference><reference><reference-id>25818407</reference-id><title>A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.</title><authors>Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk R</authors><journal>British journal of haematology</journal><issue>5</issue><year>2015</year><page>694-700</page></reference><reference><reference-id>ASCO 2016, Abstract 7008</reference-id><title>Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.</title><authors>Cortes JE, Kantarjian HM, Kadia TM, et al. </authors><journal>J Clin Oncol</journal><year>2016</year><page>Abstract 7008</page></reference><reference><reference-id>ASH 2016, Abstract 1071</reference-id><title>Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)</title><authors>Wang ES, Stone RM, Tallman MS, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 2071</page></reference><reference><reference-id>ASH 2014, Abstract 388</reference-id><title>388 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
</title><authors>Borthakur G, Kantarjian HM, O'Brien S et al.</authors><journal>Blood</journal><year>2014</year></reference><reference><reference-id>ASH 2014, Abstract 6</reference-id><title>Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial</title><authors>Rollig C, Muller-Tidow C, Huttmann A et al.</authors><journal>Blood</journal><year>2014</year><page>Abstract 6</page></reference><reference><reference-id>26549589</reference-id><title>Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.</title><authors>Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus C, Brandts C, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause S, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut I, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel W, Ehninger G</authors><journal>The Lancet. Oncology</journal><issue>16</issue><year>2015</year><page>1691-9</page></reference><reference><reference-id>23897964</reference-id><title>Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.</title><authors>Serve H, Krug U, Wagner R, Sauerland M, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer K, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel W</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>25</issue><year>2013</year><page>3110-8</page></reference><reference><reference-id>ASCO 2013, Abstract 7023</reference-id><title>Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).</title><authors>Perl AE, Dohner H, Rousselot PH, et al. </authors><journal>J Clin Onc</journal><year>2013</year><page>Abstract 7023</page></reference><reference><reference-id>ASH 2016, Abstract 1642</reference-id><title>The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial</title><authors>Abdelall W, Kantarjian HM, Borthakur G, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 1642</page></reference></references></phase-2><phase-1><content><item><text>A retrospective analysis of 17 patients with FLT3-ITD positive AML treated with sorafenib in combination with allogeneic hematopoietic stem cell transplant reported complete remission in 82% (14/17) of cases, although five patients later developed progressive disease.</text><references><reference><reference-id>26233683</reference-id><title>Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.</title><authors>Tschan-Plessl A, Halter J, Heim D, Medinger M, Passweg J, Gerull S</authors><journal>Annals of hematology</journal><issue>11</issue><year>2015</year><page>1899-905</page></reference></references></item><item><text>A Phase 1 study has reported that sunitinib treatment was associated with partial remissions of short duration in AML patients, especially those with FLT3 mutations; sunitinib was reported to decrease the number of phospho-Kit, phospho-VEGFR-2, phospho-Akt, and phospho-Stat5 cells in the bone marrow.</text><references><reference><reference-id>15459012</reference-id><title>A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.</title><authors>Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann O, O'Farrell A, Bello C, Allred R, Manning W, Cherrington J, Louie S, Hong W, Brega N, Massimini G, Scigalla P, Berdel W, Hossfeld D</authors><journal>Blood</journal><issue>3</issue><year>2005</year><page>986-93</page></reference></references></item><item><text>A preliminary analysis from a Phase 1 study of cabozantinib has reported no marrow responses in 15 evaluable AML patients.</text><references><reference><reference-id>Blood 2016, Abstract 5218</reference-id><title>A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia</title><authors>Fathi AT, Blonquist TM, Levis MJ</authors><journal>Blood</journal><issue>22</issue><year>2016</year><page>Abstract 5218</page></reference></references></item><item><text>A Phase 1 trial of nintedanib in combination with cytarabine in 13 elderly patients with AML reported one complete response, one complete response with incomplete hematologic recovery, and blast reductions in three patients, with a one year survival rate of 33%.</text><references><reference><reference-id>27716819</reference-id><title>A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.</title><authors>Schliemann C, Gerss J, Wiebe S, Mikesch J, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel W, Krug U</authors><journal>PloS one</journal><issue>10</issue><year>2016</year><page>e0164499</page></reference></references></item><item><text>A Phase 1 study in hematologic malignancies included 12 AML patients, including three FLT3-ITD positive and two FLT3 wild-type patients, and evaluated the efficacy of single agent ponatinib. The overall response rate was 25% (3/12), with two patients achieving a complete response with incomplete hematologic recovery and one partial response, all of which occurred in FLT3-ITD positive patients who were naive to Flt3 inhibitors.</text><references><reference><reference-id>ASCO 2011, Abstract 6518</reference-id><title>Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.</title><authors>Talpaz M, Shah NP, Deininger MW et al.</authors><journal>J Clin Oncol</journal><year>2011</year><page>Abstract 6518</page></reference></references></item><item><text>A Phase 1 study of quizartinib therapy in 76 patients with relapsed or refractory acute myeloid leukemia patients has reported 13% (10/76) of subjects showed complete remissions of any type and 17% (13/76) of patients had partial remissions. In the patients with FLT3-ITD, the overall response rate was 53% (9/17).</text><references><reference><reference-id>24002496</reference-id><title>Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.</title><authors>Cortes J, Kantarjian H, Foran J, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong R, James J, Levis M</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>29</issue><year>2013</year><page>3681-7</page></reference></references></item></content><references><reference><reference-id>26233683</reference-id><title>Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.</title><authors>Tschan-Plessl A, Halter J, Heim D, Medinger M, Passweg J, Gerull S</authors><journal>Annals of hematology</journal><issue>11</issue><year>2015</year><page>1899-905</page></reference><reference><reference-id>15459012</reference-id><title>A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.</title><authors>Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann O, O'Farrell A, Bello C, Allred R, Manning W, Cherrington J, Louie S, Hong W, Brega N, Massimini G, Scigalla P, Berdel W, Hossfeld D</authors><journal>Blood</journal><issue>3</issue><year>2005</year><page>986-93</page></reference><reference><reference-id>Blood 2016, Abstract 5218</reference-id><title>A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia</title><authors>Fathi AT, Blonquist TM, Levis MJ</authors><journal>Blood</journal><issue>22</issue><year>2016</year><page>Abstract 5218</page></reference><reference><reference-id>27716819</reference-id><title>A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.</title><authors>Schliemann C, Gerss J, Wiebe S, Mikesch J, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel W, Krug U</authors><journal>PloS one</journal><issue>10</issue><year>2016</year><page>e0164499</page></reference><reference><reference-id>ASCO 2011, Abstract 6518</reference-id><title>Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.</title><authors>Talpaz M, Shah NP, Deininger MW et al.</authors><journal>J Clin Oncol</journal><year>2011</year><page>Abstract 6518</page></reference><reference><reference-id>24002496</reference-id><title>Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.</title><authors>Cortes J, Kantarjian H, Foran J, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong R, James J, Levis M</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>29</issue><year>2013</year><page>3681-7</page></reference></references></phase-1><preclinical><content><item empty-type="Not applicable"><text>N/A: Preclinical data are not presented when higher level data are available.</text><references/></item></content><references/></preclinical><therapies><therapy therapeutic-level-of-evidence="A"><drug-name>Midostaurin</drug-name><targets><target>VEGFR2</target><target>PRKCB</target><target>CSF1R</target><target>KIT</target><target>FLT3</target></targets><trade-name>Rydapt</trade-name><rationale>PKCa/VEGFR2/Kit/PDGFR/Flt3 multikinase inhibitor.</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>Systemic mastocytosis</disease><disease>FLT3-positive AML</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 3</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="B/C"><drug-name>Sorafenib</drug-name><targets><target>RAF1</target><target>CSF1R</target><target>FLT1</target><target>FLT4</target><target>KIT</target><target>BRAF</target><target>PDGFRB</target><target>FLT3</target><target>RET</target></targets><trade-name>Nexavar</trade-name><rationale>Raf kinase inhibitor, also inhibits VEGFR2/Pdgfr-beta/Kit.</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>Hepatocellular carcinoma (HCC)</disease><disease>Renal cell carcinoma</disease><disease>Thyroid carcinoma</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 3</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="C"><drug-name>Ponatinib</drug-name><targets><target>VEGFR2</target><target>FGFR3</target><target>FGFR4</target><target>FGFR1</target><target>ABL1</target><target>VEGFR1</target><target>KIT</target><target>PDGFRA</target><target>FGFR2</target><target>PDGFRB</target><target>FLT3</target><target>RET</target></targets><trade-name>Iclusig</trade-name><rationale>Bcr-Abl/VEGFR-1,2,3/Fgfrs/Kit/Tie-2/Flt3 kinase inhibitor.</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>Chronic myelocytic leukemia (CML)</disease><disease>Acute lymphocytic leukemia (ALL)</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 2</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="C"><drug-name>Crenolanib</drug-name><targets><target>PDGFR</target><target>FLT3</target></targets><rationale>Small molecule kinase inhibitor of Flt3, Pdgfr-alpha, and Pdgfr-beta.</rationale><status-in-other-indications><status>Phase 3</status><disease-list><disease>GIST (Gastrointestinal stromal tumor)</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 3</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="C"><drug-name>Quizartinib</drug-name><targets><target>CSF1R</target><target>PDGFR</target><target>KIT</target><target>FLT3</target></targets><rationale>Flt3/CSF1R/Kit/PDGFR small molecule kinase inhibitor.</rationale><status-in-other-indications><status>Phase 3</status><disease-list><disease>Myelodysplastic Syndrome (MDS)</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 3</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="C/D"><drug-name>Sunitinib</drug-name><targets><target>VEGFR2</target><target>VEGFR3</target><target>CSF1R</target><target>VEGFR1</target><target>KIT</target><target>PDGFRA</target><target>PDGFRB</target><target>FLT3</target><target>RET</target></targets><trade-name>Sutent</trade-name><rationale>VEGFR2/Pdgfr-beta/Kit/Flt3 kinase inhibitor.</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>GIST (Gastrointestinal stromal tumor)</disease><disease>Pancreatic neuroendocrine tumor</disease><disease>Renal cell carcinoma</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 2</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="D"><drug-name>Nintedanib</drug-name><targets><target>VEGFR2</target><target>FGFR3</target><target>FGFR1</target><target>VEGFR3</target><target>VEGFR1</target><target>PDGFRA</target><target>FGFR2</target><target>PDGFRB</target><target>FLT3</target></targets><trade-name>Vargatef</trade-name><rationale>Multitargeted kinase inhibitor (VEGFRs, Fgfrs, Pdgfrs, Lyn, Lck, Src, Ret, Flt3).</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>Idiopathic pulmonary fibrosis</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 2</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="D"><drug-name>Cabozantinib</drug-name><targets><target>KDR</target><target>AXL</target><target>MET</target><target>KIT</target><target>FLT3</target><target>RET</target></targets><trade-name>Cometriq</trade-name><rationale>Multi-kinase inhibitor with targets including Met, Ret, VEGFR-2, and Kit.</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>Renal cell carcinoma</disease><disease>Thyroid medullary carcinoma</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 1</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="D"><drug-name>PLX3397</drug-name><targets><target>CSF1R</target><target>KIT</target><target>FLT3</target></targets><rationale>Multitargeted small molecule kinase inhibitor (Kit/CSF1R/Flt3).</rationale><status-in-other-indications><status>Phase 2</status><disease-list><disease>Glioblastoma</disease><disease>Hodgkin lymphoma (HL)</disease><disease>Head and neck squamous cell carcinoma (HNSCC)</disease><disease>Solid Tumor</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 2</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="None found"><drug-name>Pacritinib</drug-name><targets><target>JAK2</target><target>FLT3</target></targets><rationale>Jak2/Flt3 inhibitor.</rationale><status-in-other-indications><status>Phase 3</status><disease-list><disease>Primary myelofibrosis (MF)</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 2</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="None found"><drug-name>Famitinib</drug-name><targets><target>KDR</target><target>PDGFR</target><target>FLT1</target><target>KIT</target><target>FLT3</target></targets><rationale>Tyrosine kinase inhibitor targeting Kit, VEGFR-2, Pdgfr, Flt1, and Flt3.</rationale><status-in-other-indications><status>Phase 3</status><disease-list><disease>Colorectal carcinoma (CRC)</disease></disease-list></status-in-other-indications></therapy><therapy therapeutic-level-of-evidence="None found"><drug-name>Gilteritinib</drug-name><targets><target>AXL</target><target>ALK</target><target>FLT3</target></targets><rationale>Flt3/Axl inhibitor.</rationale><status-in-other-indications><status>Phase 1</status><disease-list><disease>Solid Tumor</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 2</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="None found"><drug-name>Merestinib</drug-name><targets><target>AXL</target><target>ROS1</target><target>MST1R</target><target>MET</target><target>FLT3</target></targets><rationale>Multi-kinase inhibitor targeting Met, Ros1, Axl, Flt3, and other proteins.</rationale><status-in-other-indications><status>Phase 2</status><disease-list><disease>Gallbladder carcinoma</disease><disease>Non-small cell lung carcinoma (NSCLC)</disease><disease>Cholangiocarcinoma</disease><disease>Lung cancer</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 1</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="None found"><drug-name>MGCD516</drug-name><targets><target>KDR</target><target>AXL</target><target>EPHA3</target><target>DDR2</target><target>FLT1</target><target>EPHB2</target><target>NTRK3</target><target>EPHB4</target><target>KIT</target><target>NTRK1</target><target>NTRK2</target><target>FLT3</target></targets><rationale>Multi-kinase inhibitor.</rationale><status-in-other-indications><status>Phase 1</status><disease-list><disease>Solid Tumor</disease></disease-list></status-in-other-indications></therapy></therapies><clinical-trials prioritized-by="regionally"><clinical-trial><trial-id>NCT02283177</trial-id><title>A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations</title><phase>Phase 2</phase><targets><target>FLT3</target><target>PDGFR</target></targets><overall-contact>Overall contact: Abhijit Ramachandran, aramachandran@arogpharma.com, 214-593-0515</overall-contact><markers><marker>FLT3</marker></markers><trial-sites><trial-site><center>City of Hope Medical Center</center><contact>Chatchada Karanes, MD</contact><city>Duarte</city><state>California</state><country>United States</country><email>ckaranes@coh.org</email><postal-code>91010</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Iowa Hospitals and Clinics</center><contact>Carlos Vigil, MD</contact><city>Iowa City</city><state>Iowa</state><country>United States</country><email>carlos-vigil@uiowa.edu</email><postal-code>52242</postal-code><status>Recruiting</status></trial-site><trial-site><center>Dana-Farber Cancer Institute</center><contact>Richard Stone, MD</contact><city>Boston</city><state>Massachusetts</state><country>United States</country><postal-code>02215</postal-code><status>Recruiting</status></trial-site><trial-site><center>Roswell Park Cancer Institute</center><contact>Eunice Wang, M.D.</contact><city>Buffalo</city><state>New York</state><country>United States</country><investigator>Eunice Wang, M.D.</investigator><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Memorial Sloan Kettering Cancer Center</center><contact>Martin Tallman, MD.</contact><city>New York</city><state>New York</state><country>United States</country><investigator>Faye Feller, M.D.</investigator><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Weill Cornell Medical College</center><contact>Gail Roboz, MD</contact><city>New York</city><state>New York</state><country>United States</country><email>gar2001@med.cornell.edu</email><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Cleveland Clinic</center><contact>Hetty Carraway, MD</contact><city>Cleveland</city><state>Ohio</state><country>United States</country><postal-code>44195</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Texas Southwestern Medical Center</center><contact>Robert Collins, MD</contact><city>Dallas</city><state>Texas</state><country>United States</country><email>robert.collins@utsouthwestern.edu</email><investigator>Robert Collins, MD</investigator><postal-code>75390</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fred Hutchinson Cancer Research Center</center><contact>Roland Walter, MD, PhD</contact><city>Seattle</city><state>Washington</state><country>United States</country><postal-code>98195</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02752035</trial-id><title>A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy</title><phase>Phase 2/Phase 3</phase><targets><target>ALK</target><target>AXL</target><target>DNMT</target><target>FLT3</target></targets><overall-contact>Overall contact: Astellas Pharma Global Development, astellas.registration@astellas.com, 800-888-7704 x5473</overall-contact><markers><marker>FLT3</marker><marker>TET2</marker></markers><trial-sites><trial-site><center>Site US10007</center><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10004</center><city>New Haven</city><state>Connecticut</state><country>United States</country><postal-code>06510-3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10006</center><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>32610-0278</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10036</center><city>Augusta</city><state>Georgia</state><country>United States</country><postal-code>30912</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10010</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60611-5975</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10037</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10003</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10023</center><city>Maywood</city><state>Illinois</state><country>United States</country><postal-code>60153</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10018</center><city>Louisville</city><state>Kentucky</state><country>United States</country><postal-code>40207</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10021</center><city>New Orleans</city><state>Louisiana</state><country>United States</country><postal-code>70112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10035</center><city>Brewer</city><state>Maine</state><country>United States</country><postal-code>04412</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10005</center><city>Hackensack</city><state>New Jersey</state><country>United States</country><postal-code>7601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10011</center><city>Morristown</city><state>New Jersey</state><country>United States</country><postal-code>07962</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10033</center><city>Buffalo</city><state>New York</state><country>United States</country><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10039</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10022</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10016</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10012</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10009</center><city>Syracuse</city><state>New York</state><country>United States</country><postal-code>13210</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10015</center><city>Oklahoma City</city><state>Oklahoma</state><country>United States</country><postal-code>73104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10031</center><city>Hershey</city><state>Pennsylvania</state><country>United States</country><postal-code>17033-0850</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10034</center><city>Greenville</city><state>South Carolina</state><country>United States</country><postal-code>26615</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10028</center><city>Dallas</city><state>Texas</state><country>United States</country><postal-code>75246</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10002</center><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10026</center><city>Seattle</city><state>Washington</state><country>United States</country><postal-code>98104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61012</center><city>Camperdown</city><state>New South Wales</state><country>Australia</country><postal-code>2050</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61004</center><city>Liverpool</city><state>New South Wales</state><country>Australia</country><postal-code>2170</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61008</center><city>Adelaide</city><state>South Australia</state><country>Australia</country><postal-code>SA 5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61007</center><city>Geelong</city><state>Victoria</state><country>Australia</country><postal-code>3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32003</center><city>Bruxelles</city><state>Bruxelles-Capitale, Region de</state><country>Belgium</country><postal-code>1200</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32007</center><city>Brussel</city><state>Bruxelles</state><country>Belgium</country><postal-code>1090</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32006</center><city>Gent</city><country>Belgium</country><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15009</center><city>Edmonton</city><state>Alberta</state><country>Canada</country><postal-code>T6G 2B7</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15004</center><city>Halifax</city><state>Nova Scotia</state><country>Canada</country><postal-code>B3H 2Y9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15002</center><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 2M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15006</center><city>Montreal</city><state>Quebec</state><country>Canada</country><postal-code>H4A 3J1</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33002</center><city>Pessac</city><state>Gironde</state><country>France</country><postal-code>33604</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33015</center><city>Rouen</city><state>Haute-Normandie</state><country>France</country><postal-code>76038</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33016</center><city>Limoges</city><state>Haute-Vienne</state><country>France</country><postal-code>87042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33019</center><city>Montpellier Cedex 5</city><state>Herault</state><country>France</country><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33018</center><city>Rennes</city><state>Ille-et-Vilaine</state><country>France</country><postal-code>35033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33001</center><city>Nantes cedex 01</city><state>Loire-Atlantique</state><country>France</country><postal-code>44093</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33014</center><city>Vandoeuvre les Nancy</city><state>Meurthe-et-Moselle</state><country>France</country><postal-code>54500</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33013</center><city>Pierre-Benite</city><state>Rhone</state><country>France</country><postal-code>69310</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33017</center><city>Le Mans</city><state>Sarthe</state><country>France</country><postal-code>72037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33005</center><city>Amiens</city><state>Somme</state><country>France</country><postal-code>80054</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33012</center><city>Poitiers</city><state>Vienne</state><country>France</country><postal-code>86000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33009</center><city>Angers</city><country>France</country><postal-code>49033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33007</center><city>Le Chesnay Cedex</city><country>France</country><postal-code>78157</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33004</center><city>Lille cedex</city><country>France</country><postal-code>59020</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33006</center><city>Lille</city><country>France</country><postal-code>59037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49002</center><city>Tuebingen</city><state>Baden-Wurttemberg</state><country>Germany</country><postal-code>72076</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49007</center><city>Munchen</city><state>Bayern</state><country>Germany</country><postal-code>81737</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49012</center><city>Braunschweig</city><state>Niedersachsen</state><country>Germany</country><postal-code>38118</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49004</center><city>Hannover</city><state>Niedersachsen</state><country>Germany</country><postal-code>30625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49008</center><city>Bonn</city><state>Nordrhein-Westfalen</state><country>Germany</country><postal-code>53105</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49009</center><city>Halle (Saale)</city><state>Sachsen-Anhalt</state><country>Germany</country><postal-code>06120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49013</center><city>Heilbronn</city><country>Germany</country><postal-code>74078</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49011</center><city>Stuttgart</city><country>Germany</country><postal-code>70376</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81027</center><city>Matsuyama</city><state>Ehime</state><country>Japan</country><postal-code>790-0024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81024</center><city>Gifu</city><state>Gihu</state><country>Japan</country><postal-code>500-8513</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81010</center><city>Maebashi</city><state>Gunma</state><country>Japan</country><postal-code>371-0821</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81006</center><city>Sapporo</city><state>Hokkaido</state><country>Japan</country><postal-code>060-8648</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81014</center><city>Shinagawa-ku</city><state>Tokyo</state><country>Japan</country><postal-code>141-8625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81022</center><city>Tachikawa</city><state>Tokyo</state><country>Japan</country><postal-code>190-0014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81017</center><city>Nagasaki</city><country>Japan</country><postal-code>852-8511</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81019</center><city>Toyama</city><country>Japan</country><postal-code>930-8550</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82003</center><city>Namdong</city><state>Incheon Gwang'yeogsiv</state><country>Korea, Republic of</country><postal-code>405 760</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82010</center><city>Hwasungun</city><state>Jeonranamdo</state><country>Korea, Republic of</country><postal-code>58128</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82013</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>05505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82008</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>06351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82006</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>110-744</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82002</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>137-701</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82001</center><city>Ulsan</city><state>Ulsan Gwang'yeogsi</state><country>Korea, Republic of</country><postal-code>682-714</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82014</center><city>Busan</city><country>Korea, Republic of</country><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82012</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>156-707</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48003</center><city>Lublin</city><state>Lubelskie</state><country>Poland</country><postal-code>20-081</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48005</center><city>Krakow</city><state>Małopolskie</state><country>Poland</country><postal-code>31-501</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48002</center><city>Opole</city><state>Opolskie</state><country>Poland</country><postal-code>45-061</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48001</center><city>Olsztyn</city><state>Warmińsko-mazurskie</state><country>Poland</country><postal-code>10-228</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34011</center><city>Coruna</city><state>A Coruna</state><country>Spain</country><postal-code>15006</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34003</center><city>Oviedo</city><state>Asturias</state><country>Spain</country><postal-code>33011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34007</center><city>Palma de Mallorca</city><state>Baleares</state><country>Spain</country><postal-code>07010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34008</center><city>Barcelona</city><country>Spain</country><postal-code>08003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34004</center><city>Barcelona</city><country>Spain</country><postal-code>08035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34010</center><city>Barcelona</city><country>Spain</country><postal-code>08036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34009</center><city>Barcelona</city><country>Spain</country><postal-code>8041</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34002</center><city>Caceres</city><country>Spain</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34005</center><city>Valencia</city><country>Spain</country><postal-code>46026</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88605</center><city>Kweishan Hsiang</city><state>Taoyuan</state><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88604</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88607</center><city>Taichung</city><country>Taiwan</country><postal-code>40705</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88602</center><city>Tainan</city><country>Taiwan</country><postal-code>704</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88609</center><city>Tainan</city><country>Taiwan</country><postal-code>736</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88601</center><city>Taipei</city><country>Taiwan</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88608</center><city>Taipei</city><country>Taiwan</country><postal-code>10449</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88610</center><city>Taipei</city><country>Taiwan</country><postal-code>11217</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44004</center><city>London</city><state>London, City of</state><country>United Kingdom</country><postal-code>EC1A 7BE</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02668653</trial-id><title>Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)</title><phase>Phase 3</phase><targets><target>CSF1R</target><target>FLT3</target><target>KIT</target><target>PDGFR</target></targets><overall-contact>Overall contact: James J. Hanyok, PharmD, jhanyok@dsi.com, 732-590-4881</overall-contact><markers><marker>FLT3</marker></markers><trial-sites><trial-site><center>The University of Alabama at Birmingham</center><contact>Site Coordinator</contact><city>Birmingham</city><state>Alabama</state><country>United States</country><postal-code>35249</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Arizona Cancer Center</center><contact>Site Coordinator</contact><city>Tucson</city><state>Arizona</state><country>United States</country><postal-code>85724</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ronald Reagan UCLA Medical Center</center><contact>Site Coordinator</contact><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Florida (UF) Health Shands Hospital</center><contact>Site Coordinator</contact><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>90095-7170</postal-code><status>Recruiting</status></trial-site><trial-site><center>Rush University Medical Center</center><contact>Site Coordinator</contact><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Chicago Medical Center</center><contact>Site Coordinator</contact><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Franciscan St. Francis Health Indianapolis</center><contact>Site Coordinator</contact><city>Indianapolis</city><state>Indiana</state><country>United States</country><postal-code>46237</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Kentucky Chandler Medical Center</center><contact>Site Coordinator</contact><city>Lexington</city><state>Kentucky</state><country>United States</country><postal-code>40536-0293</postal-code><status>Recruiting</status></trial-site><trial-site><center>Louisiana State University Health Sciences Center Shreveport</center><contact>Site Coordinator</contact><city>Shreveport</city><state>Louisiana</state><country>United States</country><postal-code>71130</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hackensack Univ. Medical Center</center><contact>Site Coordinator</contact><city>Hackensack</city><state>New Jersey</state><country>United States</country><postal-code>07601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Duke Clinical Research Institute</center><contact>Site Coordinator</contact><city>Durham</city><state>North Carolina</state><country>United States</country><postal-code>27710</postal-code><status>Recruiting</status></trial-site><trial-site><center>University Hospitals Seidman Cancer Center</center><contact>Site Coordinator</contact><city>Cleveland</city><state>Ohio</state><country>United States</country><postal-code>44106</postal-code><status>Recruiting</status></trial-site><trial-site><center>Cleveland Clinic Foundation</center><contact>Site Coordinator</contact><city>Cleveland</city><state>Ohio</state><country>United States</country><postal-code>44195</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Oklahoma Medical Center</center><contact>Site Coordinator</contact><city>Oklahoma City</city><state>Oklahoma</state><country>United States</country><postal-code>73117</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital of the University of Pennsylvania</center><contact>Site Coordinator</contact><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><postal-code>19104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Thomas Jefferson University Hospital</center><contact>Site Coordinator</contact><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><postal-code>19107-4307</postal-code><status>Recruiting</status></trial-site><trial-site><center>John Theurer Cancer Center at Hackensack University Medical Center</center><contact>Site Coordinator</contact><city>Puyallup</city><state>Washington</state><country>United States</country><postal-code>98374-2115</postal-code><status>Recruiting</status></trial-site><trial-site><center>West Virginia University Hospitals, Inc.</center><contact>Site Coordinator</contact><city>Morgantown</city><state>West Virginia</state><country>United States</country><postal-code>26506</postal-code><status>Recruiting</status></trial-site><trial-site><center>Calvary Mater Newcastle</center><contact>Site Coordinator</contact><city>Waratah</city><state>New South Wales</state><country>Australia</country><postal-code>2298</postal-code><status>Recruiting</status></trial-site><trial-site><center>Townsville Hospital (TTH)</center><contact>Site Coordinator</contact><city>Douglas</city><state>Queensland</state><country>Australia</country><postal-code>4814</postal-code><status>Recruiting</status></trial-site><trial-site><center>Princess Alexandra Hospital</center><contact>Site Coordinator</contact><city>Woolloongabba</city><state>Queensland</state><country>Australia</country><postal-code>4102</postal-code><status>Recruiting</status></trial-site><trial-site><center>Royal Adelaide Hospital</center><contact>Site Coordinator</contact><city>Adelaide</city><state>South Australia</state><country>Australia</country><postal-code>5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Flinders Medical Centre</center><contact>Site Coordinator</contact><city>Bedford Park</city><state>South Australia</state><country>Australia</country><postal-code>5042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fiona Stanley Hospital</center><contact>Site Coordinator</contact><city>Murdoch</city><state>Western Australia</state><country>Australia</country><postal-code>6150</postal-code><status>Recruiting</status></trial-site><trial-site><center>AZ Sint-Jan Brugge-Oostende AV</center><contact>Site Coordinator</contact><city>Brugge</city><country>Belgium</country><postal-code>8000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitair Ziekenhuis Gent</center><contact>Site Coordinator</contact><city>Gent</city><country>Belgium</country><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>UCL Mont-Godinne</center><contact>Site Coordinator</contact><city>Yvoir</city><country>Belgium</country><postal-code>5530</postal-code><status>Recruiting</status></trial-site><trial-site><center>University Multiprofile Hospital for Active Treatment "Dr. G. Stranski" EAD</center><contact>Site Coordinator</contact><city>Pleven</city><country>Bulgaria</country><postal-code>5800</postal-code><status>Recruiting</status></trial-site><trial-site><center>University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD</center><contact>Site Coordinator</contact><city>Sofia</city><country>Bulgaria</country><postal-code>1000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tom Baker Cancer Centre</center><contact>Site Coordinator</contact><city>Calgary</city><state>Alberta</state><country>Canada</country><postal-code>T2N 4N2</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Alberta Hospital</center><contact>Site Coordinator</contact><city>Edmonton</city><state>Alberta</state><country>Canada</country><postal-code>T6G-3G3</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vancouver General Hospital (VGH)</center><contact>Site Coordinator</contact><city>Vancouver</city><state>British Columbia</state><country>Canada</country><postal-code>V5Z 1M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Princess Margaret Cancer Centre</center><contact>Site Coordinator</contact><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 1X5</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinička Bolnica Dubrava</center><contact>Site Coordinator</contact><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinička Bolnica Merkur</center><contact>Site Coordinator</contact><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Bolnički Centar Zagreb</center><contact>Site Coordinator</contact><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultní Nemocnice Hradec Králové</center><contact>Site Coordinator</contact><city>Hradec Kralove</city><country>Czechia</country><postal-code>500 05</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultní Nemocnice Olomouc</center><contact>Site Coordinator</contact><city>Olomouc</city><country>Czechia</country><postal-code>775 20</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultní Nemocnice Ostrava</center><contact>Site Coordinator</contact><city>Ostrava</city><country>Czechia</country><postal-code>708 52</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultni Nemocnice Plzen</center><contact>Site Coordinator</contact><city>Pilsen</city><country>Czechia</country><postal-code>304 60</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vseobecna Fakultni Nemocnice, Ustav hematologie a krevni transfuze (UHKT)</center><contact>Site Coordinator</contact><city>Praha 2</city><country>Czechia</country><postal-code>128 20</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital A. Michallon</center><contact>Site Coordinator</contact><city>Grenoble</city><country>France</country><postal-code>38043</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier de Versailles - Hôpital André Mignot</center><contact>Site Coordinator</contact><city>Le Chesnay</city><country>France</country><postal-code>78150</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier du Mans</center><contact>Site Coordinator</contact><city>Le Mans</city><country>France</country><postal-code>72037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez</center><contact>Site Coordinator</contact><city>Lille</city><country>France</country><postal-code>59037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Léon Bérard</center><contact>Site Coordinator</contact><city>Lyon</city><country>France</country><postal-code>69373</postal-code><status>Recruiting</status></trial-site><trial-site><center>L'Institut Paoli - Calmettes</center><contact>Site Coordinator</contact><city>Marguerittes</city><country>France</country><postal-code>13009</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital de la Conception</center><contact>Site Coordinator</contact><city>Marseille</city><country>France</country><postal-code>13385</postal-code><status>Recruiting</status></trial-site><trial-site><center>CHRU Montpellier - Saint Eloi</center><contact>Site Coordinator</contact><city>Montpellier</city><country>France</country><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Saint-Antoine</center><contact>Site Coordinator</contact><city>Paris</city><country>France</country><postal-code>75012</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Saint-Louis</center><contact>Site Coordinator</contact><city>Paris</city><country>France</country><postal-code>75475</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Haut-Lévêque</center><contact>Site Coordinator</contact><city>Pessac</city><country>France</country><postal-code>33604</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier Lyon-Sud</center><contact>Site Coordinator</contact><city>Pierre Benite</city><country>France</country><postal-code>69495</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Henri Becquerel - Centre de Lutte Contre le Cancer</center><contact>Site Coordinator</contact><city>Rouen</city><country>France</country><postal-code>76038</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan</center><contact>Site Coordinator</contact><city>Toulouse</city><country>France</country><postal-code>31059</postal-code><status>Recruiting</status></trial-site><trial-site><center>HELIOS Klinikum Bad Saarow</center><contact>Site Coordinator</contact><city>Bad Saarow</city><country>Germany</country><postal-code>15526</postal-code><status>Recruiting</status></trial-site><trial-site><center>Charité - Universitätsmedizin Berlin</center><contact>Site Coordinator</contact><city>Berlin</city><country>Germany</country><postal-code>10117</postal-code><status>Recruiting</status></trial-site><trial-site><center>Städtisches Klinikum Braunschweig gGmbH</center><contact>Site Coordinator</contact><city>Braunschweig</city><country>Germany</country><postal-code>38114</postal-code><status>Recruiting</status></trial-site><trial-site><center>Marien Hospital Düsseldorf GmbH</center><contact>Site Coordinator</contact><city>Düsseldorf</city><country>Germany</country><postal-code>40479</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Essen</center><contact>Site Coordinator</contact><city>Essen</city><country>Germany</country><postal-code>45122</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Frankfurt</center><contact>Site Coordinator</contact><city>Frankfurt am Main</city><country>Germany</country><postal-code>60590</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Halle (Saale)</center><contact>Site Coordinator</contact><city>Halle</city><country>Germany</country><postal-code>6120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Hamburg-Eppendorf (UKE)</center><contact>Site Coordinator</contact><city>Hamburg</city><country>Germany</country><postal-code>22083</postal-code><status>Recruiting</status></trial-site><trial-site><center>Evangelisches Krankenhaus Hamm gGmbH</center><contact>Site Coordinator</contact><city>Hamm</city><country>Germany</country><postal-code>59063</postal-code><status>Recruiting</status></trial-site><trial-site><center>Medizinische Hochschule Hannover (MHH)</center><contact>Site Coordinator</contact><city>Hannöver</city><country>Germany</country><postal-code>30625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Münster</center><contact>Site Coordinator</contact><city>Heidelberg</city><country>Germany</country><postal-code>69115</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Tübingen</center><contact>Site Coordinator</contact><city>Heidelberg</city><country>Germany</country><postal-code>69115</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Heidelberg</center><contact>Site Coordinator</contact><city>Heidelberg</city><country>Germany</country><postal-code>69120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Marien Hospital Herne</center><contact>Site Coordinator</contact><city>Herne</city><country>Germany</country><postal-code>44625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Leipzig</center><contact>Site Coordinator</contact><city>Leipzig</city><country>Germany</country><postal-code>4103</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</center><contact>Site Coordinator</contact><city>Mainz</city><country>Germany</country><postal-code>55131</postal-code><status>Recruiting</status></trial-site><trial-site><center>Stauferklinikum Schwäbisch Gmünd</center><contact>Site Coordinator</contact><city>Mutlangen</city><country>Germany</country><postal-code>73557</postal-code><status>Recruiting</status></trial-site><trial-site><center>HELIOS Klinikum Wuppertal</center><contact>Site Coordinator</contact><city>Wuppertal</city><country>Germany</country><postal-code>42283</postal-code><status>Recruiting</status></trial-site><trial-site><center>Prince of Wales Hospital</center><contact>Site Coordinator</contact><city>Hong Kong</city><country>Hong Kong</country><status>Recruiting</status></trial-site><trial-site><center>Queen Mary Hospital</center><contact>Site Coordinator</contact><city>Hong Kong</city><country>Hong Kong</country><status>Recruiting</status></trial-site><trial-site><center>Markusovszky Egyetemi Oktatókórház</center><contact>Site Coordinator</contact><city>Budapest</city><country>Hungary</country><postal-code>1051</postal-code><status>Recruiting</status></trial-site><trial-site><center>Szegedi Tudományegyetem</center><contact>Site Coordinator</contact><city>Budapest</city><country>Hungary</country><postal-code>1051</postal-code><status>Recruiting</status></trial-site><trial-site><center>Semmelweis Egyetem</center><contact>Site Coordinator</contact><city>Budapest</city><country>Hungary</country><postal-code>1083</postal-code><status>Recruiting</status></trial-site><trial-site><center>Debreceni Egyetem Klinikai Központ</center><contact>Site Coordinator</contact><city>Debrecen</city><country>Hungary</country><postal-code>4032</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pecsi Tudomanyegyetem Klinikai Központ</center><contact>Site Coordinator</contact><city>Pécs</city><country>Hungary</country><postal-code>7624</postal-code><status>Recruiting</status></trial-site><trial-site><center>Markusovszky Egyetemi Oktatókórház Belgyógyászati és Onkohaematológiai Centrum</center><contact>Site Coordinator</contact><city>Szombathely</city><country>Hungary</country><postal-code>9700</postal-code><status>Recruiting</status></trial-site><trial-site><center>Assaf Harofeh Medical Center</center><contact>Site Coordinator</contact><city>Be'er Ya'aqov</city><state>Tsifrin</state><country>Israel</country><postal-code>70300</postal-code><status>Recruiting</status></trial-site><trial-site><center>Bnai Zion Medical Center</center><contact>Site Coordinator</contact><city>Haifa</city><country>Israel</country><postal-code>31048</postal-code><status>Recruiting</status></trial-site><trial-site><center>Rambam Medical Center</center><contact>Site Coordinator</contact><city>Haifa</city><country>Israel</country><postal-code>31096</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hadassah University Medical Center</center><contact>Site Coordinator</contact><city>Jerusalem</city><country>Israel</country><postal-code>91120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Rabin Medical Center - Beilinson Hospital</center><contact>Site Coordinator</contact><city>Petaẖ Tiqwa</city><country>Israel</country><postal-code>49100</postal-code><status>Recruiting</status></trial-site><trial-site><center>The Chaim Sheba Medical Center</center><contact>Site Coordinator</contact><city>Ramat-Gan</city><country>Israel</country><postal-code>52621</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tel Aviv Sourasky Medical Center</center><contact>Site Coordinator</contact><city>Tel Aviv</city><country>Israel</country><postal-code>64239</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Nazionale SS.Antonio e Biagio e Cesare Arrigo</center><contact>Site Coordinator</contact><city>Alessandria</city><country>Italy</country><postal-code>15121</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi</center><contact>Site Coordinator</contact><city>Bologna</city><country>Italy</country><postal-code>40138</postal-code><status>Recruiting</status></trial-site><trial-site><center>AO Brotzu - Ospedale Oncologico "Businco"</center><contact>Site Coordinator</contact><city>Cagliari</city><country>Italy</country><postal-code>9121</postal-code><status>Recruiting</status></trial-site><trial-site><center>IRCCS AOU San Martino - IST</center><contact>Site Coordinator</contact><city>Genova</city><country>Italy</country><postal-code>16132</postal-code><status>Recruiting</status></trial-site><trial-site><center>ASST Grande Ospedale Metropolitano Niguarda</center><contact>Site Coordinator</contact><city>Milano</city><country>Italy</country><postal-code>20162</postal-code><status>Recruiting</status></trial-site><trial-site><center>A.O.R.N. "A. Cardarelli"</center><contact>Site Coordinator</contact><city>Napoli</city><country>Italy</country><postal-code>80131</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero Universitaria Maggiore della Carità di Novara</center><contact>Site Coordinator</contact><city>Novara</city><country>Italy</country><postal-code>28100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero - Universitaria San Luigi Gonzaga</center><contact>Site Coordinator</contact><city>Orbassano (TO)</city><country>Italy</country><postal-code>10043</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello</center><contact>Site Coordinator</contact><city>Palermo</city><country>Italy</country><postal-code>90146</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fondazione Policlinico Universitario Agostino Gemelli</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>133</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ospedale S. Eugenio</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>133</postal-code><status>Recruiting</status></trial-site><trial-site><center>Policlinico Tor Vergata</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>133</postal-code><status>Recruiting</status></trial-site><trial-site><center>IRCCS Ospedale San Raffaele</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>20132</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero-Universitaria Careggi</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>50134</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>56126</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Universitaria "Federico II"</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>80131</postal-code><status>Recruiting</status></trial-site><trial-site><center>Istituto Clinico Humanitas</center><contact>Site Coordinator</contact><city>Rozzano</city><country>Italy</country><postal-code>20089</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Universitaria Senese</center><contact>Site Coordinator</contact><city>Siena</city><country>Italy</country><postal-code>53100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino - Ospedale Molinette</center><contact>Site Coordinator</contact><city>Torino</city><country>Italy</country><postal-code>10126</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Ordine Mauriziano di Torino</center><contact>Site Coordinator</contact><city>Torino</city><country>Italy</country><postal-code>10128</postal-code><status>Recruiting</status></trial-site><trial-site><center>ASST dei Sette Laghi - Ospedale di Circolo e Fondazione Macchi Varese</center><contact>Site Coordinator</contact><city>Varese</city><country>Italy</country><postal-code>21100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Inje University Haeundae Paik Hospital</center><contact>Site Coordinator</contact><city>Busan</city><country>Korea, Republic of</country><postal-code>48108</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pusan National University Hospital</center><contact>Site Coordinator</contact><city>Busan</city><country>Korea, Republic of</country><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Kyungpook National University Hospital</center><contact>Site Coordinator</contact><city>Daegu</city><country>Korea, Republic of</country><postal-code>41944</postal-code><status>Recruiting</status></trial-site><trial-site><center>Yeungnam University Medical Center</center><contact>Site Coordinator</contact><city>Daegu</city><country>Korea, Republic of</country><postal-code>42415</postal-code><status>Recruiting</status></trial-site><trial-site><center>Daegu Catholic University Medical Center</center><contact>Site Coordinator</contact><city>Daegu</city><country>Korea, Republic of</country><postal-code>42472</postal-code><status>Recruiting</status></trial-site><trial-site><center>Chonnam National University Hwasun Hospital</center><contact>Site Coordinator</contact><city>Hwasun</city><country>Korea, Republic of</country><postal-code>58128</postal-code><status>Recruiting</status></trial-site><trial-site><center>Gachon University Gil Hospital</center><contact>Site Coordinator</contact><city>Incheon</city><country>Korea, Republic of</country><postal-code>21565</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Bundang Hospital</center><contact>Site Coordinator</contact><city>Seongnam-si</city><country>Korea, Republic of</country><postal-code>13620</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>3080</postal-code><status>Recruiting</status></trial-site><trial-site><center>Severance Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>3722</postal-code><status>Recruiting</status></trial-site><trial-site><center>SoonChunHyang University Seoul Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>4401</postal-code><status>Recruiting</status></trial-site><trial-site><center>Konkuk University Medical Center</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>5030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Asan Medical Center</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>5505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Samsung Medical Center</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>6351</postal-code><status>Recruiting</status></trial-site><trial-site><center>The Catholic University of Korea, Seoul St. Mary's Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>6591</postal-code><status>Recruiting</status></trial-site><trial-site><center>Korea University Guro Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>8308</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ajou University Hospital</center><contact>Site Coordinator</contact><city>Sŏwŏn</city><country>Korea, Republic of</country><postal-code>16499</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ulsan University Hospital (UUH)</center><contact>Site Coordinator</contact><city>Ulsan</city><country>Korea, Republic of</country><postal-code>44033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Szpital Uniwersytecki w Krakowie</center><contact>Site Coordinator</contact><city>Kraków</city><country>Poland</country><postal-code>31-501</postal-code><status>Recruiting</status></trial-site><trial-site><center>Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka</center><contact>Site Coordinator</contact><city>Słupsk</city><country>Poland</country><postal-code>76-200</postal-code><status>Recruiting</status></trial-site><trial-site><center>Instytut Hematologii i Transfuzjologi</center><contact>Site Coordinator</contact><city>Warszawa</city><country>Poland</country><postal-code>00-957</postal-code><status>Recruiting</status></trial-site><trial-site><center>Samodzielny Publiczny Szpital Kliniczny Nr. 1 we Wrocławiu</center><contact>Site Coordinator</contact><city>Warszawa</city><country>Poland</country><postal-code>50367</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centro Hospitalar e Universitário de Coimbra, EPE - Hospitais da Universidade de Coimbra</center><contact>Site Coordinator</contact><city>Coimbra</city><country>Portugal</country><postal-code>3000-075</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António</center><contact>Site Coordinator</contact><city>Porto</city><country>Portugal</country><postal-code>4099-001</postal-code><status>Recruiting</status></trial-site><trial-site><center>Instituto Português Oncologia do Porto Francisco Gentil, EPE</center><contact>Site Coordinator</contact><city>Porto</city><country>Portugal</country><postal-code>4200-072</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centro Hospitalar de São João, EPE - Hospital de São João</center><contact>Site Coordinator</contact><city>Porto</city><country>Portugal</country><postal-code>4200-319</postal-code><status>Recruiting</status></trial-site><trial-site><center>Institutul Regional de Oncologie Iași</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Clinic Colentina</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Clinic Coltea</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Universitar de Urgenta Bucuresti</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj Napoca</center><contact>Site Coordinator</contact><city>Cluj-Napoca</city><country>Romania</country><postal-code>400124</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Clinic Judetean de Urgenta Tîrgu - Mures</center><contact>Site Coordinator</contact><city>Târgu-Mureş</city><country>Romania</country><postal-code>540042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Penza Regional Oncology Dispensary</center><contact>Site Coordinator</contact><city>Penza</city><country>Russian Federation</country><postal-code>440071</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ryazan Regional Clinical Hospital</center><contact>Site Coordinator</contact><city>Ryazan'</city><country>Russian Federation</country><postal-code>390039</postal-code><status>Recruiting</status></trial-site><trial-site><center>Saratov State Medical University named after V.I. Razumovsky</center><contact>Site Coordinator</contact><city>Saratov</city><country>Russian Federation</country><postal-code>410012</postal-code><status>Recruiting</status></trial-site><trial-site><center>Russian Research Institute of Hematology and Blood Transfusion</center><contact>Site Coordinator</contact><city>St. Petersburg</city><country>Russian Federation</country><postal-code>191024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Leningrad Regional Clinic and Hospital</center><contact>Site Coordinator</contact><city>St. Petersburg</city><country>Russian Federation</country><postal-code>194291</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tula Regional Clinical Hospital</center><contact>Site Coordinator</contact><city>Tula</city><country>Russian Federation</country><postal-code>300053</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Centar Srbije</center><contact>Site Coordinator</contact><city>Belgrade</city><country>Serbia</country><postal-code>11000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Centar Niš</center><contact>Site Coordinator</contact><city>Nis</city><country>Serbia</country><postal-code>18000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Centar Vojvodine</center><contact>Site Coordinator</contact><city>Novi Sad</city><country>Serbia</country><postal-code>21101</postal-code><status>Recruiting</status></trial-site><trial-site><center>National University Hospital (S) Pte Ltd</center><contact>Site Coordinator</contact><city>Singapore</city><country>Singapore</country><postal-code>119074</postal-code><status>Recruiting</status></trial-site><trial-site><center>Singapore General Hospital</center><contact>Site Coordinator</contact><city>Singapore</city><country>Singapore</country><postal-code>138543</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari Son Espases</center><contact>Site Coordinator</contact><city>Palma</city><state>Mallorca</state><country>Spain</country><postal-code>7014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario de Alicante</center><contact>Site Coordinator</contact><city>Alicante</city><country>Spain</country><postal-code>3010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Catalan Institute of Oncology (ICO)</center><contact>Site Coordinator</contact><city>Badalona</city><country>Spain</country><postal-code>8916</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital del Mar</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Vall d'Hebron</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clinic i Provincial</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Duran i Reynals</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8907</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital de Basurto</center><contact>Site Coordinator</contact><city>Bilbao</city><country>Spain</country><postal-code>48013</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital San Pedro de Alcántara</center><contact>Site Coordinator</contact><city>Cáceres</city><country>Spain</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Reina Sofía</center><contact>Site Coordinator</contact><city>Córdoba</city><country>Spain</country><postal-code>14004</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari de Girona Doctor Josep Trueta</center><city>Girona</city><country>Spain</country><postal-code>17007</postal-code><status>Enrolling by invitation</status></trial-site><trial-site><center>Complejo Hospitalario Universitario Granada</center><contact>Site Coordinator</contact><city>Granada</city><country>Spain</country><postal-code>18014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario Gregorio Marañón</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28007</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Ramón y Cajal</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28034</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clínico San Carlos</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28040</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario 12 de Octubre</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28041</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Quirón Madrid</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28223</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Puerta de Hierro - Majadahonda</center><contact>Site Coordinator</contact><city>Majadahonda</city><country>Spain</country><postal-code>28222</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Regional Universitario de Málaga - Hospital General</center><contact>Site Coordinator</contact><city>Málaga</city><country>Spain</country><postal-code>29010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Central de Asturias</center><contact>Site Coordinator</contact><city>Oviedo</city><country>Spain</country><postal-code>33011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Complejo Hospitalario de Navarra</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fundación Jiménez Díaz</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clínico Universitario "Lozano Blesa"</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario Morales Meseguer</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Miguel Servet</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Álvaro Cunqueiro</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hosp Universitario Salamanca</center><contact>Site Coordinator</contact><city>Salamanca</city><country>Spain</country><postal-code>37007</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Marqués de Valdecilla</center><contact>Site Coordinator</contact><city>Santander</city><country>Spain</country><postal-code>39008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario</center><contact>Site Coordinator</contact><city>Santiago de Compostela</city><country>Spain</country><postal-code>15706</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Virgen del Rocío (2)</center><contact>Site Coordinator</contact><city>Sevilla</city><country>Spain</country><postal-code>41013</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Virgen del Rocío</center><contact>Site Coordinator</contact><city>Sevilla</city><country>Spain</country><postal-code>41013</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari Joan XXIII de Tarragona</center><contact>Site Coordinator</contact><city>Tarragona</city><country>Spain</country><postal-code>43005</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clinico Universitario de Valencia</center><contact>Site Coordinator</contact><city>Valencia</city><country>Spain</country><postal-code>46010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Dr. Peset</center><contact>Site Coordinator</contact><city>Valencia</city><country>Spain</country><postal-code>46017</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari i Politècnic La Fe</center><contact>Site Coordinator</contact><city>Valencia</city><country>Spain</country><postal-code>CP 46026</postal-code><status>Recruiting</status></trial-site><trial-site><center>Chang Gung Medical Foundation - Kaohsiung Branch</center><contact>Site Coordinator</contact><city>Kaohsiung</city><state>Niaosong District</state><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>China Medical University Hospital</center><contact>Site Coordinator</contact><city>Taichung</city><country>Taiwan</country><postal-code>40447</postal-code><status>Recruiting</status></trial-site><trial-site><center>National Cheng Kung University Hospital</center><contact>Site Coordinator</contact><city>Tainan</city><country>Taiwan</country><postal-code>704</postal-code><status>Recruiting</status></trial-site><trial-site><center>National Taiwan University Hospital</center><contact>Site Coordinator</contact><city>Taipei</city><country>Taiwan</country><postal-code>100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Taipei Veterans General Hospital</center><contact>Site Coordinator</contact><city>Taipei</city><country>Taiwan</country><postal-code>11217</postal-code><status>Recruiting</status></trial-site><trial-site><center>Chang Gung Medical Foundation - Linkou Branch</center><contact>Site Coordinator</contact><city>Taoyuan</city><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Poltava Regional Clinical Hospital named after M. V. Sklifosovskoho</center><contact>Site Coordinator</contact><city>Poltava</city><country>Ukraine</country><postal-code>36011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vinnitsa Regional Clinical Hospital im. N.I. Pirogov</center><contact>Site Coordinator</contact><city>Vinnytsia</city><country>Ukraine</country><postal-code>21018</postal-code><status>Recruiting</status></trial-site><trial-site><center>Zhitomir Regional Clinical Hospital</center><contact>Site Coordinator</contact><city>Zhytomyr</city><country>Ukraine</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>East Kent Hospitals University NHS Foundation Trust - Kent and Canterbury Hospital</center><contact>Site Coordinator</contact><city>Canterbury</city><country>United Kingdom</country><postal-code>CT1 3NG</postal-code><status>Recruiting</status></trial-site><trial-site><center>Maidstone and Tunbridge Wells NHS Trust - Maidstone Hospital</center><contact>Site Coordinator</contact><city>Maidstone</city><country>United Kingdom</country><postal-code>ME16 9QQ</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02421939</trial-id><title>A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation</title><phase>Phase 3</phase><targets><target>ALK</target><target>AXL</target><target>DNMT</target><target>FLT3</target><target>TOP2A</target></targets><overall-contact>Overall contact: Astellas Pharma Global Development, Astellas.registration@astellas.com, 800-888-7704 x5473</overall-contact><markers><marker>FLT3</marker></markers><trial-sites><trial-site><center>Site US10011</center><city>Birmingham</city><state>Alabama</state><country>United States</country><postal-code>35294-0006</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10012</center><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095-1752</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10076</center><city>Orange</city><state>California</state><country>United States</country><postal-code>92868</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10073</center><city>San Francisco</city><state>California</state><country>United States</country><postal-code>94143</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10067</center><city>New Haven</city><state>Connecticut</state><country>United States</country><postal-code>06504</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10045</center><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>32610</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10081</center><city>Atlanta</city><state>Georgia</state><country>United States</country><postal-code>30342</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10006</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10086</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10083</center><city>Evanston</city><state>Illinois</state><country>United States</country><postal-code>60201</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10033</center><city>Maywood</city><state>Illinois</state><country>United States</country><postal-code>60153</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10075</center><city>Westwood</city><state>Kansas</state><country>United States</country><postal-code>66205</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10074</center><city>Louisville</city><state>Kentucky</state><country>United States</country><postal-code>40202</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10048</center><city>New Orleans</city><state>Louisiana</state><country>United States</country><postal-code>70112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10005</center><city>Baltimore</city><state>Maryland</state><country>United States</country><postal-code>21201</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10034</center><city>Boston</city><state>Massachusetts</state><country>United States</country><postal-code>02114</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10022</center><city>Boston</city><state>Massachusetts</state><country>United States</country><postal-code>02215</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10085</center><city>Boston</city><state>Massachusetts</state><country>United States</country><postal-code>02215</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10054</center><city>Worcester</city><state>Massachusetts</state><country>United States</country><postal-code>01655</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10087</center><city>Detroit</city><state>Michigan</state><country>United States</country><postal-code>48201</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10057</center><city>Minneapolis</city><state>Minnesota</state><country>United States</country><postal-code>55455</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10023</center><city>Lebanon</city><state>New Hampshire</state><country>United States</country><postal-code>03756-1000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10027</center><city>Hackensack</city><state>New Jersey</state><country>United States</country><postal-code>07601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10077</center><city>New Brunswick</city><state>New Jersey</state><country>United States</country><postal-code>08903</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10001</center><city>Buffalo</city><state>New York</state><country>United States</country><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10037</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10029</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10008</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10032</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10013</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10072</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10079</center><city>Stony Brook</city><state>New York</state><country>United States</country><postal-code>11794</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10046</center><city>Syracuse</city><state>New York</state><country>United States</country><postal-code>13210</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10024</center><city>Durham</city><state>North Carolina</state><country>United States</country><postal-code>27710</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10078</center><city>Winston-Salem</city><state>North Carolina</state><country>United States</country><postal-code>27157</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10044</center><city>Cleveland</city><state>Ohio</state><country>United States</country><postal-code>44106</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10084</center><city>Columbus</city><state>Ohio</state><country>United States</country><postal-code>43210</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10058</center><city>Oklahoma City</city><state>Oklahoma</state><country>United States</country><postal-code>73104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10041</center><city>Hershey</city><state>Pennsylvania</state><country>United States</country><postal-code>17033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10010</center><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><postal-code>19104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10080</center><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><postal-code>19107</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10014</center><city>Charleston</city><state>South Carolina</state><country>United States</country><postal-code>29425</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10063</center><city>Nashville</city><state>Tennessee</state><country>United States</country><postal-code>37232-0656</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10007</center><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10035</center><city>Milwaukee</city><state>Wisconsin</state><country>United States</country><postal-code>53226</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32008</center><city>Bruxelles</city><state>Bruxelles-Capitale, Region de</state><country>Belgium</country><postal-code>1000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32010</center><city>Antwerp</city><country>Belgium</country><postal-code>2060</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32001</center><city>Brugge</city><country>Belgium</country><postal-code>8000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32002</center><city>Yvoir</city><country>Belgium</country><postal-code>5530</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15004</center><city>Edmonton</city><state>Alberta</state><country>Canada</country><postal-code>T6G 2G3</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15001</center><city>Hamilton</city><state>Ontario</state><country>Canada</country><postal-code>L8V 1C3</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15015</center><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 2M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15003</center><city>Montreal</city><state>Quebec</state><country>Canada</country><postal-code>H1T 2M4</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15016</center><city>Montreal</city><state>Quebec</state><country>Canada</country><postal-code>H3H 2R9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33011</center><city>Angers</city><country>France</country><postal-code>49000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33013</center><city>Brest</city><country>France</country><postal-code>29609</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33002</center><city>Le Chesnay Cedex</city><country>France</country><postal-code>78157</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33010</center><city>Lille</city><country>France</country><postal-code>59037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33009</center><city>Pessac</city><country>France</country><postal-code>33604</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33014</center><city>Rennes</city><country>France</country><postal-code>35033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33008</center><city>Toulouse</city><country>France</country><postal-code>31059</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49009</center><city>Dresden</city><country>Germany</country><postal-code>01307</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49011</center><city>Leipzig</city><country>Germany</country><postal-code>04103</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49003</center><city>Marburg</city><country>Germany</country><postal-code>35043</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49002</center><city>Munchen</city><country>Germany</country><postal-code>81737</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49010</center><city>Tubingen</city><country>Germany</country><postal-code>72076</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49004</center><city>Wurzburg</city><country>Germany</country><postal-code>97070</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IE35304</center><city>Dublin</city><country>Ireland</country><postal-code>9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IL97201</center><city>Ashkelon</city><country>Israel</country><postal-code>78278</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IL97209</center><city>Haifa</city><country>Israel</country><postal-code>31096</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IL97203</center><city>Jerusalem</city><country>Israel</country><postal-code>91031</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IL97210</center><city>Jerusalem</city><country>Israel</country><postal-code>91120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IL97206</center><city>Petah Tikva</city><country>Israel</country><postal-code>49100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IL97208</center><city>Rehovot</city><country>Israel</country><postal-code>76100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39005</center><city>Bologna</city><country>Italy</country><postal-code>40138</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39010</center><city>Brescia</city><country>Italy</country><postal-code>25126</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39001</center><city>Milan</city><country>Italy</country><postal-code>20132</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39004</center><city>Palermo</city><country>Italy</country><postal-code>90146</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39007</center><city>Roma</city><country>Italy</country><postal-code>00189</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39002</center><city>Varese</city><country>Italy</country><postal-code>21100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81012</center><city>Sendai-shi</city><state>Miyagi</state><country>Japan</country><postal-code>983-8520</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81011</center><city>Miyakojima-ku</city><state>Osaka</state><country>Japan</country><postal-code>534-0021</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81004</center><city>Shinagawa-ku</city><state>Tokyo</state><country>Japan</country><postal-code>141-8625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81023</center><city>Akita</city><country>Japan</country><postal-code>010-8543</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81021</center><city>Aomori-city</city><country>Japan</country><postal-code>030-8553</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81026</center><city>Fukui</city><country>Japan</country><postal-code>910-1193</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81001</center><city>Fukuoka</city><country>Japan</country><postal-code>812-0054</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81003</center><city>Gunma</city><country>Japan</country><postal-code>371-0821</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81009</center><city>Isehara</city><country>Japan</country><postal-code>259-1193</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81020</center><city>Kawagoe</city><country>Japan</country><postal-code>3508550</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81018</center><city>Kobe</city><country>Japan</country><postal-code>650-0047</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81013</center><city>Kumamoto</city><country>Japan</country><postal-code>860-0008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81007</center><city>Kurashiki</city><country>Japan</country><postal-code>710-8602</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81025</center><city>Kyoto-city</city><country>Japan</country><postal-code>602-8566</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81008</center><city>Nagasaki</city><country>Japan</country><postal-code>852-8501</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81002</center><city>Nagoya</city><country>Japan</country><postal-code>460-0001</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81010</center><city>Narita</city><country>Japan</country><postal-code>286-8523</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81024</center><city>Okayama</city><country>Japan</country><postal-code>7008558</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81014</center><city>Osaka</city><country>Japan</country><postal-code>589-8511</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81016</center><city>Sapporo</city><country>Japan</country><postal-code>060-8648</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81027</center><city>Shimotsuke</city><country>Japan</country><postal-code>323-0112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81022</center><city>Shinjuku-ku</city><country>Japan</country><postal-code>160-8582</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81005</center><city>Tokyo</city><country>Japan</country><postal-code>104-0045</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81017</center><city>Tsukuba</city><country>Japan</country><postal-code>305-8576</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81006</center><city>Yokohama</city><country>Japan</country><postal-code>232-0024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82005</center><city>Suwon-si</city><state>Gyeonggi-do</state><country>Korea, Republic of</country><postal-code>443380</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82010</center><city>Busan</city><country>Korea, Republic of</country><postal-code>602739</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82009</center><city>Goyang</city><country>Korea, Republic of</country><postal-code>602-715</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82003</center><city>Jellanam - do</city><country>Korea, Republic of</country><postal-code>519-809</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82007</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>110-744</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82004</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>120-752</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82001</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>135710</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82002</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>137701</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82008</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>138-736</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82011</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>156-707</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48002</center><city>Gdansk</city><country>Poland</country><postal-code>80-952</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48005</center><city>Opole</city><country>Poland</country><postal-code>45-372</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48003</center><city>Slupsk</city><country>Poland</country><postal-code>76-200</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48004</center><city>Wroclaw</city><country>Poland</country><postal-code>50-367</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34009</center><city>Badalona</city><country>Spain</country><postal-code>08025</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34011</center><city>Barcelona</city><country>Spain</country><postal-code>08035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34012</center><city>Barcelona</city><country>Spain</country><postal-code>08036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34010</center><city>Barcelona</city><country>Spain</country><postal-code>08916</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34016</center><city>Girona</city><country>Spain</country><postal-code>17007</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34005</center><city>L'Hospitalet de Llobregat</city><country>Spain</country><postal-code>08907</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34015</center><city>Madrid</city><country>Spain</country><postal-code>28006</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34014</center><city>Salamanca</city><country>Spain</country><postal-code>37007</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34017</center><city>Valencia</city><country>Spain</country><postal-code>46026</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88606</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88604</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88609</center><city>Taichung City</city><country>Taiwan</country><postal-code>40705</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88608</center><city>Taichung</city><country>Taiwan</country><postal-code>404</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88601</center><city>Tainan</city><country>Taiwan</country><postal-code>704</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88603</center><city>Taipei</city><country>Taiwan</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88610</center><city>Taipei</city><country>Taiwan</country><postal-code>10449</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88611</center><city>Taipei</city><country>Taiwan</country><postal-code>112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88602</center><city>Taipei</city><country>Taiwan</country><postal-code>114</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88605</center><city>Taoyuan County</city><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90001</center><city>Ankara</city><country>Turkey</country><postal-code>06100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90004</center><city>Ankara</city><country>Turkey</country><postal-code>06500</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90008</center><city>Izmir</city><country>Turkey</country><postal-code>35340</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44014</center><city>Bournemouth</city><country>United Kingdom</country><postal-code>BH7 7DW</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44013</center><city>Harrow</city><country>United Kingdom</country><postal-code>HA1 3UJ</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44003</center><city>Manchester</city><country>United Kingdom</country><postal-code>M13 9WL</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44015</center><city>Plymouth</city><country>United Kingdom</country><postal-code>PL6 8DH</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02927262</trial-id><title>A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission</title><phase>Phase 3</phase><targets><target>ALK</target><target>AXL</target><target>FLT3</target></targets><overall-contact>Overall contact: Astellas Pharma Global Development, astellas.registration@astellas.com, 800-888-7704 x5473</overall-contact><markers><marker>FLT3</marker></markers><trial-sites><trial-site><center>Site US10013</center><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10023</center><city>Whittier</city><state>California</state><country>United States</country><postal-code>90603</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10017</center><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>32610-0278</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10030</center><city>Jacksonville</city><state>Florida</state><country>United States</country><postal-code>32204</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10019</center><city>Augusta</city><state>Georgia</state><country>United States</country><postal-code>30912</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10012</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10015</center><city>Louisville</city><state>Kentucky</state><country>United States</country><postal-code>40207</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10026</center><city>Boston</city><state>Massachusetts</state><country>United States</country><postal-code>02111</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10004</center><city>Detroit</city><state>Michigan</state><country>United States</country><postal-code>48202</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10024</center><city>Hawthorne</city><state>New York</state><country>United States</country><postal-code>10532</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10018</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10016</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10028</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10021</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10025</center><city>Syracuse</city><state>New York</state><country>United States</country><postal-code>13210</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10002</center><city>Durham</city><state>North Carolina</state><country>United States</country><postal-code>27705</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10022</center><city>Canton</city><state>Ohio</state><country>United States</country><postal-code>44718</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10007</center><city>Portland</city><state>Oregon</state><country>United States</country><postal-code>97239</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10020</center><city>Charleston</city><state>South Carolina</state><country>United States</country><postal-code>29425</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10029</center><city>Greenville</city><state>South Carolina</state><country>United States</country><postal-code>26615</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10009</center><city>Fairfax</city><state>Virginia</state><country>United States</country><postal-code>22031</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10031</center><city>Seattle</city><state>Washington</state><country>United States</country><postal-code>98104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61006</center><city>Liverpool</city><state>New South Wales</state><country>Australia</country><postal-code>2170</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61002</center><city>Southport</city><state>Queensland</state><country>Australia</country><postal-code>4215</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61005</center><city>Geelong</city><state>Victoria</state><country>Australia</country><postal-code>3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15001</center><city>Halifax</city><state>Nova Scotia</state><country>Canada</country><postal-code>B3H2Y9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15003</center><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 2M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15005</center><city>Montreal</city><state>Quebec</state><country>Canada</country><postal-code>H4A 3J1</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15004</center><city>Regina</city><state>Saskatchewan</state><country>Canada</country><postal-code>S4T 7T1</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site HR38501</center><city>Zagreb</city><state>Grad Zagreb</state><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DK45002</center><city>Arhus</city><state>Region Midtjylland</state><country>Denmark</country><postal-code>DK 8000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DK45003</center><city>Odense</city><state>Region Syddanmark</state><country>Denmark</country><postal-code>5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33016</center><city>Aix-en-Provence cedex</city><state>Bouches-du-Rhone</state><country>France</country><postal-code>13616</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33004</center><city>Brest</city><state>Finistere</state><country>France</country><postal-code>29609</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33003</center><city>Toulouse Cedex 9</city><state>Haute-Garonne</state><country>France</country><postal-code>31059</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33002</center><city>Tours cedex 01</city><state>Indre-et-Loire</state><country>France</country><postal-code>37044</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33010</center><city>Perpignan</city><state>Languedoc-Roussillon</state><country>France</country><postal-code>66046</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33014</center><city>Vandoeuvre les Nancy</city><state>Meurthe-et-Moselle</state><country>France</country><postal-code>54511</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33017</center><city>Avignon</city><state>Provence-Alpes-Cote-d'Azur</state><country>France</country><postal-code>84902</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33007</center><city>Pierre-Benite</city><state>Rhone</state><country>France</country><postal-code>69310</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33006</center><city>Meaux</city><state>Seine-et-Marne</state><country>France</country><postal-code>77100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33018</center><city>Argenteuil</city><state>Val-d'Oise</state><country>France</country><postal-code>95107</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33001</center><city>Bayonne</city><country>France</country><postal-code>64100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33009</center><city>Mulhouse</city><country>France</country><postal-code>68070</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33008</center><city>Nice Cedex 2</city><country>France</country><postal-code>06189</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33013</center><city>Strasbourg</city><country>France</country><postal-code>67000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49009</center><city>Rostock</city><state>Mecklenburg-Vorpommern</state><country>Germany</country><postal-code>18057</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49001</center><city>Duisburg</city><state>Nordrhein-Westfalen</state><country>Germany</country><postal-code>47166</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49005</center><city>Greifswald</city><country>Germany</country><postal-code>17475</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49008</center><city>Stuttgart</city><country>Germany</country><postal-code>70376</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GR30010</center><city>Athens</city><state>Attiki</state><country>Greece</country><postal-code>10676</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GR30002</center><city>Alexandroupolis</city><state>Evros</state><country>Greece</country><postal-code>68100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GR30004</center><city>Thessaloniki</city><state>Kentriki Makedonia</state><country>Greece</country><postal-code>57010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site HU36006</center><city>Szeged</city><state>Csongrad</state><country>Hungary</country><postal-code>H-6725</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site HU36003</center><city>Nyiregyhaza</city><state>Szabolcs-Szatmar-Bereg</state><country>Hungary</country><postal-code>H-4400</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site HU36001</center><city>Budapest</city><country>Hungary</country><postal-code>H 1083</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site HU36004</center><city>Debrecen</city><country>Hungary</country><postal-code>H-4032</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site HU36007</center><city>Pecs</city><country>Hungary</country><postal-code>H-7624</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39004</center><city>Castelfranco Veneto (TV)</city><state>Treviso</state><country>Italy</country><postal-code>31033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39007</center><city>Mirano</city><state>Venezia</state><country>Italy</country><postal-code>30035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39008</center><city>Bergamo</city><country>Italy</country><postal-code>24127</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site IT39009</center><city>Catania</city><country>Italy</country><postal-code>95124</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81018</center><city>Nagoya</city><state>Aiti</state><country>Japan</country><postal-code>453-8511</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81025</center><city>Matsuyama</city><state>Ehime</state><country>Japan</country><postal-code>790-0024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81007</center><city>Maebashi</city><state>Gunma</state><country>Japan</country><postal-code>371-0821</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81024</center><city>Sapporo</city><state>Hokkaido</state><country>Japan</country><postal-code>003-0006</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81022</center><city>Sapporo</city><state>Hokkaido</state><country>Japan</country><postal-code>060-8648</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81012</center><city>Kobe</city><state>Hyogo</state><country>Japan</country><postal-code>650-0047</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81004</center><city>Kanazawa</city><state>Isikawa</state><country>Japan</country><postal-code>920-8530</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81003</center><city>Isehara</city><state>Kanagawa</state><country>Japan</country><postal-code>259-1193</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81009</center><city>Yokohama</city><state>Kanagawa</state><country>Japan</country><postal-code>232-0024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81014</center><city>Sendai-shi</city><state>Miyagi</state><country>Japan</country><postal-code>983 8520</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81013</center><city>Kurashiki</city><state>Okayama</state><country>Japan</country><postal-code>710-8602</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81005</center><city>Narita</city><state>Tiba</state><country>Japan</country><postal-code>286-8523</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81008</center><city>Shinagawa-ku</city><state>Tokyo</state><country>Japan</country><postal-code>141-8625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81011</center><city>Tachikawa</city><state>Tokyo</state><country>Japan</country><postal-code>190-0014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81021</center><city>Akita</city><country>Japan</country><postal-code>010-8543</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81010</center><city>Aomori-city</city><country>Japan</country><postal-code>030-8553</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81002</center><city>Fukui</city><country>Japan</country><postal-code>910-1193</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81020</center><city>Fukuoka</city><country>Japan</country><postal-code>812-8582</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81015</center><city>Kyoto</city><country>Japan</country><postal-code>602 8566</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81001</center><city>Nagano</city><country>Japan</country><postal-code>380-8582</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81016</center><city>Nagasaki</city><country>Japan</country><postal-code>8528102</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81006</center><city>Nagoya</city><country>Japan</country><postal-code>460-0001</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81017</center><city>Okayama</city><country>Japan</country><postal-code>7008558</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81019</center><city>Osaka</city><country>Japan</country><postal-code>565-0871</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81023</center><city>Shimotsuke</city><country>Japan</country><postal-code>323-0112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82005</center><city>Suwon-si</city><state>Gyeonggi-do</state><country>Korea, Republic of</country><postal-code>16499</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82014</center><city>Bucheon-Si</city><state>Gyeonggido</state><country>Korea, Republic of</country><postal-code>14584</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82013</center><city>Goyang</city><state>Gyeonggido</state><country>Korea, Republic of</country><postal-code>10408</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82008</center><city>Namdong</city><state>Incheon Gwang'yeogsiv</state><country>Korea, Republic of</country><postal-code>405 760</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82003</center><city>Hwasungun</city><state>Jeonranamdo</state><country>Korea, Republic of</country><postal-code>58128</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82012</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>06351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82007</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>110-744</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82006</center><city>Busan</city><country>Korea, Republic of</country><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82004</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>05505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82002</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>06591</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82009</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>120-752</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82001</center><city>Ulsan</city><country>Korea, Republic of</country><postal-code>44033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48003</center><city>Warszawa</city><state>Mazowieckie</state><country>Poland</country><postal-code>02-106</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48001</center><city>Olsztyn</city><state>Warmińsko-mazurskie</state><country>Poland</country><postal-code>10-228</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48002</center><city>Bydgoszcz</city><country>Poland</country><postal-code>85-168</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PT35106</center><city>Coimbra</city><country>Portugal</country><postal-code>3000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PT35103</center><city>Lisboa</city><country>Portugal</country><postal-code>1169-050</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PT35101</center><city>Porto</city><country>Portugal</country><postal-code>4200-072</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site RS38101</center><city>Belgrade</city><country>Serbia</country><postal-code>11000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34009</center><city>Vitoria</city><state>Alava</state><country>Spain</country><postal-code>01009</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34001</center><city>L'Hospitalet de Llobregat</city><state>Barcelona</state><country>Spain</country><postal-code>08907</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34010</center><city>Pamplona</city><state>Navarra</state><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34003</center><city>Girona</city><country>Spain</country><postal-code>17007</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34008</center><city>Madrid</city><country>Spain</country><postal-code>28040</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34012</center><city>Sevilla</city><country>Spain</country><postal-code>41014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34006</center><city>Valladolid</city><country>Spain</country><postal-code>47005</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site SE46003</center><city>Stockholm</city><state>Stockholms lan</state><country>Sweden</country><postal-code>171 76</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88601</center><city>Kweishan Hsiang</city><state>Taoyuan</state><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88605</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88604</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88606</center><city>Taichung</city><country>Taiwan</country><postal-code>40705</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88602</center><city>Taipei</city><country>Taiwan</country><postal-code>10449</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88603</center><city>Taipei</city><country>Taiwan</country><postal-code>114</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90006</center><city>Ankara</city><country>Turkey</country><postal-code>06500</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90011</center><city>Aydin</city><country>Turkey</country><postal-code>09100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90005</center><city>Denizli</city><country>Turkey</country><postal-code>20070</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90003</center><city>Izmir</city><country>Turkey</country><postal-code>35340</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90001</center><city>Kayseri</city><country>Turkey</country><postal-code>38039</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TR90007</center><city>Samsun</city><country>Turkey</country><postal-code>55139</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44019</center><city>Plymouth</city><state>Devon</state><country>United Kingdom</country><postal-code>PL6 8DH</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44006</center><city>Cottingham</city><state>East Riding of Yorkshire</state><country>United Kingdom</country><postal-code>HU165JQ</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44018</center><city>London</city><state>London, City of</state><country>United Kingdom</country><postal-code>WC1E 6BT</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44002</center><city>Birmingham</city><country>United Kingdom</country><postal-code>B95SS</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44005</center><city>Bristol</city><country>United Kingdom</country><postal-code>BS2 8ED</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44015</center><city>Cardiff</city><country>United Kingdom</country><postal-code>CF4 4XN</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44020</center><city>Leeds</city><country>United Kingdom</country><postal-code>LS9 7TF</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial></clinical-trials><clinical-trials prioritized-by="clinically"><clinical-trial><trial-id>NCT02283177</trial-id><title>A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations</title><phase>Phase 2</phase><targets><target>FLT3</target><target>PDGFR</target></targets><overall-contact>Overall contact: Abhijit Ramachandran, aramachandran@arogpharma.com, 214-593-0515</overall-contact><markers><marker>FLT3</marker></markers><trial-sites><trial-site><center>City of Hope Medical Center</center><contact>Chatchada Karanes, MD</contact><city>Duarte</city><state>California</state><country>United States</country><email>ckaranes@coh.org</email><postal-code>91010</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Iowa Hospitals and Clinics</center><contact>Carlos Vigil, MD</contact><city>Iowa City</city><state>Iowa</state><country>United States</country><email>carlos-vigil@uiowa.edu</email><postal-code>52242</postal-code><status>Recruiting</status></trial-site><trial-site><center>Dana-Farber Cancer Institute</center><contact>Richard Stone, MD</contact><city>Boston</city><state>Massachusetts</state><country>United States</country><postal-code>02215</postal-code><status>Recruiting</status></trial-site><trial-site><center>Roswell Park Cancer Institute</center><contact>Eunice Wang, M.D.</contact><city>Buffalo</city><state>New York</state><country>United States</country><investigator>Eunice Wang, M.D.</investigator><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Memorial Sloan Kettering Cancer Center</center><contact>Martin Tallman, MD.</contact><city>New York</city><state>New York</state><country>United States</country><investigator>Faye Feller, M.D.</investigator><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Weill Cornell Medical College</center><contact>Gail Roboz, MD</contact><city>New York</city><state>New York</state><country>United States</country><email>gar2001@med.cornell.edu</email><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Cleveland Clinic</center><contact>Hetty Carraway, MD</contact><city>Cleveland</city><state>Ohio</state><country>United States</country><postal-code>44195</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Texas Southwestern Medical Center</center><contact>Robert Collins, MD</contact><city>Dallas</city><state>Texas</state><country>United States</country><email>robert.collins@utsouthwestern.edu</email><investigator>Robert Collins, MD</investigator><postal-code>75390</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fred Hutchinson Cancer Research Center</center><contact>Roland Walter, MD, PhD</contact><city>Seattle</city><state>Washington</state><country>United States</country><postal-code>98195</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02752035</trial-id><title>A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy</title><phase>Phase 2/Phase 3</phase><targets><target>ALK</target><target>AXL</target><target>DNMT</target><target>FLT3</target></targets><overall-contact>Overall contact: Astellas Pharma Global Development, astellas.registration@astellas.com, 800-888-7704 x5473</overall-contact><markers><marker>FLT3</marker><marker>TET2</marker></markers><trial-sites><trial-site><center>Site US10007</center><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10004</center><city>New Haven</city><state>Connecticut</state><country>United States</country><postal-code>06510-3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10006</center><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>32610-0278</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10036</center><city>Augusta</city><state>Georgia</state><country>United States</country><postal-code>30912</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10010</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60611-5975</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10037</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10003</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10023</center><city>Maywood</city><state>Illinois</state><country>United States</country><postal-code>60153</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10018</center><city>Louisville</city><state>Kentucky</state><country>United States</country><postal-code>40207</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10021</center><city>New Orleans</city><state>Louisiana</state><country>United States</country><postal-code>70112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10035</center><city>Brewer</city><state>Maine</state><country>United States</country><postal-code>04412</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10005</center><city>Hackensack</city><state>New Jersey</state><country>United States</country><postal-code>7601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10011</center><city>Morristown</city><state>New Jersey</state><country>United States</country><postal-code>07962</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10033</center><city>Buffalo</city><state>New York</state><country>United States</country><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10039</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10022</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10016</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10012</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10009</center><city>Syracuse</city><state>New York</state><country>United States</country><postal-code>13210</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10015</center><city>Oklahoma City</city><state>Oklahoma</state><country>United States</country><postal-code>73104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10031</center><city>Hershey</city><state>Pennsylvania</state><country>United States</country><postal-code>17033-0850</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10034</center><city>Greenville</city><state>South Carolina</state><country>United States</country><postal-code>26615</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10028</center><city>Dallas</city><state>Texas</state><country>United States</country><postal-code>75246</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10002</center><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10026</center><city>Seattle</city><state>Washington</state><country>United States</country><postal-code>98104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61012</center><city>Camperdown</city><state>New South Wales</state><country>Australia</country><postal-code>2050</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61004</center><city>Liverpool</city><state>New South Wales</state><country>Australia</country><postal-code>2170</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61008</center><city>Adelaide</city><state>South Australia</state><country>Australia</country><postal-code>SA 5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61007</center><city>Geelong</city><state>Victoria</state><country>Australia</country><postal-code>3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32003</center><city>Bruxelles</city><state>Bruxelles-Capitale, Region de</state><country>Belgium</country><postal-code>1200</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32007</center><city>Brussel</city><state>Bruxelles</state><country>Belgium</country><postal-code>1090</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32006</center><city>Gent</city><country>Belgium</country><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15009</center><city>Edmonton</city><state>Alberta</state><country>Canada</country><postal-code>T6G 2B7</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15004</center><city>Halifax</city><state>Nova Scotia</state><country>Canada</country><postal-code>B3H 2Y9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15002</center><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 2M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15006</center><city>Montreal</city><state>Quebec</state><country>Canada</country><postal-code>H4A 3J1</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33002</center><city>Pessac</city><state>Gironde</state><country>France</country><postal-code>33604</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33015</center><city>Rouen</city><state>Haute-Normandie</state><country>France</country><postal-code>76038</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33016</center><city>Limoges</city><state>Haute-Vienne</state><country>France</country><postal-code>87042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33019</center><city>Montpellier Cedex 5</city><state>Herault</state><country>France</country><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33018</center><city>Rennes</city><state>Ille-et-Vilaine</state><country>France</country><postal-code>35033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33001</center><city>Nantes cedex 01</city><state>Loire-Atlantique</state><country>France</country><postal-code>44093</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33014</center><city>Vandoeuvre les Nancy</city><state>Meurthe-et-Moselle</state><country>France</country><postal-code>54500</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33013</center><city>Pierre-Benite</city><state>Rhone</state><country>France</country><postal-code>69310</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33017</center><city>Le Mans</city><state>Sarthe</state><country>France</country><postal-code>72037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33005</center><city>Amiens</city><state>Somme</state><country>France</country><postal-code>80054</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33012</center><city>Poitiers</city><state>Vienne</state><country>France</country><postal-code>86000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33009</center><city>Angers</city><country>France</country><postal-code>49033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33007</center><city>Le Chesnay Cedex</city><country>France</country><postal-code>78157</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33004</center><city>Lille cedex</city><country>France</country><postal-code>59020</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33006</center><city>Lille</city><country>France</country><postal-code>59037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49002</center><city>Tuebingen</city><state>Baden-Wurttemberg</state><country>Germany</country><postal-code>72076</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49007</center><city>Munchen</city><state>Bayern</state><country>Germany</country><postal-code>81737</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49012</center><city>Braunschweig</city><state>Niedersachsen</state><country>Germany</country><postal-code>38118</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49004</center><city>Hannover</city><state>Niedersachsen</state><country>Germany</country><postal-code>30625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49008</center><city>Bonn</city><state>Nordrhein-Westfalen</state><country>Germany</country><postal-code>53105</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49009</center><city>Halle (Saale)</city><state>Sachsen-Anhalt</state><country>Germany</country><postal-code>06120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49013</center><city>Heilbronn</city><country>Germany</country><postal-code>74078</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49011</center><city>Stuttgart</city><country>Germany</country><postal-code>70376</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81027</center><city>Matsuyama</city><state>Ehime</state><country>Japan</country><postal-code>790-0024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81024</center><city>Gifu</city><state>Gihu</state><country>Japan</country><postal-code>500-8513</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81010</center><city>Maebashi</city><state>Gunma</state><country>Japan</country><postal-code>371-0821</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81006</center><city>Sapporo</city><state>Hokkaido</state><country>Japan</country><postal-code>060-8648</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81014</center><city>Shinagawa-ku</city><state>Tokyo</state><country>Japan</country><postal-code>141-8625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81022</center><city>Tachikawa</city><state>Tokyo</state><country>Japan</country><postal-code>190-0014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81017</center><city>Nagasaki</city><country>Japan</country><postal-code>852-8511</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81019</center><city>Toyama</city><country>Japan</country><postal-code>930-8550</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82003</center><city>Namdong</city><state>Incheon Gwang'yeogsiv</state><country>Korea, Republic of</country><postal-code>405 760</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82010</center><city>Hwasungun</city><state>Jeonranamdo</state><country>Korea, Republic of</country><postal-code>58128</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82013</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>05505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82008</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>06351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82006</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>110-744</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82002</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>137-701</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82001</center><city>Ulsan</city><state>Ulsan Gwang'yeogsi</state><country>Korea, Republic of</country><postal-code>682-714</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82014</center><city>Busan</city><country>Korea, Republic of</country><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82012</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>156-707</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48003</center><city>Lublin</city><state>Lubelskie</state><country>Poland</country><postal-code>20-081</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48005</center><city>Krakow</city><state>Małopolskie</state><country>Poland</country><postal-code>31-501</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48002</center><city>Opole</city><state>Opolskie</state><country>Poland</country><postal-code>45-061</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48001</center><city>Olsztyn</city><state>Warmińsko-mazurskie</state><country>Poland</country><postal-code>10-228</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34011</center><city>Coruna</city><state>A Coruna</state><country>Spain</country><postal-code>15006</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34003</center><city>Oviedo</city><state>Asturias</state><country>Spain</country><postal-code>33011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34007</center><city>Palma de Mallorca</city><state>Baleares</state><country>Spain</country><postal-code>07010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34008</center><city>Barcelona</city><country>Spain</country><postal-code>08003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34004</center><city>Barcelona</city><country>Spain</country><postal-code>08035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34010</center><city>Barcelona</city><country>Spain</country><postal-code>08036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34009</center><city>Barcelona</city><country>Spain</country><postal-code>8041</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34002</center><city>Caceres</city><country>Spain</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34005</center><city>Valencia</city><country>Spain</country><postal-code>46026</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88605</center><city>Kweishan Hsiang</city><state>Taoyuan</state><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88604</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88607</center><city>Taichung</city><country>Taiwan</country><postal-code>40705</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88602</center><city>Tainan</city><country>Taiwan</country><postal-code>704</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88609</center><city>Tainan</city><country>Taiwan</country><postal-code>736</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88601</center><city>Taipei</city><country>Taiwan</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88608</center><city>Taipei</city><country>Taiwan</country><postal-code>10449</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88610</center><city>Taipei</city><country>Taiwan</country><postal-code>11217</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44004</center><city>London</city><state>London, City of</state><country>United Kingdom</country><postal-code>EC1A 7BE</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02196857</trial-id><title>Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation</title><phase>Phase 2</phase><targets><target>BRAF</target><target>CSF1R</target><target>DNMT</target><target>FLT1</target><target>FLT3</target><target>FLT4</target><target>KIT</target><target>PDGFRB</target><target>RAF1</target><target>RET</target></targets><overall-contact>Overall contact: Farhad Ravandi-Kashani, MD, 713-792-7305</overall-contact><markers><marker>FLT3</marker><marker>TET2</marker></markers><trial-sites><trial-site><center>University of Texas MD Anderson Cancer Center</center><contact>MD Anderson Cancer Center</contact><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02400281</trial-id><title>Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients</title><phase>Phase 1/Phase 2</phase><targets><target>DNMT</target><target>FLT3</target><target>PDGFR</target><target>TOP2A</target></targets><overall-contact>Overall contact: Abhijit Ramachandran, aramachandran@arogpharma.com, 214-593-0515</overall-contact><markers><marker>FLT3</marker><marker>TET2</marker></markers><trial-sites><trial-site><center>MD Anderson Cancer Center</center><contact>Jorge Cortes, MD</contact><city>Houston</city><state>Texas</state><country>United States</country><email>jcortes@mdanderson.edu</email><postal-code>77030</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02668653</trial-id><title>Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)</title><phase>Phase 3</phase><targets><target>CSF1R</target><target>FLT3</target><target>KIT</target><target>PDGFR</target></targets><overall-contact>Overall contact: James J. Hanyok, PharmD, jhanyok@dsi.com, 732-590-4881</overall-contact><markers><marker>FLT3</marker></markers><trial-sites><trial-site><center>The University of Alabama at Birmingham</center><contact>Site Coordinator</contact><city>Birmingham</city><state>Alabama</state><country>United States</country><postal-code>35249</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Arizona Cancer Center</center><contact>Site Coordinator</contact><city>Tucson</city><state>Arizona</state><country>United States</country><postal-code>85724</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ronald Reagan UCLA Medical Center</center><contact>Site Coordinator</contact><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Florida (UF) Health Shands Hospital</center><contact>Site Coordinator</contact><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>90095-7170</postal-code><status>Recruiting</status></trial-site><trial-site><center>Rush University Medical Center</center><contact>Site Coordinator</contact><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Chicago Medical Center</center><contact>Site Coordinator</contact><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Franciscan St. Francis Health Indianapolis</center><contact>Site Coordinator</contact><city>Indianapolis</city><state>Indiana</state><country>United States</country><postal-code>46237</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Kentucky Chandler Medical Center</center><contact>Site Coordinator</contact><city>Lexington</city><state>Kentucky</state><country>United States</country><postal-code>40536-0293</postal-code><status>Recruiting</status></trial-site><trial-site><center>Louisiana State University Health Sciences Center Shreveport</center><contact>Site Coordinator</contact><city>Shreveport</city><state>Louisiana</state><country>United States</country><postal-code>71130</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hackensack Univ. Medical Center</center><contact>Site Coordinator</contact><city>Hackensack</city><state>New Jersey</state><country>United States</country><postal-code>07601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Duke Clinical Research Institute</center><contact>Site Coordinator</contact><city>Durham</city><state>North Carolina</state><country>United States</country><postal-code>27710</postal-code><status>Recruiting</status></trial-site><trial-site><center>University Hospitals Seidman Cancer Center</center><contact>Site Coordinator</contact><city>Cleveland</city><state>Ohio</state><country>United States</country><postal-code>44106</postal-code><status>Recruiting</status></trial-site><trial-site><center>Cleveland Clinic Foundation</center><contact>Site Coordinator</contact><city>Cleveland</city><state>Ohio</state><country>United States</country><postal-code>44195</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Oklahoma Medical Center</center><contact>Site Coordinator</contact><city>Oklahoma City</city><state>Oklahoma</state><country>United States</country><postal-code>73117</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital of the University of Pennsylvania</center><contact>Site Coordinator</contact><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><postal-code>19104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Thomas Jefferson University Hospital</center><contact>Site Coordinator</contact><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><postal-code>19107-4307</postal-code><status>Recruiting</status></trial-site><trial-site><center>John Theurer Cancer Center at Hackensack University Medical Center</center><contact>Site Coordinator</contact><city>Puyallup</city><state>Washington</state><country>United States</country><postal-code>98374-2115</postal-code><status>Recruiting</status></trial-site><trial-site><center>West Virginia University Hospitals, Inc.</center><contact>Site Coordinator</contact><city>Morgantown</city><state>West Virginia</state><country>United States</country><postal-code>26506</postal-code><status>Recruiting</status></trial-site><trial-site><center>Calvary Mater Newcastle</center><contact>Site Coordinator</contact><city>Waratah</city><state>New South Wales</state><country>Australia</country><postal-code>2298</postal-code><status>Recruiting</status></trial-site><trial-site><center>Townsville Hospital (TTH)</center><contact>Site Coordinator</contact><city>Douglas</city><state>Queensland</state><country>Australia</country><postal-code>4814</postal-code><status>Recruiting</status></trial-site><trial-site><center>Princess Alexandra Hospital</center><contact>Site Coordinator</contact><city>Woolloongabba</city><state>Queensland</state><country>Australia</country><postal-code>4102</postal-code><status>Recruiting</status></trial-site><trial-site><center>Royal Adelaide Hospital</center><contact>Site Coordinator</contact><city>Adelaide</city><state>South Australia</state><country>Australia</country><postal-code>5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Flinders Medical Centre</center><contact>Site Coordinator</contact><city>Bedford Park</city><state>South Australia</state><country>Australia</country><postal-code>5042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fiona Stanley Hospital</center><contact>Site Coordinator</contact><city>Murdoch</city><state>Western Australia</state><country>Australia</country><postal-code>6150</postal-code><status>Recruiting</status></trial-site><trial-site><center>AZ Sint-Jan Brugge-Oostende AV</center><contact>Site Coordinator</contact><city>Brugge</city><country>Belgium</country><postal-code>8000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitair Ziekenhuis Gent</center><contact>Site Coordinator</contact><city>Gent</city><country>Belgium</country><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>UCL Mont-Godinne</center><contact>Site Coordinator</contact><city>Yvoir</city><country>Belgium</country><postal-code>5530</postal-code><status>Recruiting</status></trial-site><trial-site><center>University Multiprofile Hospital for Active Treatment "Dr. G. Stranski" EAD</center><contact>Site Coordinator</contact><city>Pleven</city><country>Bulgaria</country><postal-code>5800</postal-code><status>Recruiting</status></trial-site><trial-site><center>University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD</center><contact>Site Coordinator</contact><city>Sofia</city><country>Bulgaria</country><postal-code>1000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tom Baker Cancer Centre</center><contact>Site Coordinator</contact><city>Calgary</city><state>Alberta</state><country>Canada</country><postal-code>T2N 4N2</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Alberta Hospital</center><contact>Site Coordinator</contact><city>Edmonton</city><state>Alberta</state><country>Canada</country><postal-code>T6G-3G3</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vancouver General Hospital (VGH)</center><contact>Site Coordinator</contact><city>Vancouver</city><state>British Columbia</state><country>Canada</country><postal-code>V5Z 1M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Princess Margaret Cancer Centre</center><contact>Site Coordinator</contact><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 1X5</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinička Bolnica Dubrava</center><contact>Site Coordinator</contact><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinička Bolnica Merkur</center><contact>Site Coordinator</contact><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Bolnički Centar Zagreb</center><contact>Site Coordinator</contact><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultní Nemocnice Hradec Králové</center><contact>Site Coordinator</contact><city>Hradec Kralove</city><country>Czechia</country><postal-code>500 05</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultní Nemocnice Olomouc</center><contact>Site Coordinator</contact><city>Olomouc</city><country>Czechia</country><postal-code>775 20</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultní Nemocnice Ostrava</center><contact>Site Coordinator</contact><city>Ostrava</city><country>Czechia</country><postal-code>708 52</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fakultni Nemocnice Plzen</center><contact>Site Coordinator</contact><city>Pilsen</city><country>Czechia</country><postal-code>304 60</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vseobecna Fakultni Nemocnice, Ustav hematologie a krevni transfuze (UHKT)</center><contact>Site Coordinator</contact><city>Praha 2</city><country>Czechia</country><postal-code>128 20</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital A. Michallon</center><contact>Site Coordinator</contact><city>Grenoble</city><country>France</country><postal-code>38043</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier de Versailles - Hôpital André Mignot</center><contact>Site Coordinator</contact><city>Le Chesnay</city><country>France</country><postal-code>78150</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier du Mans</center><contact>Site Coordinator</contact><city>Le Mans</city><country>France</country><postal-code>72037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez</center><contact>Site Coordinator</contact><city>Lille</city><country>France</country><postal-code>59037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Léon Bérard</center><contact>Site Coordinator</contact><city>Lyon</city><country>France</country><postal-code>69373</postal-code><status>Recruiting</status></trial-site><trial-site><center>L'Institut Paoli - Calmettes</center><contact>Site Coordinator</contact><city>Marguerittes</city><country>France</country><postal-code>13009</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital de la Conception</center><contact>Site Coordinator</contact><city>Marseille</city><country>France</country><postal-code>13385</postal-code><status>Recruiting</status></trial-site><trial-site><center>CHRU Montpellier - Saint Eloi</center><contact>Site Coordinator</contact><city>Montpellier</city><country>France</country><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Saint-Antoine</center><contact>Site Coordinator</contact><city>Paris</city><country>France</country><postal-code>75012</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Saint-Louis</center><contact>Site Coordinator</contact><city>Paris</city><country>France</country><postal-code>75475</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Haut-Lévêque</center><contact>Site Coordinator</contact><city>Pessac</city><country>France</country><postal-code>33604</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier Lyon-Sud</center><contact>Site Coordinator</contact><city>Pierre Benite</city><country>France</country><postal-code>69495</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Henri Becquerel - Centre de Lutte Contre le Cancer</center><contact>Site Coordinator</contact><city>Rouen</city><country>France</country><postal-code>76038</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan</center><contact>Site Coordinator</contact><city>Toulouse</city><country>France</country><postal-code>31059</postal-code><status>Recruiting</status></trial-site><trial-site><center>HELIOS Klinikum Bad Saarow</center><contact>Site Coordinator</contact><city>Bad Saarow</city><country>Germany</country><postal-code>15526</postal-code><status>Recruiting</status></trial-site><trial-site><center>Charité - Universitätsmedizin Berlin</center><contact>Site Coordinator</contact><city>Berlin</city><country>Germany</country><postal-code>10117</postal-code><status>Recruiting</status></trial-site><trial-site><center>Städtisches Klinikum Braunschweig gGmbH</center><contact>Site Coordinator</contact><city>Braunschweig</city><country>Germany</country><postal-code>38114</postal-code><status>Recruiting</status></trial-site><trial-site><center>Marien Hospital Düsseldorf GmbH</center><contact>Site Coordinator</contact><city>Düsseldorf</city><country>Germany</country><postal-code>40479</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Essen</center><contact>Site Coordinator</contact><city>Essen</city><country>Germany</country><postal-code>45122</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Frankfurt</center><contact>Site Coordinator</contact><city>Frankfurt am Main</city><country>Germany</country><postal-code>60590</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Halle (Saale)</center><contact>Site Coordinator</contact><city>Halle</city><country>Germany</country><postal-code>6120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Hamburg-Eppendorf (UKE)</center><contact>Site Coordinator</contact><city>Hamburg</city><country>Germany</country><postal-code>22083</postal-code><status>Recruiting</status></trial-site><trial-site><center>Evangelisches Krankenhaus Hamm gGmbH</center><contact>Site Coordinator</contact><city>Hamm</city><country>Germany</country><postal-code>59063</postal-code><status>Recruiting</status></trial-site><trial-site><center>Medizinische Hochschule Hannover (MHH)</center><contact>Site Coordinator</contact><city>Hannöver</city><country>Germany</country><postal-code>30625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Münster</center><contact>Site Coordinator</contact><city>Heidelberg</city><country>Germany</country><postal-code>69115</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Tübingen</center><contact>Site Coordinator</contact><city>Heidelberg</city><country>Germany</country><postal-code>69115</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Heidelberg</center><contact>Site Coordinator</contact><city>Heidelberg</city><country>Germany</country><postal-code>69120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Marien Hospital Herne</center><contact>Site Coordinator</contact><city>Herne</city><country>Germany</country><postal-code>44625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Leipzig</center><contact>Site Coordinator</contact><city>Leipzig</city><country>Germany</country><postal-code>4103</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</center><contact>Site Coordinator</contact><city>Mainz</city><country>Germany</country><postal-code>55131</postal-code><status>Recruiting</status></trial-site><trial-site><center>Stauferklinikum Schwäbisch Gmünd</center><contact>Site Coordinator</contact><city>Mutlangen</city><country>Germany</country><postal-code>73557</postal-code><status>Recruiting</status></trial-site><trial-site><center>HELIOS Klinikum Wuppertal</center><contact>Site Coordinator</contact><city>Wuppertal</city><country>Germany</country><postal-code>42283</postal-code><status>Recruiting</status></trial-site><trial-site><center>Prince of Wales Hospital</center><contact>Site Coordinator</contact><city>Hong Kong</city><country>Hong Kong</country><status>Recruiting</status></trial-site><trial-site><center>Queen Mary Hospital</center><contact>Site Coordinator</contact><city>Hong Kong</city><country>Hong Kong</country><status>Recruiting</status></trial-site><trial-site><center>Markusovszky Egyetemi Oktatókórház</center><contact>Site Coordinator</contact><city>Budapest</city><country>Hungary</country><postal-code>1051</postal-code><status>Recruiting</status></trial-site><trial-site><center>Szegedi Tudományegyetem</center><contact>Site Coordinator</contact><city>Budapest</city><country>Hungary</country><postal-code>1051</postal-code><status>Recruiting</status></trial-site><trial-site><center>Semmelweis Egyetem</center><contact>Site Coordinator</contact><city>Budapest</city><country>Hungary</country><postal-code>1083</postal-code><status>Recruiting</status></trial-site><trial-site><center>Debreceni Egyetem Klinikai Központ</center><contact>Site Coordinator</contact><city>Debrecen</city><country>Hungary</country><postal-code>4032</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pecsi Tudomanyegyetem Klinikai Központ</center><contact>Site Coordinator</contact><city>Pécs</city><country>Hungary</country><postal-code>7624</postal-code><status>Recruiting</status></trial-site><trial-site><center>Markusovszky Egyetemi Oktatókórház Belgyógyászati és Onkohaematológiai Centrum</center><contact>Site Coordinator</contact><city>Szombathely</city><country>Hungary</country><postal-code>9700</postal-code><status>Recruiting</status></trial-site><trial-site><center>Assaf Harofeh Medical Center</center><contact>Site Coordinator</contact><city>Be'er Ya'aqov</city><state>Tsifrin</state><country>Israel</country><postal-code>70300</postal-code><status>Recruiting</status></trial-site><trial-site><center>Bnai Zion Medical Center</center><contact>Site Coordinator</contact><city>Haifa</city><country>Israel</country><postal-code>31048</postal-code><status>Recruiting</status></trial-site><trial-site><center>Rambam Medical Center</center><contact>Site Coordinator</contact><city>Haifa</city><country>Israel</country><postal-code>31096</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hadassah University Medical Center</center><contact>Site Coordinator</contact><city>Jerusalem</city><country>Israel</country><postal-code>91120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Rabin Medical Center - Beilinson Hospital</center><contact>Site Coordinator</contact><city>Petaẖ Tiqwa</city><country>Israel</country><postal-code>49100</postal-code><status>Recruiting</status></trial-site><trial-site><center>The Chaim Sheba Medical Center</center><contact>Site Coordinator</contact><city>Ramat-Gan</city><country>Israel</country><postal-code>52621</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tel Aviv Sourasky Medical Center</center><contact>Site Coordinator</contact><city>Tel Aviv</city><country>Israel</country><postal-code>64239</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Nazionale SS.Antonio e Biagio e Cesare Arrigo</center><contact>Site Coordinator</contact><city>Alessandria</city><country>Italy</country><postal-code>15121</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi</center><contact>Site Coordinator</contact><city>Bologna</city><country>Italy</country><postal-code>40138</postal-code><status>Recruiting</status></trial-site><trial-site><center>AO Brotzu - Ospedale Oncologico "Businco"</center><contact>Site Coordinator</contact><city>Cagliari</city><country>Italy</country><postal-code>9121</postal-code><status>Recruiting</status></trial-site><trial-site><center>IRCCS AOU San Martino - IST</center><contact>Site Coordinator</contact><city>Genova</city><country>Italy</country><postal-code>16132</postal-code><status>Recruiting</status></trial-site><trial-site><center>ASST Grande Ospedale Metropolitano Niguarda</center><contact>Site Coordinator</contact><city>Milano</city><country>Italy</country><postal-code>20162</postal-code><status>Recruiting</status></trial-site><trial-site><center>A.O.R.N. "A. Cardarelli"</center><contact>Site Coordinator</contact><city>Napoli</city><country>Italy</country><postal-code>80131</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero Universitaria Maggiore della Carità di Novara</center><contact>Site Coordinator</contact><city>Novara</city><country>Italy</country><postal-code>28100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero - Universitaria San Luigi Gonzaga</center><contact>Site Coordinator</contact><city>Orbassano (TO)</city><country>Italy</country><postal-code>10043</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello</center><contact>Site Coordinator</contact><city>Palermo</city><country>Italy</country><postal-code>90146</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fondazione Policlinico Universitario Agostino Gemelli</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>133</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ospedale S. Eugenio</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>133</postal-code><status>Recruiting</status></trial-site><trial-site><center>Policlinico Tor Vergata</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>133</postal-code><status>Recruiting</status></trial-site><trial-site><center>IRCCS Ospedale San Raffaele</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>20132</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero-Universitaria Careggi</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>50134</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>56126</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Universitaria "Federico II"</center><contact>Site Coordinator</contact><city>Roma</city><country>Italy</country><postal-code>80131</postal-code><status>Recruiting</status></trial-site><trial-site><center>Istituto Clinico Humanitas</center><contact>Site Coordinator</contact><city>Rozzano</city><country>Italy</country><postal-code>20089</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Universitaria Senese</center><contact>Site Coordinator</contact><city>Siena</city><country>Italy</country><postal-code>53100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino - Ospedale Molinette</center><contact>Site Coordinator</contact><city>Torino</city><country>Italy</country><postal-code>10126</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Ordine Mauriziano di Torino</center><contact>Site Coordinator</contact><city>Torino</city><country>Italy</country><postal-code>10128</postal-code><status>Recruiting</status></trial-site><trial-site><center>ASST dei Sette Laghi - Ospedale di Circolo e Fondazione Macchi Varese</center><contact>Site Coordinator</contact><city>Varese</city><country>Italy</country><postal-code>21100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Inje University Haeundae Paik Hospital</center><contact>Site Coordinator</contact><city>Busan</city><country>Korea, Republic of</country><postal-code>48108</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pusan National University Hospital</center><contact>Site Coordinator</contact><city>Busan</city><country>Korea, Republic of</country><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Kyungpook National University Hospital</center><contact>Site Coordinator</contact><city>Daegu</city><country>Korea, Republic of</country><postal-code>41944</postal-code><status>Recruiting</status></trial-site><trial-site><center>Yeungnam University Medical Center</center><contact>Site Coordinator</contact><city>Daegu</city><country>Korea, Republic of</country><postal-code>42415</postal-code><status>Recruiting</status></trial-site><trial-site><center>Daegu Catholic University Medical Center</center><contact>Site Coordinator</contact><city>Daegu</city><country>Korea, Republic of</country><postal-code>42472</postal-code><status>Recruiting</status></trial-site><trial-site><center>Chonnam National University Hwasun Hospital</center><contact>Site Coordinator</contact><city>Hwasun</city><country>Korea, Republic of</country><postal-code>58128</postal-code><status>Recruiting</status></trial-site><trial-site><center>Gachon University Gil Hospital</center><contact>Site Coordinator</contact><city>Incheon</city><country>Korea, Republic of</country><postal-code>21565</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Bundang Hospital</center><contact>Site Coordinator</contact><city>Seongnam-si</city><country>Korea, Republic of</country><postal-code>13620</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>3080</postal-code><status>Recruiting</status></trial-site><trial-site><center>Severance Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>3722</postal-code><status>Recruiting</status></trial-site><trial-site><center>SoonChunHyang University Seoul Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>4401</postal-code><status>Recruiting</status></trial-site><trial-site><center>Konkuk University Medical Center</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>5030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Asan Medical Center</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>5505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Samsung Medical Center</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>6351</postal-code><status>Recruiting</status></trial-site><trial-site><center>The Catholic University of Korea, Seoul St. Mary's Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>6591</postal-code><status>Recruiting</status></trial-site><trial-site><center>Korea University Guro Hospital</center><contact>Site Coordinator</contact><city>Seoul</city><country>Korea, Republic of</country><postal-code>8308</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ajou University Hospital</center><contact>Site Coordinator</contact><city>Sŏwŏn</city><country>Korea, Republic of</country><postal-code>16499</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ulsan University Hospital (UUH)</center><contact>Site Coordinator</contact><city>Ulsan</city><country>Korea, Republic of</country><postal-code>44033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Szpital Uniwersytecki w Krakowie</center><contact>Site Coordinator</contact><city>Kraków</city><country>Poland</country><postal-code>31-501</postal-code><status>Recruiting</status></trial-site><trial-site><center>Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka</center><contact>Site Coordinator</contact><city>Słupsk</city><country>Poland</country><postal-code>76-200</postal-code><status>Recruiting</status></trial-site><trial-site><center>Instytut Hematologii i Transfuzjologi</center><contact>Site Coordinator</contact><city>Warszawa</city><country>Poland</country><postal-code>00-957</postal-code><status>Recruiting</status></trial-site><trial-site><center>Samodzielny Publiczny Szpital Kliniczny Nr. 1 we Wrocławiu</center><contact>Site Coordinator</contact><city>Warszawa</city><country>Poland</country><postal-code>50367</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centro Hospitalar e Universitário de Coimbra, EPE - Hospitais da Universidade de Coimbra</center><contact>Site Coordinator</contact><city>Coimbra</city><country>Portugal</country><postal-code>3000-075</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António</center><contact>Site Coordinator</contact><city>Porto</city><country>Portugal</country><postal-code>4099-001</postal-code><status>Recruiting</status></trial-site><trial-site><center>Instituto Português Oncologia do Porto Francisco Gentil, EPE</center><contact>Site Coordinator</contact><city>Porto</city><country>Portugal</country><postal-code>4200-072</postal-code><status>Recruiting</status></trial-site><trial-site><center>Centro Hospitalar de São João, EPE - Hospital de São João</center><contact>Site Coordinator</contact><city>Porto</city><country>Portugal</country><postal-code>4200-319</postal-code><status>Recruiting</status></trial-site><trial-site><center>Institutul Regional de Oncologie Iași</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Clinic Colentina</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Clinic Coltea</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Universitar de Urgenta Bucuresti</center><contact>Site Coordinator</contact><city>Bucuresti</city><country>Romania</country><postal-code>20125</postal-code><status>Recruiting</status></trial-site><trial-site><center>Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj Napoca</center><contact>Site Coordinator</contact><city>Cluj-Napoca</city><country>Romania</country><postal-code>400124</postal-code><status>Recruiting</status></trial-site><trial-site><center>Spitalul Clinic Judetean de Urgenta Tîrgu - Mures</center><contact>Site Coordinator</contact><city>Târgu-Mureş</city><country>Romania</country><postal-code>540042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Penza Regional Oncology Dispensary</center><contact>Site Coordinator</contact><city>Penza</city><country>Russian Federation</country><postal-code>440071</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ryazan Regional Clinical Hospital</center><contact>Site Coordinator</contact><city>Ryazan'</city><country>Russian Federation</country><postal-code>390039</postal-code><status>Recruiting</status></trial-site><trial-site><center>Saratov State Medical University named after V.I. Razumovsky</center><contact>Site Coordinator</contact><city>Saratov</city><country>Russian Federation</country><postal-code>410012</postal-code><status>Recruiting</status></trial-site><trial-site><center>Russian Research Institute of Hematology and Blood Transfusion</center><contact>Site Coordinator</contact><city>St. Petersburg</city><country>Russian Federation</country><postal-code>191024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Leningrad Regional Clinic and Hospital</center><contact>Site Coordinator</contact><city>St. Petersburg</city><country>Russian Federation</country><postal-code>194291</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tula Regional Clinical Hospital</center><contact>Site Coordinator</contact><city>Tula</city><country>Russian Federation</country><postal-code>300053</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Centar Srbije</center><contact>Site Coordinator</contact><city>Belgrade</city><country>Serbia</country><postal-code>11000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Centar Niš</center><contact>Site Coordinator</contact><city>Nis</city><country>Serbia</country><postal-code>18000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinički Centar Vojvodine</center><contact>Site Coordinator</contact><city>Novi Sad</city><country>Serbia</country><postal-code>21101</postal-code><status>Recruiting</status></trial-site><trial-site><center>National University Hospital (S) Pte Ltd</center><contact>Site Coordinator</contact><city>Singapore</city><country>Singapore</country><postal-code>119074</postal-code><status>Recruiting</status></trial-site><trial-site><center>Singapore General Hospital</center><contact>Site Coordinator</contact><city>Singapore</city><country>Singapore</country><postal-code>138543</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari Son Espases</center><contact>Site Coordinator</contact><city>Palma</city><state>Mallorca</state><country>Spain</country><postal-code>7014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario de Alicante</center><contact>Site Coordinator</contact><city>Alicante</city><country>Spain</country><postal-code>3010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Catalan Institute of Oncology (ICO)</center><contact>Site Coordinator</contact><city>Badalona</city><country>Spain</country><postal-code>8916</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital del Mar</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Vall d'Hebron</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clinic i Provincial</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Duran i Reynals</center><contact>Site Coordinator</contact><city>Barcelona</city><country>Spain</country><postal-code>8907</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital de Basurto</center><contact>Site Coordinator</contact><city>Bilbao</city><country>Spain</country><postal-code>48013</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital San Pedro de Alcántara</center><contact>Site Coordinator</contact><city>Cáceres</city><country>Spain</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Reina Sofía</center><contact>Site Coordinator</contact><city>Córdoba</city><country>Spain</country><postal-code>14004</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari de Girona Doctor Josep Trueta</center><city>Girona</city><country>Spain</country><postal-code>17007</postal-code><status>Enrolling by invitation</status></trial-site><trial-site><center>Complejo Hospitalario Universitario Granada</center><contact>Site Coordinator</contact><city>Granada</city><country>Spain</country><postal-code>18014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario Gregorio Marañón</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28007</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Ramón y Cajal</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28034</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clínico San Carlos</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28040</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario 12 de Octubre</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28041</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Quirón Madrid</center><contact>Site Coordinator</contact><city>Madrid</city><country>Spain</country><postal-code>28223</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Puerta de Hierro - Majadahonda</center><contact>Site Coordinator</contact><city>Majadahonda</city><country>Spain</country><postal-code>28222</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Regional Universitario de Málaga - Hospital General</center><contact>Site Coordinator</contact><city>Málaga</city><country>Spain</country><postal-code>29010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Central de Asturias</center><contact>Site Coordinator</contact><city>Oviedo</city><country>Spain</country><postal-code>33011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Complejo Hospitalario de Navarra</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fundación Jiménez Díaz</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clínico Universitario "Lozano Blesa"</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario Morales Meseguer</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Miguel Servet</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Álvaro Cunqueiro</center><contact>Site Coordinator</contact><city>Pamplona</city><country>Spain</country><postal-code>31008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hosp Universitario Salamanca</center><contact>Site Coordinator</contact><city>Salamanca</city><country>Spain</country><postal-code>37007</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Marqués de Valdecilla</center><contact>Site Coordinator</contact><city>Santander</city><country>Spain</country><postal-code>39008</postal-code><status>Recruiting</status></trial-site><trial-site><center>Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario</center><contact>Site Coordinator</contact><city>Santiago de Compostela</city><country>Spain</country><postal-code>15706</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Virgen del Rocío (2)</center><contact>Site Coordinator</contact><city>Sevilla</city><country>Spain</country><postal-code>41013</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Virgen del Rocío</center><contact>Site Coordinator</contact><city>Sevilla</city><country>Spain</country><postal-code>41013</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari Joan XXIII de Tarragona</center><contact>Site Coordinator</contact><city>Tarragona</city><country>Spain</country><postal-code>43005</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Clinico Universitario de Valencia</center><contact>Site Coordinator</contact><city>Valencia</city><country>Spain</country><postal-code>46010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitario Dr. Peset</center><contact>Site Coordinator</contact><city>Valencia</city><country>Spain</country><postal-code>46017</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital Universitari i Politècnic La Fe</center><contact>Site Coordinator</contact><city>Valencia</city><country>Spain</country><postal-code>CP 46026</postal-code><status>Recruiting</status></trial-site><trial-site><center>Chang Gung Medical Foundation - Kaohsiung Branch</center><contact>Site Coordinator</contact><city>Kaohsiung</city><state>Niaosong District</state><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>China Medical University Hospital</center><contact>Site Coordinator</contact><city>Taichung</city><country>Taiwan</country><postal-code>40447</postal-code><status>Recruiting</status></trial-site><trial-site><center>National Cheng Kung University Hospital</center><contact>Site Coordinator</contact><city>Tainan</city><country>Taiwan</country><postal-code>704</postal-code><status>Recruiting</status></trial-site><trial-site><center>National Taiwan University Hospital</center><contact>Site Coordinator</contact><city>Taipei</city><country>Taiwan</country><postal-code>100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Taipei Veterans General Hospital</center><contact>Site Coordinator</contact><city>Taipei</city><country>Taiwan</country><postal-code>11217</postal-code><status>Recruiting</status></trial-site><trial-site><center>Chang Gung Medical Foundation - Linkou Branch</center><contact>Site Coordinator</contact><city>Taoyuan</city><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Poltava Regional Clinical Hospital named after M. V. Sklifosovskoho</center><contact>Site Coordinator</contact><city>Poltava</city><country>Ukraine</country><postal-code>36011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vinnitsa Regional Clinical Hospital im. N.I. Pirogov</center><contact>Site Coordinator</contact><city>Vinnytsia</city><country>Ukraine</country><postal-code>21018</postal-code><status>Recruiting</status></trial-site><trial-site><center>Zhitomir Regional Clinical Hospital</center><contact>Site Coordinator</contact><city>Zhytomyr</city><country>Ukraine</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>East Kent Hospitals University NHS Foundation Trust - Kent and Canterbury Hospital</center><contact>Site Coordinator</contact><city>Canterbury</city><country>United Kingdom</country><postal-code>CT1 3NG</postal-code><status>Recruiting</status></trial-site><trial-site><center>Maidstone and Tunbridge Wells NHS Trust - Maidstone Hospital</center><contact>Site Coordinator</contact><city>Maidstone</city><country>United Kingdom</country><postal-code>ME16 9QQ</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial></clinical-trials></biomarker-content><biomarker-content A46b97766-87a2-4938-9c23-3cdd5c4ddac4="A26b4d334-cff4-45ec-8460-36bbb087b249" alteration-name="W288fs" marker="NPM1" test-type="MUTN (seq)" user-alteration-name="W288fs"><A857c13ba-8bdf-4eb1-877f-a4958f249a17>Aa13f6f49-197e-4b25-b30d-146a64836e5d</A857c13ba-8bdf-4eb1-877f-a4958f249a17><biomarker-summary><content><item><text>NPM1-W288fs exhibits altered function compared to wild-type.</text><references/></item></content><references/></biomarker-summary><biomarker-summary content-type="clinical-relevance"><content><item><text>NPM1 encodes nucleophosmin (Npm1), a multifunctional protein that regulates the ARF/p53 pathway and enhances Myc oncogenic activities.</text><references><reference><reference-id>16794633</reference-id><title>Nucleophosmin and cancer.</title><authors>Grisendi S, Mecucci C, Falini B, Pandolfi P</authors><journal>Nature reviews. Cancer</journal><issue>7</issue><year>2006</year><page>493-505</page></reference><reference><reference-id>19652540</reference-id><title>The Myc-nucleophosmin-ARF network: a complex web unveiled.</title><authors>Li Z, Hann S</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>17</issue><year>2009</year><page>2703-7</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>22631075</reference-id><title>Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.</title><authors>Liu Y, Zhang F, Zhang X, Qi L, Yang L, Guo H, Zhang N</authors><journal>Journal of biomedical science</journal><year>2012</year><page>53</page></reference></references></item><item><text>NPM1 mutations, particularly C-terminal truncations, have been reported frequently in myeloid malignancies, and although mutation has not been commonly found in solid tumors, overexpression of the Npm1 protein has been reported.</text><references><reference><reference-id>23436734</reference-id><title>Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.</title><authors>Federici L, Falini B</authors><journal>Protein science : a publication of the Protein Society</journal><issue>5</issue><year>2013</year><page>545-56</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>21258971</reference-id><title>Nucleophosmin delocalization in thyroid tumour cells.</title><authors>Pianta A, Puppin C, Passon N, Franzoni A, Romanello M, Tell G, Di Loreto C, Bulotta S, Russo D, Damante G</authors><journal>Endocrine pathology</journal><issue>1</issue><year>2011</year><page>18-23</page></reference><reference><reference-id>17504301</reference-id><title>Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.</title><authors>Jeong E, Lee S, Yoo N, Lee S</authors><journal>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</journal><issue>4</issue><year>2007</year><page>341-6</page></reference></references></item><item><text>There are currently no therapeutic approaches targeting alterations in NPM1 or changes in Npm1 protein expression.</text><references/></item></content><references><reference><reference-id>16794633</reference-id><title>Nucleophosmin and cancer.</title><authors>Grisendi S, Mecucci C, Falini B, Pandolfi P</authors><journal>Nature reviews. Cancer</journal><issue>7</issue><year>2006</year><page>493-505</page></reference><reference><reference-id>19652540</reference-id><title>The Myc-nucleophosmin-ARF network: a complex web unveiled.</title><authors>Li Z, Hann S</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>17</issue><year>2009</year><page>2703-7</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>22631075</reference-id><title>Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.</title><authors>Liu Y, Zhang F, Zhang X, Qi L, Yang L, Guo H, Zhang N</authors><journal>Journal of biomedical science</journal><year>2012</year><page>53</page></reference><reference><reference-id>23436734</reference-id><title>Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.</title><authors>Federici L, Falini B</authors><journal>Protein science : a publication of the Protein Society</journal><issue>5</issue><year>2013</year><page>545-56</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>21258971</reference-id><title>Nucleophosmin delocalization in thyroid tumour cells.</title><authors>Pianta A, Puppin C, Passon N, Franzoni A, Romanello M, Tell G, Di Loreto C, Bulotta S, Russo D, Damante G</authors><journal>Endocrine pathology</journal><issue>1</issue><year>2011</year><page>18-23</page></reference><reference><reference-id>17504301</reference-id><title>Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.</title><authors>Jeong E, Lee S, Yoo N, Lee S</authors><journal>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</journal><issue>4</issue><year>2007</year><page>341-6</page></reference></references></biomarker-summary><biomarker-summary content-type="disease-summary"><content><item><text>NPM1 mutation in AML has been shown to result in the aberrant cytoplasmic localization of Npm1, in contrast to its normal nucleolar localization, and has been reported to play a role in the development of AML through the mislocalization and inhibition of Npm1 binding partners, including the tumor suppressor ARF.</text><references><reference><reference-id>16455950</reference-id><title>Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.</title><authors>Falini B, Bolli N, Shan J, Martelli M, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli M, Gu W, Mecucci C, Nicoletti I</authors><journal>Blood</journal><issue>11</issue><year>2006</year><page>4514-23</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>16205118</reference-id><title>Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.</title><authors>den Besten W, Kuo M, Williams R, Sherr C</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>11</issue><year>2005</year><page>1593-8</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference></references></item><item><text>NPM1 mutations in AML have been associated with M4 and M5 morphology, increased leukocyte and bone marrow blast counts, female sex, and decreased expression of CD34; NPM1 mutations have been reported more frequently in cytogenetically normal AML (CN-AML) and often occur in combination with FLT3, IDH1/2, NRAS, and DMNT3A mutations.</text><references><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>27276561</reference-id><title>Genomic Classification and Prognosis in Acute Myeloid Leukemia.</title><authors>Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones D, Teague J, Butler A, Greaves M, Ganser A, Döhner K, Schlenk R, Döhner H, Campbell P</authors><journal>The New England journal of medicine</journal><issue>23</issue><year>2016</year><page>2209-2221</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference></references></item><item><text>AML with mutant NPM1 is recognized as a subtype of AML with recurrent genetic abnormalities in the WHO classification of myeloid neoplasms and acute leukemia.</text><references><reference><reference-id>27069254</reference-id><title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</title><authors>Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M, Bloomfield C, Cazzola M, Vardiman J</authors><journal>Blood</journal><issue>20</issue><year>2016</year><page>2391-405</page></reference></references></item><item><text>NPM1 mutations in the absence of FLT3-ITD have been associated with favorable outcomes in AML, especially in cytogenetically normal AML (CN-AML), while NPM1 mutations in the presence of FLT3-ITD have been associated with an intermediate prognosis.</text><references><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></item><item><text>Additionally, monitoring of mutant NPM1 transcript levels has been reported to be useful in the detection of minimal residual disease (MRD) and prediction of disease relapse.</text><references><reference><reference-id>19587375</reference-id><title>Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.</title><authors>Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T</authors><journal>Blood</journal><issue>11</issue><year>2009</year><page>2220-31</page></reference><reference><reference-id>21555683</reference-id><title>Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.</title><authors>Krönke J, Schlenk R, Jensen K, Tschürtz F, Corbacioglu A, Gaidzik V, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>19</issue><year>2011</year><page>2709-16</page></reference><reference><reference-id>23656730</reference-id><title>The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.</title><authors>Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C</authors><journal>Blood</journal><issue>1</issue><year>2013</year><page>83-92</page></reference><reference><reference-id>24816240</reference-id><title>Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.</title><authors>Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander S, Subklewe M, Sauerland M, Berdel W, Büchner T, Wörmann B, Hiddemann W, Spiekermann K</authors><journal>Haematologica</journal><issue>8</issue><year>2014</year><page>1317-25</page></reference><reference><reference-id>26789727</reference-id><title>Assessment of Minimal Residual Disease in Standard-Risk AML.</title><authors>Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett A, Grimwade D</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2016</year><page>422-33</page></reference></references></item></content><references><reference><reference-id>16455950</reference-id><title>Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.</title><authors>Falini B, Bolli N, Shan J, Martelli M, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli M, Gu W, Mecucci C, Nicoletti I</authors><journal>Blood</journal><issue>11</issue><year>2006</year><page>4514-23</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>16205118</reference-id><title>Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.</title><authors>den Besten W, Kuo M, Williams R, Sherr C</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>11</issue><year>2005</year><page>1593-8</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>27276561</reference-id><title>Genomic Classification and Prognosis in Acute Myeloid Leukemia.</title><authors>Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones D, Teague J, Butler A, Greaves M, Ganser A, Döhner K, Schlenk R, Döhner H, Campbell P</authors><journal>The New England journal of medicine</journal><issue>23</issue><year>2016</year><page>2209-2221</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference><reference><reference-id>27069254</reference-id><title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</title><authors>Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M, Bloomfield C, Cazzola M, Vardiman J</authors><journal>Blood</journal><issue>20</issue><year>2016</year><page>2391-405</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference><reference><reference-id>19587375</reference-id><title>Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.</title><authors>Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T</authors><journal>Blood</journal><issue>11</issue><year>2009</year><page>2220-31</page></reference><reference><reference-id>21555683</reference-id><title>Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.</title><authors>Krönke J, Schlenk R, Jensen K, Tschürtz F, Corbacioglu A, Gaidzik V, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>19</issue><year>2011</year><page>2709-16</page></reference><reference><reference-id>23656730</reference-id><title>The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.</title><authors>Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C</authors><journal>Blood</journal><issue>1</issue><year>2013</year><page>83-92</page></reference><reference><reference-id>24816240</reference-id><title>Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.</title><authors>Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander S, Subklewe M, Sauerland M, Berdel W, Büchner T, Wörmann B, Hiddemann W, Spiekermann K</authors><journal>Haematologica</journal><issue>8</issue><year>2014</year><page>1317-25</page></reference><reference><reference-id>26789727</reference-id><title>Assessment of Minimal Residual Disease in Standard-Risk AML.</title><authors>Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett A, Grimwade D</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2016</year><page>422-33</page></reference></references></biomarker-summary><molecular-function><content><item><text>NPM1 W288fs is expected to effectively truncate the Npm1 protein at amino acid 288 of 294 (UniProt). This truncation results in the loss of two tryptophan residues, W288 and W290, that are critical for nucleolar localization of Npm1.</text><references><reference><reference-id>12450141</reference-id><title>Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization.</title><authors>Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H</authors><journal>Bioscience, biotechnology, and biochemistry</journal><issue>10</issue><year>2002</year><page>2239-42</page></reference><reference><reference-id>17488663</reference-id><title>Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.</title><authors>Falini B, Nicoletti I, Bolli N, Martelli M, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli M</authors><journal>Haematologica</journal><issue>4</issue><year>2007</year><page>519-32</page></reference></references></item><item><text>In addition, the resulting protein would also lack a lysine residue at position 292, one of six lysines that undergo acetylation, which enhances the interaction of Npm1 with acetylated histones and is required for the enhancement of chromatin transcription.</text><references><reference><reference-id>16107701</reference-id><title>Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription.</title><authors>Swaminathan V, Kishore A, Febitha K, Kundu T</authors><journal>Molecular and cellular biology</journal><issue>17</issue><year>2005</year><page>7534-45</page></reference></references></item><item><text>Several C-terminal NPM1 truncating alterations, and frameshift alterations at W288, have been reported to result in mislocalization of Npm1 and a gain in oncogenic function through deregulation of downstream pathways.</text><references><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>17488663</reference-id><title>Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.</title><authors>Falini B, Nicoletti I, Bolli N, Martelli M, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli M</authors><journal>Haematologica</journal><issue>4</issue><year>2007</year><page>519-32</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>18625840</reference-id><title>Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma.</title><authors>Bonetti P, Davoli T, Sironi C, Amati B, Pelicci P, Colombo E</authors><journal>The Journal of cell biology</journal><issue>1</issue><year>2008</year><page>19-26</page></reference><reference><reference-id>19569254</reference-id><title>Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.</title><authors>Rau R, Brown P</authors><journal>Hematological oncology</journal><issue>4</issue><year>2009</year><page>171-81</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference></references></item><item><text>Therefore, although this alteration results in loss of the nucleolar localization domain, it is predicted to be associated with promotion of tumorigenesis.</text><references/></item></content><references><reference><reference-id>12450141</reference-id><title>Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization.</title><authors>Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H</authors><journal>Bioscience, biotechnology, and biochemistry</journal><issue>10</issue><year>2002</year><page>2239-42</page></reference><reference><reference-id>17488663</reference-id><title>Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.</title><authors>Falini B, Nicoletti I, Bolli N, Martelli M, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli M</authors><journal>Haematologica</journal><issue>4</issue><year>2007</year><page>519-32</page></reference><reference><reference-id>16107701</reference-id><title>Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription.</title><authors>Swaminathan V, Kishore A, Febitha K, Kundu T</authors><journal>Molecular and cellular biology</journal><issue>17</issue><year>2005</year><page>7534-45</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>18625840</reference-id><title>Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma.</title><authors>Bonetti P, Davoli T, Sironi C, Amati B, Pelicci P, Colombo E</authors><journal>The Journal of cell biology</journal><issue>1</issue><year>2008</year><page>19-26</page></reference><reference><reference-id>19569254</reference-id><title>Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.</title><authors>Rau R, Brown P</authors><journal>Hematological oncology</journal><issue>4</issue><year>2009</year><page>171-81</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference></references></molecular-function><incidence><content><item><text>NPM1 mutations have been reported in 32% (5959/18460) of Acute myelocytic leukemia (AML) samples analyzed in COSMIC (Apr 2017).</text><references/></item><item><text>NPM1 mutations have been reported in 27% of Acute myelocytic leukemia (AML) samples (cBioPortal for Cancer Genomics, Apr 2017).</text><references/></item><item><text>NPM1 mutations, predominately resulting in C-terminal truncations, have been reported in 27-35% of AML samples and in 46-53% of cytogenetically normal AML (CN-AML) samples analyzed in scientific studies.</text><references><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference></references></item></content><references><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference></references></incidence><role-in-disease><content><item><text>NPM1 mutations, particularly C-terminal truncations, have been reported frequently in myeloid malignancies, and although mutation has not been commonly found in solid tumors, overexpression of the Npm1 protein has been reported.</text><references><reference><reference-id>23436734</reference-id><title>Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.</title><authors>Federici L, Falini B</authors><journal>Protein science : a publication of the Protein Society</journal><issue>5</issue><year>2013</year><page>545-56</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>21258971</reference-id><title>Nucleophosmin delocalization in thyroid tumour cells.</title><authors>Pianta A, Puppin C, Passon N, Franzoni A, Romanello M, Tell G, Di Loreto C, Bulotta S, Russo D, Damante G</authors><journal>Endocrine pathology</journal><issue>1</issue><year>2011</year><page>18-23</page></reference><reference><reference-id>17504301</reference-id><title>Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.</title><authors>Jeong E, Lee S, Yoo N, Lee S</authors><journal>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</journal><issue>4</issue><year>2007</year><page>341-6</page></reference></references></item><item><text>Alterations in NPM1 and changes in Npm1 expression have been reported to affect the ARF/p53 pathway, and Npm1 has also been reported to function as a histone chaperone protein.</text><references><reference><reference-id>25349213</reference-id><title>Loss of nucleolar histone chaperone NPM1 triggers rearrangement of heterochromatin and synergizes with a deficiency in DNA methyltransferase DNMT3A to drive ribosomal DNA transcription.</title><authors>Holmberg Olausson K, Nistér M, Lindström M</authors><journal>The Journal of biological chemistry</journal><issue>50</issue><year>2014</year><page>34601-19</page></reference><reference><reference-id>26559910</reference-id><title>NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape.</title><authors>Holmberg Olausson K, Elsir T, Moazemi Goudarzi K, Nistér M, Lindström M</authors><journal>Scientific reports</journal><year>2015</year><page>16495</page></reference><reference><reference-id>22053282</reference-id><title>How does the NPM1 mutant induce leukemia?</title><authors>Sportoletti P</authors><journal>Pediatric reports</journal><year>2011</year><page>e6</page></reference><reference><reference-id>15684379</reference-id><title>Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.</title><authors>Korgaonkar C, Hagen J, Tompkins V, Frazier A, Allamargot C, Quelle F, Quelle D</authors><journal>Molecular and cellular biology</journal><issue>4</issue><year>2005</year><page>1258-71</page></reference></references></item><item><text>NPM1 mutation in AML has been shown to result in the aberrant cytoplasmic localization of Npm1, in contrast to its normal nucleolar localization, and has been reported to play a role in the development of AML through the mislocalization and inhibition of Npm1 binding partners, including the tumor suppressor ARF.</text><references><reference><reference-id>16455950</reference-id><title>Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.</title><authors>Falini B, Bolli N, Shan J, Martelli M, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli M, Gu W, Mecucci C, Nicoletti I</authors><journal>Blood</journal><issue>11</issue><year>2006</year><page>4514-23</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>16205118</reference-id><title>Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.</title><authors>den Besten W, Kuo M, Williams R, Sherr C</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>11</issue><year>2005</year><page>1593-8</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference></references></item><item><text>NPM1 mutations in AML have been associated with M4 and M5 morphology, increased leukocyte and bone marrow blast counts, female sex, and decreased expression of CD34; NPM1 mutations have been reported more frequently in cytogenetically normal AML (CN-AML) and often occur in combination with FLT3, IDH1/2, NRAS, and DMNT3A mutations.</text><references><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>27276561</reference-id><title>Genomic Classification and Prognosis in Acute Myeloid Leukemia.</title><authors>Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones D, Teague J, Butler A, Greaves M, Ganser A, Döhner K, Schlenk R, Döhner H, Campbell P</authors><journal>The New England journal of medicine</journal><issue>23</issue><year>2016</year><page>2209-2221</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference></references></item><item><text>Additionally, monitoring of mutant NPM1 transcript levels has been reported to be useful in the detection of minimal residual disease (MRD) and prediction of disease relapse.</text><references><reference><reference-id>19587375</reference-id><title>Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.</title><authors>Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T</authors><journal>Blood</journal><issue>11</issue><year>2009</year><page>2220-31</page></reference><reference><reference-id>21555683</reference-id><title>Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.</title><authors>Krönke J, Schlenk R, Jensen K, Tschürtz F, Corbacioglu A, Gaidzik V, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>19</issue><year>2011</year><page>2709-16</page></reference><reference><reference-id>23656730</reference-id><title>The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.</title><authors>Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C</authors><journal>Blood</journal><issue>1</issue><year>2013</year><page>83-92</page></reference><reference><reference-id>24816240</reference-id><title>Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.</title><authors>Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander S, Subklewe M, Sauerland M, Berdel W, Büchner T, Wörmann B, Hiddemann W, Spiekermann K</authors><journal>Haematologica</journal><issue>8</issue><year>2014</year><page>1317-25</page></reference><reference><reference-id>26789727</reference-id><title>Assessment of Minimal Residual Disease in Standard-Risk AML.</title><authors>Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett A, Grimwade D</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2016</year><page>422-33</page></reference></references></item></content><references><reference><reference-id>23436734</reference-id><title>Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.</title><authors>Federici L, Falini B</authors><journal>Protein science : a publication of the Protein Society</journal><issue>5</issue><year>2013</year><page>545-56</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>21258971</reference-id><title>Nucleophosmin delocalization in thyroid tumour cells.</title><authors>Pianta A, Puppin C, Passon N, Franzoni A, Romanello M, Tell G, Di Loreto C, Bulotta S, Russo D, Damante G</authors><journal>Endocrine pathology</journal><issue>1</issue><year>2011</year><page>18-23</page></reference><reference><reference-id>17504301</reference-id><title>Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.</title><authors>Jeong E, Lee S, Yoo N, Lee S</authors><journal>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</journal><issue>4</issue><year>2007</year><page>341-6</page></reference><reference><reference-id>25349213</reference-id><title>Loss of nucleolar histone chaperone NPM1 triggers rearrangement of heterochromatin and synergizes with a deficiency in DNA methyltransferase DNMT3A to drive ribosomal DNA transcription.</title><authors>Holmberg Olausson K, Nistér M, Lindström M</authors><journal>The Journal of biological chemistry</journal><issue>50</issue><year>2014</year><page>34601-19</page></reference><reference><reference-id>26559910</reference-id><title>NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape.</title><authors>Holmberg Olausson K, Elsir T, Moazemi Goudarzi K, Nistér M, Lindström M</authors><journal>Scientific reports</journal><year>2015</year><page>16495</page></reference><reference><reference-id>22053282</reference-id><title>How does the NPM1 mutant induce leukemia?</title><authors>Sportoletti P</authors><journal>Pediatric reports</journal><year>2011</year><page>e6</page></reference><reference><reference-id>15684379</reference-id><title>Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.</title><authors>Korgaonkar C, Hagen J, Tompkins V, Frazier A, Allamargot C, Quelle F, Quelle D</authors><journal>Molecular and cellular biology</journal><issue>4</issue><year>2005</year><page>1258-71</page></reference><reference><reference-id>16455950</reference-id><title>Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.</title><authors>Falini B, Bolli N, Shan J, Martelli M, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli M, Gu W, Mecucci C, Nicoletti I</authors><journal>Blood</journal><issue>11</issue><year>2006</year><page>4514-23</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>16205118</reference-id><title>Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.</title><authors>den Besten W, Kuo M, Williams R, Sherr C</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>11</issue><year>2005</year><page>1593-8</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>27276561</reference-id><title>Genomic Classification and Prognosis in Acute Myeloid Leukemia.</title><authors>Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones D, Teague J, Butler A, Greaves M, Ganser A, Döhner K, Schlenk R, Döhner H, Campbell P</authors><journal>The New England journal of medicine</journal><issue>23</issue><year>2016</year><page>2209-2221</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference><reference><reference-id>19587375</reference-id><title>Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.</title><authors>Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T</authors><journal>Blood</journal><issue>11</issue><year>2009</year><page>2220-31</page></reference><reference><reference-id>21555683</reference-id><title>Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.</title><authors>Krönke J, Schlenk R, Jensen K, Tschürtz F, Corbacioglu A, Gaidzik V, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>19</issue><year>2011</year><page>2709-16</page></reference><reference><reference-id>23656730</reference-id><title>The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.</title><authors>Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C</authors><journal>Blood</journal><issue>1</issue><year>2013</year><page>83-92</page></reference><reference><reference-id>24816240</reference-id><title>Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.</title><authors>Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander S, Subklewe M, Sauerland M, Berdel W, Büchner T, Wörmann B, Hiddemann W, Spiekermann K</authors><journal>Haematologica</journal><issue>8</issue><year>2014</year><page>1317-25</page></reference><reference><reference-id>26789727</reference-id><title>Assessment of Minimal Residual Disease in Standard-Risk AML.</title><authors>Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett A, Grimwade D</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2016</year><page>422-33</page></reference></references></role-in-disease><diagnostic-significance><variant diagnostic-level-of-evidence="A"><content><item><text>AML with mutant NPM1 is recognized as a subtype of AML with recurrent genetic abnormalities in the WHO classification of myeloid neoplasms and acute leukemia.</text><references><reference><reference-id>27069254</reference-id><title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</title><authors>Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M, Bloomfield C, Cazzola M, Vardiman J</authors><journal>Blood</journal><issue>20</issue><year>2016</year><page>2391-405</page></reference></references></item></content><references><reference><reference-id>27069254</reference-id><title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</title><authors>Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M, Bloomfield C, Cazzola M, Vardiman J</authors><journal>Blood</journal><issue>20</issue><year>2016</year><page>2391-405</page></reference></references></variant></diagnostic-significance><prognostic-significance><variant prognostic-level-of-evidence="A"><content><item><text>NPM1 mutations in the absence of FLT3-ITD have been associated with favorable outcomes in AML, especially in cytogenetically normal AML (CN-AML).</text><references><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></item></content><references><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></variant><interaction prognostic-level-of-evidence="A"><content><item><text>However, NPM1 mutations in the presence of FLT3-ITD have been associated with an intermediate prognosis.</text><references><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference></references></item></content><references><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference></references></interaction></prognostic-significance><drug-sensitivity><content><item><text>Although several compounds have been investigated preclinically for their effects on NPM1 alterations and the downstream effects, there are currently no clinically relevant therapeutic approaches targeting alterations in NPM1 or changes in Npm1 protein expression.</text><references><reference><reference-id>19734942</reference-id><title>RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells.</title><authors>Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y, Yang C</authors><journal>Oncogene</journal><issue>47</issue><year>2009</year><page>4201-11</page></reference><reference><reference-id>18345031</reference-id><title>NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.</title><authors>Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D</authors><journal>Oncogene</journal><issue>30</issue><year>2008</year><page>4210-20</page></reference><reference><reference-id>25242579</reference-id><title>Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.</title><authors>Yi S, Wen L, He J, Wang Y, Zhao F, Zhao J, Zhao Z, Cui G, Chen Y</authors><journal>Annals of hematology</journal><issue>2</issue><year>2015</year><page>201-10</page></reference></references></item><item><text>NPM1 mutation or cytoplasmic Npm1 expression in AML patients has been associated with increased response and complete remission rates following induction chemotherapy.</text><references><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>15994285</reference-id><title>Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.</title><authors>Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2005</year><page>2854-61</page></reference></references></item></content><references><reference><reference-id>19734942</reference-id><title>RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells.</title><authors>Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y, Yang C</authors><journal>Oncogene</journal><issue>47</issue><year>2009</year><page>4201-11</page></reference><reference><reference-id>18345031</reference-id><title>NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.</title><authors>Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D</authors><journal>Oncogene</journal><issue>30</issue><year>2008</year><page>4210-20</page></reference><reference><reference-id>25242579</reference-id><title>Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.</title><authors>Yi S, Wen L, He J, Wang Y, Zhao F, Zhao J, Zhao Z, Cui G, Chen Y</authors><journal>Annals of hematology</journal><issue>2</issue><year>2015</year><page>201-10</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>15994285</reference-id><title>Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.</title><authors>Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2005</year><page>2854-61</page></reference></references></drug-sensitivity><drug-resistance><content/><references/></drug-resistance><fda-approved><content><item empty-type="None"><text>None.</text><references/></item></content><references/></fda-approved><phase-3><content><item empty-type="None"><text>None.</text><references/></item></content><references/></phase-3><phase-2><content><item empty-type="None"><text>None.</text><references/></item></content><references/></phase-2><phase-1><content><item empty-type="None"><text>None.</text><references/></item></content><references/></phase-1><preclinical><content><item empty-type="None"><text>None.</text><references/></item></content><references/></preclinical><clinical-trials prioritized-by="regionally"><curation-notes><curation-note>At this time, there are no therapies or clinical trials available to target this alteration.</curation-note></curation-notes></clinical-trials><clinical-trials prioritized-by="clinically"><curation-notes><curation-note>At this time, there are no therapies or clinical trials available to target this alteration.</curation-note></curation-notes></clinical-trials></biomarker-content><biomarker-content A7a3290d9-6293-4153-b566-01d170375249="A9a6df334-db7a-4189-8131-de0b7445fcef" alteration-name="R1214W" marker="TET2" test-type="MUTN (seq)" user-alteration-name="R1214W"><Aa78028f2-e7b0-431a-8c50-8e79acce7dd9>Ac9ef39dc-ef76-4624-88e9-38956ce11e19</Aa78028f2-e7b0-431a-8c50-8e79acce7dd9><biomarker-summary><content><item><text>TET2-R1214W is an inactivating mutation.</text><references/></item></content><references/></biomarker-summary><biomarker-summary content-type="clinical-relevance"><content><item><text>TET2 is a tumor suppressor that functions to create modified nucleotide precursors to methylated DNA.</text><references><reference><reference-id>22240200</reference-id><title>TET2, a tumor suppressor in hematological disorders.</title><authors>Mercher T, Quivoron C, Couronné L, Bastard C, Vainchenker W, Bernard O</authors><journal>Biochimica et biophysica acta</journal><issue>2</issue><year>2012</year><page>173-7</page></reference><reference><reference-id>19372255</reference-id><title>Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.</title><authors>Jankowska A, Szpurka H, Tiu R, Makishima H, Afable M, Huh J, O'Keefe C, Ganetzky R, McDevitt M, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2009</year><page>6403-10</page></reference><reference><reference-id>20639862</reference-id><title>Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.</title><authors>Ito S, D'Alessio A, Taranova O, Hong K, Sowers L, Zhang Y</authors><journal>Nature</journal><issue>7310</issue><year>2010</year><page>1129-33</page></reference></references></item><item><text>There are currently no approved therapies available to directly address TET2 mutation or loss of functional Tet2 protein. However, the use of DNA methyltransferase (DNMT) inhibitors is under investigation in multiple tumor types to address inactivating alterations in TET2.</text><references><reference><reference-id>22289496</reference-id><title>p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.</title><authors>Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B</authors><journal>Seminars in oncology</journal><issue>1</issue><year>2012</year><page>97-108</page></reference><reference><reference-id>9988266</reference-id><title>Cancer epigenetics comes of age.</title><authors>Jones P, Laird P</authors><journal>Nature genetics</journal><issue>2</issue><year>1999</year><page>163-7</page></reference><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference></references></item></content><references><reference><reference-id>22240200</reference-id><title>TET2, a tumor suppressor in hematological disorders.</title><authors>Mercher T, Quivoron C, Couronné L, Bastard C, Vainchenker W, Bernard O</authors><journal>Biochimica et biophysica acta</journal><issue>2</issue><year>2012</year><page>173-7</page></reference><reference><reference-id>19372255</reference-id><title>Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.</title><authors>Jankowska A, Szpurka H, Tiu R, Makishima H, Afable M, Huh J, O'Keefe C, Ganetzky R, McDevitt M, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2009</year><page>6403-10</page></reference><reference><reference-id>20639862</reference-id><title>Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.</title><authors>Ito S, D'Alessio A, Taranova O, Hong K, Sowers L, Zhang Y</authors><journal>Nature</journal><issue>7310</issue><year>2010</year><page>1129-33</page></reference><reference><reference-id>22289496</reference-id><title>p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.</title><authors>Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B</authors><journal>Seminars in oncology</journal><issue>1</issue><year>2012</year><page>97-108</page></reference><reference><reference-id>9988266</reference-id><title>Cancer epigenetics comes of age.</title><authors>Jones P, Laird P</authors><journal>Nature genetics</journal><issue>2</issue><year>1999</year><page>163-7</page></reference><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference></references></biomarker-summary><biomarker-summary content-type="disease-summary"><content><item><text>TET2 has been reported to function as a tumor suppressor in myeloid malignancies and play a role in hematopoietic cell homeostasis; deletion of TET2 in mice has been shown to result in the development of myeloid malignancies resembling chronic myelomonocytic leukemia (CMML) and MDS.</text><references><reference><reference-id>21803851</reference-id><title>Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.</title><authors>Li Z, Cai X, Cai C, Wang J, Zhang W, Petersen B, Yang F, Xu M</authors><journal>Blood</journal><issue>17</issue><year>2011</year><page>4509-18</page></reference><reference><reference-id>21723201</reference-id><title>TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.</title><authors>Quivoron C, Couronné L, Della Valle V, Lopez C, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern M, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard O</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>25-38</page></reference><reference><reference-id>25601757</reference-id><title>WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.</title><authors>Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H, Jiao B, Ren R, Ye D, Guan K, Xiong Y</authors><journal>Molecular cell</journal><issue>4</issue><year>2015</year><page>662-73</page></reference><reference><reference-id>25886910</reference-id><title>Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.</title><authors>Rasmussen K, Jia G, Johansen J, Pedersen M, Rapin N, Bagger F, Porse B, Bernard O, Christensen J, Helin K</authors><journal>Genes &amp; development</journal><issue>9</issue><year>2015</year><page>910-22</page></reference><reference><reference-id>21723200</reference-id><title>Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.</title><authors>Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer S, Melnick A, Godley L, Aifantis I, Levine R</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>11-24</page></reference><reference><reference-id>26607761</reference-id><title>Acute loss of TET function results in aggressive myeloid cancer in mice.</title><authors>An J, González-Avalos E, Chawla A, Jeong M, López-Moyado I, Li W, Goodell M, Chavez L, Ko M, Rao A</authors><journal>Nature communications</journal><year>2015</year><page>10071</page></reference></references></item><item><text>TET2 mutations have also been associated with secondary leukemia, and either alone or combination with other mutations, including in FLT3, have been reported to play a role in the progression of MDS to AML.</text><references><reference><reference-id>24778653</reference-id><title>The epigenetic landscape of acute myeloid leukemia.</title><authors>Conway O'Brien E, Prideaux S, Chevassut T</authors><journal>Advances in hematology</journal><year>2014</year><page>103175</page></reference><reference><reference-id>20068184</reference-id><title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.</title><authors>Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine R, Verstovsek S</authors><journal>Cancer research</journal><issue>2</issue><year>2010</year><page>447-52</page></reference><reference><reference-id>19483684</reference-id><title>Acquired mutations in TET2 are common in myelodysplastic syndromes.</title><authors>Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M, Stevens-Linders E, van Hoogen P, van Kessel A, Raymakers R, Kamping E, Verhoef G, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden B, Jansen J</authors><journal>Nature genetics</journal><issue>7</issue><year>2009</year><page>838-42</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25200248</reference-id><title>Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.</title><authors>Scopim-Ribeiro R, Machado-Neto J, Campos P, Silva C, Favaro P, Lorand-Metze I, Costa F, Saad S, Traina F</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>413-8</page></reference><reference><reference-id>23996483</reference-id><title>Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.</title><authors>Lin T, Nagata Y, Kao H, Sanada M, Okuno Y, Huang C, Liang D, Kuo M, Lai C, Lee E, Shih Y, Tanaka H, Shiraishi Y, Chiba K, Lin T, Wu J, Miyano S, Ogawa S, Shih L</authors><journal>Haematologica</journal><issue>1</issue><year>2014</year><page>28-36</page></reference></references></item><item><text>Several studies in AML have correlated TET2 mutation and decreased TET2 mRNA expression with poor prognosis, particularly among cytogenetically-normal (CN) or favorable-risk AML patients.</text><references><reference><reference-id>24524305</reference-id><title>Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.</title><authors>Liu W, Tan X, Luo X, Guo B, Wei Z, Ke Q, He S, Cen H</authors><journal>Leukemia &amp; lymphoma</journal><issue>12</issue><year>2014</year><page>2691-8</page></reference><reference><reference-id>22116554</reference-id><title>Landscape of TET2 mutations in acute myeloid leukemia.</title><authors>Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A</authors><journal>Leukemia</journal><issue>5</issue><year>2012</year><page>934-42</page></reference><reference><reference-id>21343549</reference-id><title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.</title><authors>Metzeler K, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland K, Schwind S, Whitman S, Wu Y, Blum W, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>10</issue><year>2011</year><page>1373-81</page></reference><reference><reference-id>19420352</reference-id><title>Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.</title><authors>Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau M, Beran M, Tallman M, Ebert B, Kantarjian H, Stone R, Gilliland D, Crispino J, Levine R</authors><journal>Blood</journal><issue>1</issue><year>2009</year><page>144-7</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference><reference><reference-id>23521373</reference-id><title>CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.</title><authors>Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S</authors><journal>British journal of haematology</journal><issue>5</issue><year>2013</year><page>649-58</page></reference><reference><reference-id>28070990</reference-id><title>A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.</title><authors>Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, Yang Y, Li L, Yeh S, Bai L, Liao Y, Lin C, Hsieh C, Lin C, Lin C, Lien M, Chen T, Ni Y, Chiu C</authors><journal>Cancer medicine</journal><issue>2</issue><year>2017</year><page>349-360</page></reference></references></item><item><text>Studies in AML and MDS have reported higher response rates to hypomethylating agents, including azacitidine and decitabine, in patients with mutant TET2.</text><references><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference><reference><reference-id>25224413</reference-id><title>TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.</title><authors>Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone R, Neuberg D, Steensma D, Ebert B</authors><journal>Blood</journal><issue>17</issue><year>2014</year><page>2705-12</page></reference><reference><reference-id>22915641</reference-id><title>Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.</title><authors>Sekeres M, Tiu R, Komrokji R, Lancet J, Advani A, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List A, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2012</year><page>4945-51</page></reference><reference><reference-id>24045501</reference-id><title>Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.</title><authors>Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe C, Sekeres M, Advani A, Kalaycio M, Copelan E, Saunthararajah Y, Olalla Saad S, Maciejewski J, Tiu R</authors><journal>Leukemia</journal><issue>1</issue><year>2014</year><page>78-87</page></reference><reference><reference-id>28193779</reference-id><title>Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.</title><authors>Shih A, Meydan C, Shank K, Garrett-Bakelman F, Ward P, Intlekofer A, Nazir A, Stein E, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason C, Yen K, Thompson C, Melnick A, Levine R</authors><journal>Cancer discovery</journal><issue>5</issue><year>2017</year><page>494-505</page></reference></references></item></content><references><reference><reference-id>21803851</reference-id><title>Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.</title><authors>Li Z, Cai X, Cai C, Wang J, Zhang W, Petersen B, Yang F, Xu M</authors><journal>Blood</journal><issue>17</issue><year>2011</year><page>4509-18</page></reference><reference><reference-id>21723201</reference-id><title>TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.</title><authors>Quivoron C, Couronné L, Della Valle V, Lopez C, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern M, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard O</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>25-38</page></reference><reference><reference-id>25601757</reference-id><title>WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.</title><authors>Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H, Jiao B, Ren R, Ye D, Guan K, Xiong Y</authors><journal>Molecular cell</journal><issue>4</issue><year>2015</year><page>662-73</page></reference><reference><reference-id>25886910</reference-id><title>Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.</title><authors>Rasmussen K, Jia G, Johansen J, Pedersen M, Rapin N, Bagger F, Porse B, Bernard O, Christensen J, Helin K</authors><journal>Genes &amp; development</journal><issue>9</issue><year>2015</year><page>910-22</page></reference><reference><reference-id>21723200</reference-id><title>Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.</title><authors>Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer S, Melnick A, Godley L, Aifantis I, Levine R</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>11-24</page></reference><reference><reference-id>26607761</reference-id><title>Acute loss of TET function results in aggressive myeloid cancer in mice.</title><authors>An J, González-Avalos E, Chawla A, Jeong M, López-Moyado I, Li W, Goodell M, Chavez L, Ko M, Rao A</authors><journal>Nature communications</journal><year>2015</year><page>10071</page></reference><reference><reference-id>24778653</reference-id><title>The epigenetic landscape of acute myeloid leukemia.</title><authors>Conway O'Brien E, Prideaux S, Chevassut T</authors><journal>Advances in hematology</journal><year>2014</year><page>103175</page></reference><reference><reference-id>20068184</reference-id><title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.</title><authors>Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine R, Verstovsek S</authors><journal>Cancer research</journal><issue>2</issue><year>2010</year><page>447-52</page></reference><reference><reference-id>19483684</reference-id><title>Acquired mutations in TET2 are common in myelodysplastic syndromes.</title><authors>Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M, Stevens-Linders E, van Hoogen P, van Kessel A, Raymakers R, Kamping E, Verhoef G, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden B, Jansen J</authors><journal>Nature genetics</journal><issue>7</issue><year>2009</year><page>838-42</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25200248</reference-id><title>Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.</title><authors>Scopim-Ribeiro R, Machado-Neto J, Campos P, Silva C, Favaro P, Lorand-Metze I, Costa F, Saad S, Traina F</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>413-8</page></reference><reference><reference-id>23996483</reference-id><title>Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.</title><authors>Lin T, Nagata Y, Kao H, Sanada M, Okuno Y, Huang C, Liang D, Kuo M, Lai C, Lee E, Shih Y, Tanaka H, Shiraishi Y, Chiba K, Lin T, Wu J, Miyano S, Ogawa S, Shih L</authors><journal>Haematologica</journal><issue>1</issue><year>2014</year><page>28-36</page></reference><reference><reference-id>24524305</reference-id><title>Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.</title><authors>Liu W, Tan X, Luo X, Guo B, Wei Z, Ke Q, He S, Cen H</authors><journal>Leukemia &amp; lymphoma</journal><issue>12</issue><year>2014</year><page>2691-8</page></reference><reference><reference-id>22116554</reference-id><title>Landscape of TET2 mutations in acute myeloid leukemia.</title><authors>Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A</authors><journal>Leukemia</journal><issue>5</issue><year>2012</year><page>934-42</page></reference><reference><reference-id>21343549</reference-id><title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.</title><authors>Metzeler K, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland K, Schwind S, Whitman S, Wu Y, Blum W, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>10</issue><year>2011</year><page>1373-81</page></reference><reference><reference-id>19420352</reference-id><title>Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.</title><authors>Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau M, Beran M, Tallman M, Ebert B, Kantarjian H, Stone R, Gilliland D, Crispino J, Levine R</authors><journal>Blood</journal><issue>1</issue><year>2009</year><page>144-7</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference><reference><reference-id>23521373</reference-id><title>CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.</title><authors>Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S</authors><journal>British journal of haematology</journal><issue>5</issue><year>2013</year><page>649-58</page></reference><reference><reference-id>28070990</reference-id><title>A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.</title><authors>Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, Yang Y, Li L, Yeh S, Bai L, Liao Y, Lin C, Hsieh C, Lin C, Lin C, Lien M, Chen T, Ni Y, Chiu C</authors><journal>Cancer medicine</journal><issue>2</issue><year>2017</year><page>349-360</page></reference><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference><reference><reference-id>25224413</reference-id><title>TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.</title><authors>Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone R, Neuberg D, Steensma D, Ebert B</authors><journal>Blood</journal><issue>17</issue><year>2014</year><page>2705-12</page></reference><reference><reference-id>22915641</reference-id><title>Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.</title><authors>Sekeres M, Tiu R, Komrokji R, Lancet J, Advani A, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List A, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2012</year><page>4945-51</page></reference><reference><reference-id>24045501</reference-id><title>Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.</title><authors>Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe C, Sekeres M, Advani A, Kalaycio M, Copelan E, Saunthararajah Y, Olalla Saad S, Maciejewski J, Tiu R</authors><journal>Leukemia</journal><issue>1</issue><year>2014</year><page>78-87</page></reference><reference><reference-id>28193779</reference-id><title>Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.</title><authors>Shih A, Meydan C, Shank K, Garrett-Bakelman F, Ward P, Intlekofer A, Nazir A, Stein E, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason C, Yen K, Thompson C, Melnick A, Levine R</authors><journal>Cancer discovery</journal><issue>5</issue><year>2017</year><page>494-505</page></reference></references></biomarker-summary><molecular-function><content><item><text>TET2 R1214W is a missense alteration located in the cysteine-rich domain of the Tet2 protein.</text><references><reference><reference-id>28130413</reference-id><title>The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36.</title><authors>Yamagata K, Kobayashi A</authors><journal>Journal of biochemistry</journal><issue>4</issue><year>2017</year><page>327-330</page></reference></references></item><item><text>TET2 R1214W has been reported  to impair 5hmC production and Tet2 recruitment to a Tet2 target locus as compared with wild-type Tet2.</text><references><reference><reference-id>28130413</reference-id><title>The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36.</title><authors>Yamagata K, Kobayashi A</authors><journal>Journal of biochemistry</journal><issue>4</issue><year>2017</year><page>327-330</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference></references></item><item><text>In addition, the NCCN Guidelines (v.2.2017) state that nonsense, frameshift, splice site, and missense alterations in any of the codons spanning TET2 amino acids 1134-1444 or 1842-1921 likely indicate clonal hematopoiesis in myelodysplastic syndrome (MDS) patients and are associated with an otherwise normal karyotype, occurring most frequently in chronic myelomonocytic leukemia (CMML) patients.</text><references/></item></content><references><reference><reference-id>28130413</reference-id><title>The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36.</title><authors>Yamagata K, Kobayashi A</authors><journal>Journal of biochemistry</journal><issue>4</issue><year>2017</year><page>327-330</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference></references></molecular-function><incidence><content><item><text>TET2 mutations have been reported in 13% (778/6180) of Acute myelocytic leukemia (AML) samples analyzed in COSMIC (Apr 2017).</text><references/></item><item><text>TET2 mutations have been reported in 8.5-8.6% of Acute myelocytic leukemia (AML) samples (cBioPortal for Cancer Genomics, Apr 2017).</text><references/></item><item><text>TET2 mutations have been variably reported in 8-27% of AML cases, including 6-32% of cytogenetically normal AML (CN-AML) cases and 24-30% of secondary AML cases.</text><references><reference><reference-id>19474426</reference-id><title>Mutation in TET2 in myeloid cancers.</title><authors>Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic J, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus F, Marzac C, Casadevall N, Lacombe C, Romana S, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard O</authors><journal>The New England journal of medicine</journal><issue>22</issue><year>2009</year><page>2289-301</page></reference><reference><reference-id>20068184</reference-id><title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.</title><authors>Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine R, Verstovsek S</authors><journal>Cancer research</journal><issue>2</issue><year>2010</year><page>447-52</page></reference><reference><reference-id>21343549</reference-id><title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.</title><authors>Metzeler K, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland K, Schwind S, Whitman S, Wu Y, Blum W, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>10</issue><year>2011</year><page>1373-81</page></reference><reference><reference-id>24859829</reference-id><title>TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.</title><authors>Tian X, Xu Y, Yin J, Tian H, Chen S, Wu D, Sun A</authors><journal>International journal of hematology</journal><issue>1</issue><year>2014</year><page>96-104</page></reference><reference><reference-id>22116554</reference-id><title>Landscape of TET2 mutations in acute myeloid leukemia.</title><authors>Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A</authors><journal>Leukemia</journal><issue>5</issue><year>2012</year><page>934-42</page></reference><reference><reference-id>24898826</reference-id><title>TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.</title><authors>Damm F, Markus B, Thol F, Morgan M, Göhring G, Schlegelberger B, Krauter J, Heuser M, Bernard O, Ganser A</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>10</issue><year>2014</year><page>824-32</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference><reference><reference-id>26045292</reference-id><title>Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.</title><authors>Ahn J, Kim H, Kim Y, Jung S, Yang D, Lee J, Lee I, Kim N, Minden M, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim N, Yoshida K, Ogawa S, Kim D</authors><journal>Haematologica</journal><issue>9</issue><year>2015</year><page>e351-3</page></reference><reference><reference-id>22430270</reference-id><title>TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.</title><authors>Gaidzik V, Paschka P, Späth D, Habdank M, Köhne C, Germing U, von Lilienfeld-Toal M, Held G, Horst H, Haase D, Bentz M, Götze K, Döhner H, Schlenk R, Bullinger L, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>12</issue><year>2012</year><page>1350-7</page></reference><reference><reference-id>22912701</reference-id><title>Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.</title><authors>Fernandez-Mercado M, Yip B, Pellagatti A, Davies C, Larrayoz M, Kondo T, Pérez C, Killick S, McDonald E, Odero M, Agirre X, Prósper F, Calasanz M, Wainscoat J, Boultwood J</authors><journal>PloS one</journal><issue>8</issue><year>2012</year><page>e42334</page></reference><reference><reference-id>28039446</reference-id><title>5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Ahn S, Jung S, Yang D, Lee J, Park H, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Michael S, Minden M, Kim D</authors><journal>Oncotarget</journal><issue>5</issue><year>2017</year><page>8305-8314</page></reference><reference><reference-id>28070990</reference-id><title>A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.</title><authors>Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, Yang Y, Li L, Yeh S, Bai L, Liao Y, Lin C, Hsieh C, Lin C, Lin C, Lien M, Chen T, Ni Y, Chiu C</authors><journal>Cancer medicine</journal><issue>2</issue><year>2017</year><page>349-360</page></reference></references></item></content><references><reference><reference-id>19474426</reference-id><title>Mutation in TET2 in myeloid cancers.</title><authors>Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic J, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus F, Marzac C, Casadevall N, Lacombe C, Romana S, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard O</authors><journal>The New England journal of medicine</journal><issue>22</issue><year>2009</year><page>2289-301</page></reference><reference><reference-id>20068184</reference-id><title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.</title><authors>Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine R, Verstovsek S</authors><journal>Cancer research</journal><issue>2</issue><year>2010</year><page>447-52</page></reference><reference><reference-id>21343549</reference-id><title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.</title><authors>Metzeler K, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland K, Schwind S, Whitman S, Wu Y, Blum W, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>10</issue><year>2011</year><page>1373-81</page></reference><reference><reference-id>24859829</reference-id><title>TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.</title><authors>Tian X, Xu Y, Yin J, Tian H, Chen S, Wu D, Sun A</authors><journal>International journal of hematology</journal><issue>1</issue><year>2014</year><page>96-104</page></reference><reference><reference-id>22116554</reference-id><title>Landscape of TET2 mutations in acute myeloid leukemia.</title><authors>Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A</authors><journal>Leukemia</journal><issue>5</issue><year>2012</year><page>934-42</page></reference><reference><reference-id>24898826</reference-id><title>TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.</title><authors>Damm F, Markus B, Thol F, Morgan M, Göhring G, Schlegelberger B, Krauter J, Heuser M, Bernard O, Ganser A</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>10</issue><year>2014</year><page>824-32</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference><reference><reference-id>26045292</reference-id><title>Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.</title><authors>Ahn J, Kim H, Kim Y, Jung S, Yang D, Lee J, Lee I, Kim N, Minden M, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim N, Yoshida K, Ogawa S, Kim D</authors><journal>Haematologica</journal><issue>9</issue><year>2015</year><page>e351-3</page></reference><reference><reference-id>22430270</reference-id><title>TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.</title><authors>Gaidzik V, Paschka P, Späth D, Habdank M, Köhne C, Germing U, von Lilienfeld-Toal M, Held G, Horst H, Haase D, Bentz M, Götze K, Döhner H, Schlenk R, Bullinger L, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>12</issue><year>2012</year><page>1350-7</page></reference><reference><reference-id>22912701</reference-id><title>Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.</title><authors>Fernandez-Mercado M, Yip B, Pellagatti A, Davies C, Larrayoz M, Kondo T, Pérez C, Killick S, McDonald E, Odero M, Agirre X, Prósper F, Calasanz M, Wainscoat J, Boultwood J</authors><journal>PloS one</journal><issue>8</issue><year>2012</year><page>e42334</page></reference><reference><reference-id>28039446</reference-id><title>5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Ahn S, Jung S, Yang D, Lee J, Park H, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Michael S, Minden M, Kim D</authors><journal>Oncotarget</journal><issue>5</issue><year>2017</year><page>8305-8314</page></reference><reference><reference-id>28070990</reference-id><title>A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.</title><authors>Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, Yang Y, Li L, Yeh S, Bai L, Liao Y, Lin C, Hsieh C, Lin C, Lin C, Lien M, Chen T, Ni Y, Chiu C</authors><journal>Cancer medicine</journal><issue>2</issue><year>2017</year><page>349-360</page></reference></references></incidence><role-in-disease><content><item><text>Decreased levels of 5hmC have been associated with decreased expression of Tet2 in solid tumors, as compared with normal tissues, and decreased 5hmC has been associated with tumor development in mice.</text><references><reference><reference-id>22391558</reference-id><title>Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.</title><authors>Yang H, Liu Y, Bai F, Zhang J, Ma S, Liu J, Xu Z, Zhu H, Ling Z, Ye D, Guan K, Xiong Y</authors><journal>Oncogene</journal><issue>5</issue><year>2013</year><page>663-9</page></reference><reference><reference-id>24122999</reference-id><title>Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma.</title><authors>Jäwert F, Hasséus B, Kjeller G, Magnusson B, Sand L, Larsson L</authors><journal>Anticancer research</journal><issue>10</issue><year>2013</year><page>4325-8</page></reference><reference><reference-id>26093090</reference-id><title>TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.</title><authors>Murata A, Baba Y, Ishimoto T, Miyake K, Kosumi K, Harada K, Kurashige J, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Yamamoto M, Oda S, Watanabe M, Nakao M, Baba H</authors><journal>Oncotarget</journal><issue>27</issue><year>2015</year><page>23372-82</page></reference></references></item><item><text>TET2 has been reported to function as a tumor suppressor in myeloid malignancies and play a role in hematopoietic cell homeostasis; deletion of TET2 in mice has been shown to result in the development of myeloid malignancies resembling CMML and MDS.</text><references><reference><reference-id>21803851</reference-id><title>Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.</title><authors>Li Z, Cai X, Cai C, Wang J, Zhang W, Petersen B, Yang F, Xu M</authors><journal>Blood</journal><issue>17</issue><year>2011</year><page>4509-18</page></reference><reference><reference-id>21723201</reference-id><title>TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.</title><authors>Quivoron C, Couronné L, Della Valle V, Lopez C, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern M, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard O</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>25-38</page></reference><reference><reference-id>26607761</reference-id><title>Acute loss of TET function results in aggressive myeloid cancer in mice.</title><authors>An J, González-Avalos E, Chawla A, Jeong M, López-Moyado I, Li W, Goodell M, Chavez L, Ko M, Rao A</authors><journal>Nature communications</journal><year>2015</year><page>10071</page></reference><reference><reference-id>25601757</reference-id><title>WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.</title><authors>Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H, Jiao B, Ren R, Ye D, Guan K, Xiong Y</authors><journal>Molecular cell</journal><issue>4</issue><year>2015</year><page>662-73</page></reference><reference><reference-id>25886910</reference-id><title>Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.</title><authors>Rasmussen K, Jia G, Johansen J, Pedersen M, Rapin N, Bagger F, Porse B, Bernard O, Christensen J, Helin K</authors><journal>Genes &amp; development</journal><issue>9</issue><year>2015</year><page>910-22</page></reference><reference><reference-id>21723200</reference-id><title>Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.</title><authors>Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer S, Melnick A, Godley L, Aifantis I, Levine R</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>11-24</page></reference></references></item><item><text>TET2 mutations have also been associated with secondary leukemia, and either alone or combination with other mutations, including in FLT3, have been reported to play a role in the progression of MDS to AML.</text><references><reference><reference-id>24778653</reference-id><title>The epigenetic landscape of acute myeloid leukemia.</title><authors>Conway O'Brien E, Prideaux S, Chevassut T</authors><journal>Advances in hematology</journal><year>2014</year><page>103175</page></reference><reference><reference-id>20068184</reference-id><title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.</title><authors>Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine R, Verstovsek S</authors><journal>Cancer research</journal><issue>2</issue><year>2010</year><page>447-52</page></reference><reference><reference-id>19483684</reference-id><title>Acquired mutations in TET2 are common in myelodysplastic syndromes.</title><authors>Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M, Stevens-Linders E, van Hoogen P, van Kessel A, Raymakers R, Kamping E, Verhoef G, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden B, Jansen J</authors><journal>Nature genetics</journal><issue>7</issue><year>2009</year><page>838-42</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25200248</reference-id><title>Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.</title><authors>Scopim-Ribeiro R, Machado-Neto J, Campos P, Silva C, Favaro P, Lorand-Metze I, Costa F, Saad S, Traina F</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>413-8</page></reference><reference><reference-id>23996483</reference-id><title>Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.</title><authors>Lin T, Nagata Y, Kao H, Sanada M, Okuno Y, Huang C, Liang D, Kuo M, Lai C, Lee E, Shih Y, Tanaka H, Shiraishi Y, Chiba K, Lin T, Wu J, Miyano S, Ogawa S, Shih L</authors><journal>Haematologica</journal><issue>1</issue><year>2014</year><page>28-36</page></reference></references></item></content><references><reference><reference-id>22391558</reference-id><title>Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.</title><authors>Yang H, Liu Y, Bai F, Zhang J, Ma S, Liu J, Xu Z, Zhu H, Ling Z, Ye D, Guan K, Xiong Y</authors><journal>Oncogene</journal><issue>5</issue><year>2013</year><page>663-9</page></reference><reference><reference-id>24122999</reference-id><title>Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma.</title><authors>Jäwert F, Hasséus B, Kjeller G, Magnusson B, Sand L, Larsson L</authors><journal>Anticancer research</journal><issue>10</issue><year>2013</year><page>4325-8</page></reference><reference><reference-id>26093090</reference-id><title>TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.</title><authors>Murata A, Baba Y, Ishimoto T, Miyake K, Kosumi K, Harada K, Kurashige J, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Yamamoto M, Oda S, Watanabe M, Nakao M, Baba H</authors><journal>Oncotarget</journal><issue>27</issue><year>2015</year><page>23372-82</page></reference><reference><reference-id>21803851</reference-id><title>Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.</title><authors>Li Z, Cai X, Cai C, Wang J, Zhang W, Petersen B, Yang F, Xu M</authors><journal>Blood</journal><issue>17</issue><year>2011</year><page>4509-18</page></reference><reference><reference-id>21723201</reference-id><title>TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.</title><authors>Quivoron C, Couronné L, Della Valle V, Lopez C, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern M, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard O</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>25-38</page></reference><reference><reference-id>26607761</reference-id><title>Acute loss of TET function results in aggressive myeloid cancer in mice.</title><authors>An J, González-Avalos E, Chawla A, Jeong M, López-Moyado I, Li W, Goodell M, Chavez L, Ko M, Rao A</authors><journal>Nature communications</journal><year>2015</year><page>10071</page></reference><reference><reference-id>25601757</reference-id><title>WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.</title><authors>Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H, Jiao B, Ren R, Ye D, Guan K, Xiong Y</authors><journal>Molecular cell</journal><issue>4</issue><year>2015</year><page>662-73</page></reference><reference><reference-id>25886910</reference-id><title>Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.</title><authors>Rasmussen K, Jia G, Johansen J, Pedersen M, Rapin N, Bagger F, Porse B, Bernard O, Christensen J, Helin K</authors><journal>Genes &amp; development</journal><issue>9</issue><year>2015</year><page>910-22</page></reference><reference><reference-id>21723200</reference-id><title>Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.</title><authors>Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer S, Melnick A, Godley L, Aifantis I, Levine R</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>11-24</page></reference><reference><reference-id>24778653</reference-id><title>The epigenetic landscape of acute myeloid leukemia.</title><authors>Conway O'Brien E, Prideaux S, Chevassut T</authors><journal>Advances in hematology</journal><year>2014</year><page>103175</page></reference><reference><reference-id>20068184</reference-id><title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.</title><authors>Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine R, Verstovsek S</authors><journal>Cancer research</journal><issue>2</issue><year>2010</year><page>447-52</page></reference><reference><reference-id>19483684</reference-id><title>Acquired mutations in TET2 are common in myelodysplastic syndromes.</title><authors>Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M, Stevens-Linders E, van Hoogen P, van Kessel A, Raymakers R, Kamping E, Verhoef G, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden B, Jansen J</authors><journal>Nature genetics</journal><issue>7</issue><year>2009</year><page>838-42</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>25200248</reference-id><title>Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.</title><authors>Scopim-Ribeiro R, Machado-Neto J, Campos P, Silva C, Favaro P, Lorand-Metze I, Costa F, Saad S, Traina F</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>413-8</page></reference><reference><reference-id>23996483</reference-id><title>Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.</title><authors>Lin T, Nagata Y, Kao H, Sanada M, Okuno Y, Huang C, Liang D, Kuo M, Lai C, Lee E, Shih Y, Tanaka H, Shiraishi Y, Chiba K, Lin T, Wu J, Miyano S, Ogawa S, Shih L</authors><journal>Haematologica</journal><issue>1</issue><year>2014</year><page>28-36</page></reference></references></role-in-disease><diagnostic-significance><variant diagnostic-level-of-evidence="None found"><content><item empty-type="Unknown"><text>Unknown.</text><references/></item></content><references/></variant></diagnostic-significance><prognostic-significance><variant prognostic-level-of-evidence="C"><content><item><text>Several studies in AML have correlated TET2 mutation and decreased TET2 mRNA expression with poor prognosis, particularly among cytogenetically-normal (CN) or favorable-risk AML patients.</text><references><reference><reference-id>24524305</reference-id><title>Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.</title><authors>Liu W, Tan X, Luo X, Guo B, Wei Z, Ke Q, He S, Cen H</authors><journal>Leukemia &amp; lymphoma</journal><issue>12</issue><year>2014</year><page>2691-8</page></reference><reference><reference-id>22116554</reference-id><title>Landscape of TET2 mutations in acute myeloid leukemia.</title><authors>Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A</authors><journal>Leukemia</journal><issue>5</issue><year>2012</year><page>934-42</page></reference><reference><reference-id>21343549</reference-id><title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.</title><authors>Metzeler K, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland K, Schwind S, Whitman S, Wu Y, Blum W, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>10</issue><year>2011</year><page>1373-81</page></reference><reference><reference-id>19420352</reference-id><title>Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.</title><authors>Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau M, Beran M, Tallman M, Ebert B, Kantarjian H, Stone R, Gilliland D, Crispino J, Levine R</authors><journal>Blood</journal><issue>1</issue><year>2009</year><page>144-7</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference><reference><reference-id>23521373</reference-id><title>CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.</title><authors>Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S</authors><journal>British journal of haematology</journal><issue>5</issue><year>2013</year><page>649-58</page></reference><reference><reference-id>28070990</reference-id><title>A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.</title><authors>Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, Yang Y, Li L, Yeh S, Bai L, Liao Y, Lin C, Hsieh C, Lin C, Lin C, Lien M, Chen T, Ni Y, Chiu C</authors><journal>Cancer medicine</journal><issue>2</issue><year>2017</year><page>349-360</page></reference></references></item></content><references><reference><reference-id>24524305</reference-id><title>Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.</title><authors>Liu W, Tan X, Luo X, Guo B, Wei Z, Ke Q, He S, Cen H</authors><journal>Leukemia &amp; lymphoma</journal><issue>12</issue><year>2014</year><page>2691-8</page></reference><reference><reference-id>22116554</reference-id><title>Landscape of TET2 mutations in acute myeloid leukemia.</title><authors>Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A</authors><journal>Leukemia</journal><issue>5</issue><year>2012</year><page>934-42</page></reference><reference><reference-id>21343549</reference-id><title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.</title><authors>Metzeler K, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland K, Schwind S, Whitman S, Wu Y, Blum W, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>10</issue><year>2011</year><page>1373-81</page></reference><reference><reference-id>19420352</reference-id><title>Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.</title><authors>Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau M, Beran M, Tallman M, Ebert B, Kantarjian H, Stone R, Gilliland D, Crispino J, Levine R</authors><journal>Blood</journal><issue>1</issue><year>2009</year><page>144-7</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference><reference><reference-id>23521373</reference-id><title>CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.</title><authors>Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S</authors><journal>British journal of haematology</journal><issue>5</issue><year>2013</year><page>649-58</page></reference><reference><reference-id>28070990</reference-id><title>A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.</title><authors>Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, Yang Y, Li L, Yeh S, Bai L, Liao Y, Lin C, Hsieh C, Lin C, Lin C, Lien M, Chen T, Ni Y, Chiu C</authors><journal>Cancer medicine</journal><issue>2</issue><year>2017</year><page>349-360</page></reference></references></variant></prognostic-significance><drug-sensitivity><content><item><text>There are no approved therapies that directly target loss of Tet2 function; however, loss of Tet2 function has been correlated with aberrant DNA methylation, and DNA methyltransferase (DNMT) inhibitors have been reported to be beneficial in TET2-mutant tumors.</text><references><reference><reference-id>25886910</reference-id><title>Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.</title><authors>Rasmussen K, Jia G, Johansen J, Pedersen M, Rapin N, Bagger F, Porse B, Bernard O, Christensen J, Helin K</authors><journal>Genes &amp; development</journal><issue>9</issue><year>2015</year><page>910-22</page></reference><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference><reference><reference-id>25224413</reference-id><title>TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.</title><authors>Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone R, Neuberg D, Steensma D, Ebert B</authors><journal>Blood</journal><issue>17</issue><year>2014</year><page>2705-12</page></reference><reference><reference-id>24045501</reference-id><title>Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.</title><authors>Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe C, Sekeres M, Advani A, Kalaycio M, Copelan E, Saunthararajah Y, Olalla Saad S, Maciejewski J, Tiu R</authors><journal>Leukemia</journal><issue>1</issue><year>2014</year><page>78-87</page></reference><reference><reference-id>26876596</reference-id><title>DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.</title><authors>Scourzic L, Couronné L, Pedersen M, Della Valle V, Diop M, Mylonas E, Calvo J, Mouly E, Lopez C, Martin N, Fontenay M, Bender A, Guibert S, Dubreuil P, Dessen P, Droin N, Pflumio F, Weber M, Gaulard P, Helin K, Mercher T, Bernard O</authors><journal>Leukemia</journal><issue>6</issue><year>2016</year><page>1388-98</page></reference></references></item><item><text>The DNMT inhibitors azacitidine and decitabine have been approved by the FDA for use in myelodysplastic syndrome (MDS) and are in clinical development in other cancer types.</text><references><reference><reference-id>22122748</reference-id><title>Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.</title><authors>Cowan L, Talwar S, Yang A</authors><journal>Epigenomics</journal><issue>1</issue><year>2010</year><page>71-86</page></reference><reference><reference-id>15897554</reference-id><title>Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.</title><authors>Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh L, Lee S, Leighton J, Patel H, Rahman A, Sridhara R, Wang Y, Pazdur R</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>10</issue><year>2005</year><page>3604-8</page></reference></references></item><item><text>Other DNMT inhibitors, including 5-fluoro-2-deoxycytidine (FdCyd) in combination with tetrahydrouridine (THU), are also in preclinical and clinical development.</text><references><reference><reference-id>25567350</reference-id><title>A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.</title><authors>Newman E, Morgan R, Kummar S, Beumer J, Blanchard M, Ruel C, El-Khoueiry A, Carroll M, Hou J, Li C, Lenz H, Eiseman J, Doroshow J</authors><journal>Cancer chemotherapy and pharmacology</journal><issue>3</issue><year>2015</year><page>537-46</page></reference></references></item><item><text>Studies in AML and MDS have reported higher response rates to hypomethylating agents, including azacitidine and decitabine, in patients with mutant TET2.</text><references><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference><reference><reference-id>25224413</reference-id><title>TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.</title><authors>Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone R, Neuberg D, Steensma D, Ebert B</authors><journal>Blood</journal><issue>17</issue><year>2014</year><page>2705-12</page></reference><reference><reference-id>22915641</reference-id><title>Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.</title><authors>Sekeres M, Tiu R, Komrokji R, Lancet J, Advani A, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List A, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2012</year><page>4945-51</page></reference><reference><reference-id>24045501</reference-id><title>Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.</title><authors>Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe C, Sekeres M, Advani A, Kalaycio M, Copelan E, Saunthararajah Y, Olalla Saad S, Maciejewski J, Tiu R</authors><journal>Leukemia</journal><issue>1</issue><year>2014</year><page>78-87</page></reference></references></item></content><references><reference><reference-id>25886910</reference-id><title>Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.</title><authors>Rasmussen K, Jia G, Johansen J, Pedersen M, Rapin N, Bagger F, Porse B, Bernard O, Christensen J, Helin K</authors><journal>Genes &amp; development</journal><issue>9</issue><year>2015</year><page>910-22</page></reference><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference><reference><reference-id>25224413</reference-id><title>TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.</title><authors>Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone R, Neuberg D, Steensma D, Ebert B</authors><journal>Blood</journal><issue>17</issue><year>2014</year><page>2705-12</page></reference><reference><reference-id>24045501</reference-id><title>Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.</title><authors>Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe C, Sekeres M, Advani A, Kalaycio M, Copelan E, Saunthararajah Y, Olalla Saad S, Maciejewski J, Tiu R</authors><journal>Leukemia</journal><issue>1</issue><year>2014</year><page>78-87</page></reference><reference><reference-id>26876596</reference-id><title>DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.</title><authors>Scourzic L, Couronné L, Pedersen M, Della Valle V, Diop M, Mylonas E, Calvo J, Mouly E, Lopez C, Martin N, Fontenay M, Bender A, Guibert S, Dubreuil P, Dessen P, Droin N, Pflumio F, Weber M, Gaulard P, Helin K, Mercher T, Bernard O</authors><journal>Leukemia</journal><issue>6</issue><year>2016</year><page>1388-98</page></reference><reference><reference-id>22122748</reference-id><title>Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.</title><authors>Cowan L, Talwar S, Yang A</authors><journal>Epigenomics</journal><issue>1</issue><year>2010</year><page>71-86</page></reference><reference><reference-id>15897554</reference-id><title>Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.</title><authors>Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh L, Lee S, Leighton J, Patel H, Rahman A, Sridhara R, Wang Y, Pazdur R</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>10</issue><year>2005</year><page>3604-8</page></reference><reference><reference-id>25567350</reference-id><title>A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.</title><authors>Newman E, Morgan R, Kummar S, Beumer J, Blanchard M, Ruel C, El-Khoueiry A, Carroll M, Hou J, Li C, Lenz H, Eiseman J, Doroshow J</authors><journal>Cancer chemotherapy and pharmacology</journal><issue>3</issue><year>2015</year><page>537-46</page></reference><reference><reference-id>22915641</reference-id><title>Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.</title><authors>Sekeres M, Tiu R, Komrokji R, Lancet J, Advani A, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List A, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2012</year><page>4945-51</page></reference></references></drug-sensitivity><drug-resistance><content/><references/></drug-resistance><fda-approved><content><item empty-type="None"><text>None.</text><references/></item></content><references/></fda-approved><phase-3><content><item><text>A registry study of azacitidine in 302 AML patients, including off-label use in 172 patients exhibiting greater than 30% bone marrow blasts, reported an overall response rate of 48%, with median overall survival of 9.6 months; clinically relevant median overall survival was observed in patients who achieved at least disease stabilization, including marrow stable disease (8.1 months), hematologic improvement (9.7 months), or a combination of these factors (18.9 months), as compared to patients without response or disease stabilization (3.2 months).</text><references><reference><reference-id>24951123</reference-id><title>Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.</title><authors>Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, Schreder M, Tinchon C, Sliwa T, Lang A, Sperr W, Krippl P, Geissler D, Voskova D, Schlick K, Thaler J, Machherndl-Spandl S, Theiler G, Eckmüllner O, Greil R</authors><journal>Annals of hematology</journal><issue>11</issue><year>2014</year><page>1825-38</page></reference></references></item><item><text>A Phase 3 trial in 488 patients ages 65 and older with newly diagnosed AML evaluated azacitidine versus conventional care regimens (CCR), which included best supportive care (BSC), standard induction chemotherapy (IC), and low-dose ara-c (LDAC). At a median time of follow-up of 24.4 months, median overall survival times for the azacitidine and CCR groups were 10.4 and 6.5 months, respectively, and 6.4 and 3.2 months, respectively, in patients with poor-risk cytogenetics. One year survival rates of 46.5% and 34.2% were reported; overall response rates of 27.8% and 25.9% and stable disease rates of 29.5% and 23.9%, respectively, were attained.</text><references><reference><reference-id>25987659</reference-id><title>International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts.</title><authors>Dombret H, Seymour J, Butrym A, Wierzbowska A, Selleslag D, Jang J, Kumar R, Cavenagh J, Schuh A, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali H, Martinelli G, Falantes J, Noppeney R, Stone R, Minden M, McIntyre H, Songer S, Lucy L, Beach C, Döhner H</authors><journal>Blood</journal><issue>3</issue><year>2015</year><page>291-9</page></reference></references></item><item><text>A Phase 3 trial of 485 newly diagnosed AML patients ages 65 and older reported an increase in the median overall survival with decitabine (7.7 months), as compared with supportive care or cytarabine (5.0 months), though this difference was not statistically significant.  However, complete remission was reported in 20.5% (38/185) of evaluable patients treated with decitabine, as compared with 11.1% (17/152) of those receiving cytarabine.</text><references><reference><reference-id>22689805</reference-id><title>Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.</title><authors>Kantarjian H, Thomas X, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau J, Chou W, Buckstein R, Cermak J, Kuo C, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>21</issue><year>2012</year><page>2670-7</page></reference></references></item></content><references><reference><reference-id>24951123</reference-id><title>Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.</title><authors>Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, Schreder M, Tinchon C, Sliwa T, Lang A, Sperr W, Krippl P, Geissler D, Voskova D, Schlick K, Thaler J, Machherndl-Spandl S, Theiler G, Eckmüllner O, Greil R</authors><journal>Annals of hematology</journal><issue>11</issue><year>2014</year><page>1825-38</page></reference><reference><reference-id>25987659</reference-id><title>International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts.</title><authors>Dombret H, Seymour J, Butrym A, Wierzbowska A, Selleslag D, Jang J, Kumar R, Cavenagh J, Schuh A, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali H, Martinelli G, Falantes J, Noppeney R, Stone R, Minden M, McIntyre H, Songer S, Lucy L, Beach C, Döhner H</authors><journal>Blood</journal><issue>3</issue><year>2015</year><page>291-9</page></reference><reference><reference-id>22689805</reference-id><title>Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.</title><authors>Kantarjian H, Thomas X, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau J, Chou W, Buckstein R, Cermak J, Kuo C, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>21</issue><year>2012</year><page>2670-7</page></reference></references></phase-3><phase-2><content><item><text>A Phase 1b/2 study of everolimus with azacitidine in 40 previously treated, relapsed or refractory AML patients has reported an overall response rate of 22.5% (9/40) and an overall survival of 8.5 months. Notably, in patients also receiving azoles, as compared with those not receiving azoles, an improvement in overall survival (12.8 months versus 6.0 months, respectively) and overall response rate (50% versus 16%, respectively) was reported.</text><references><reference><reference-id>27911276</reference-id><title>The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.</title><authors>Tan P, Soo Tiong I, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A</authors><journal>Oncotarget</journal><year>2016</year><page>[Epub ahead of print]</page></reference></references></item><item><text>Phase 2 studies of AML patients 60 years or older with no prior treatment have reported that decitabine treatment results in complete remission in 13-47% of cases. Additionally, all studies have reported that adverse cytogenetics did not impact response rates to decitabine.</text><references><reference><reference-id>20368434</reference-id><title>Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.</title><authors>Blum W, Garzon R, Klisovic R, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine S, Chan K, Heerema N, Bloomfield C, Grever M, Byrd J, Villalona-Calero M, Croce C, Marcucci G</authors><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><issue>16</issue><year>2010</year><page>7473-8</page></reference><reference><reference-id>20026803</reference-id><title>Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.</title><authors>Cashen A, Schiller G, O'Donnell M, DiPersio J</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>556-61</page></reference><reference><reference-id>22058219</reference-id><title>A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.</title><authors>Lübbert M, Rüter B, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans P, Döhner H</authors><journal>Haematologica</journal><issue>3</issue><year>2012</year><page>393-401</page></reference></references></item><item><text>Analysis of guadecitabine at five and ten day dosing regimens in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy reported a clinical response in 57% (29/51) of patients on the five day regimen and 48% (25/52) of patients on the ten day regimen; median overall survival times were 10.5 and 8.7 months, respectively, and similar mortality rates were reported. A subsequent analysis has reported comparable clinical activity in all analyzed prognostic subgroups; however, a worse overall survival was associated with patients with poor performance status (ECOG PS=2; only patients with PS 0-2 were evaluated), poor risk cytogenetics, and with less than six months from last therapy.</text><references><reference><reference-id>ASH 2015, Abstract 458</reference-id><title>Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)</title><authors>Kantarjian HM, Roboz GJ, Kropf PL et al.</authors><journal>Blood</journal><year>2015</year><page>Abstract 458</page></reference><reference><reference-id>ASH 2016, Abstract 904</reference-id><title>Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies</title><authors>Daver N, Kantarjian HM, Roboz GJ, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 904</page></reference></references></item></content><references><reference><reference-id>27911276</reference-id><title>The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.</title><authors>Tan P, Soo Tiong I, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A</authors><journal>Oncotarget</journal><year>2016</year><page>[Epub ahead of print]</page></reference><reference><reference-id>20368434</reference-id><title>Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.</title><authors>Blum W, Garzon R, Klisovic R, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine S, Chan K, Heerema N, Bloomfield C, Grever M, Byrd J, Villalona-Calero M, Croce C, Marcucci G</authors><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><issue>16</issue><year>2010</year><page>7473-8</page></reference><reference><reference-id>20026803</reference-id><title>Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.</title><authors>Cashen A, Schiller G, O'Donnell M, DiPersio J</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>556-61</page></reference><reference><reference-id>22058219</reference-id><title>A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.</title><authors>Lübbert M, Rüter B, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans P, Döhner H</authors><journal>Haematologica</journal><issue>3</issue><year>2012</year><page>393-401</page></reference><reference><reference-id>ASH 2015, Abstract 458</reference-id><title>Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)</title><authors>Kantarjian HM, Roboz GJ, Kropf PL et al.</authors><journal>Blood</journal><year>2015</year><page>Abstract 458</page></reference><reference><reference-id>ASH 2016, Abstract 904</reference-id><title>Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies</title><authors>Daver N, Kantarjian HM, Roboz GJ, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 904</page></reference></references></phase-2><phase-1><content><item><text>A Phase 1 study of guadecitabine in 93 patients with refractory or relapsed MDS or AML reported a clinical response in 31.2% (6/19) of MDS and 8.1% (6/74) of AML cases, with a similar side-effect profile to other hypomethylating agents.</text><references><reference><reference-id>26296954</reference-id><title>Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.</title><authors>Issa J, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths E, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder J, Azab M, Kantarjian H</authors><journal>The Lancet. Oncology</journal><issue>9</issue><year>2015</year><page>1099-1110</page></reference></references></item></content><references><reference><reference-id>26296954</reference-id><title>Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.</title><authors>Issa J, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths E, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder J, Azab M, Kantarjian H</authors><journal>The Lancet. Oncology</journal><issue>9</issue><year>2015</year><page>1099-1110</page></reference></references></phase-1><preclinical><content><item empty-type="Not applicable"><text>N/A: Preclinical data are not presented when higher level data are available.</text><references/></item></content><references/></preclinical><therapies><therapy therapeutic-level-of-evidence="C/D"><drug-name>Azacitidine</drug-name><targets><target>DNMT</target></targets><trade-name>Vidaza</trade-name><rationale>DNMT inhibitor.</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>Myelodysplastic Syndrome (MDS)</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 3</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="C/D"><drug-name>Decitabine</drug-name><targets><target>DNMT</target></targets><trade-name>Dacogen</trade-name><rationale>DNMT inhibitor.</rationale><status-in-other-indications><status>FDA Approved</status><disease-list><disease>Myelodysplastic Syndrome (MDS)</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 3</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="E"><drug-name>Guadecitabine</drug-name><targets><target>DNMT</target></targets><rationale>DNMT inhibitor.</rationale><status-in-other-indications><status>Phase 3</status><disease-list><disease>Myelodysplastic Syndrome (MDS)</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 3</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="E"><drug-name>FdCyd+THU</drug-name><targets><target>DNMT</target></targets><rationale>DNMT inhibitor.</rationale><status-in-other-indications><status>Phase 2</status><disease-list><disease>Non-small cell lung carcinoma (NSCLC)</disease><disease>Head and neck carcinoma</disease><disease>Bladder carcinoma</disease><disease>Breast carcinoma</disease><disease>Bladder urothelial (transitional cell) carcinoma</disease></disease-list></status-in-other-indications><status-in-this-indication><status>Phase 1</status><disease-list><disease>Acute myelocytic leukemia (AML)</disease></disease-list></status-in-this-indication></therapy><therapy therapeutic-level-of-evidence="None found"><drug-name>TdCyd</drug-name><targets><target>DNMT</target></targets><rationale>DNMT inhibitor.</rationale><status-in-other-indications><status>Phase 1</status><disease-list><disease>Solid Tumor</disease></disease-list></status-in-other-indications></therapy></therapies><clinical-trials prioritized-by="regionally"><clinical-trial><trial-id>NCT02752035</trial-id><title>A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy</title><phase>Phase 2/Phase 3</phase><targets><target>ALK</target><target>AXL</target><target>DNMT</target><target>FLT3</target></targets><overall-contact>Overall contact: Astellas Pharma Global Development, astellas.registration@astellas.com, 800-888-7704 x5473</overall-contact><markers><marker>TET2</marker><marker>FLT3</marker></markers><trial-sites><trial-site><center>Site US10007</center><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10004</center><city>New Haven</city><state>Connecticut</state><country>United States</country><postal-code>06510-3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10006</center><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>32610-0278</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10036</center><city>Augusta</city><state>Georgia</state><country>United States</country><postal-code>30912</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10010</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60611-5975</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10037</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10003</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10023</center><city>Maywood</city><state>Illinois</state><country>United States</country><postal-code>60153</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10018</center><city>Louisville</city><state>Kentucky</state><country>United States</country><postal-code>40207</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10021</center><city>New Orleans</city><state>Louisiana</state><country>United States</country><postal-code>70112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10035</center><city>Brewer</city><state>Maine</state><country>United States</country><postal-code>04412</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10005</center><city>Hackensack</city><state>New Jersey</state><country>United States</country><postal-code>7601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10011</center><city>Morristown</city><state>New Jersey</state><country>United States</country><postal-code>07962</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10033</center><city>Buffalo</city><state>New York</state><country>United States</country><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10039</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10022</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10016</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10012</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10009</center><city>Syracuse</city><state>New York</state><country>United States</country><postal-code>13210</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10015</center><city>Oklahoma City</city><state>Oklahoma</state><country>United States</country><postal-code>73104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10031</center><city>Hershey</city><state>Pennsylvania</state><country>United States</country><postal-code>17033-0850</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10034</center><city>Greenville</city><state>South Carolina</state><country>United States</country><postal-code>26615</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10028</center><city>Dallas</city><state>Texas</state><country>United States</country><postal-code>75246</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10002</center><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10026</center><city>Seattle</city><state>Washington</state><country>United States</country><postal-code>98104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61012</center><city>Camperdown</city><state>New South Wales</state><country>Australia</country><postal-code>2050</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61004</center><city>Liverpool</city><state>New South Wales</state><country>Australia</country><postal-code>2170</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61008</center><city>Adelaide</city><state>South Australia</state><country>Australia</country><postal-code>SA 5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61007</center><city>Geelong</city><state>Victoria</state><country>Australia</country><postal-code>3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32003</center><city>Bruxelles</city><state>Bruxelles-Capitale, Region de</state><country>Belgium</country><postal-code>1200</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32007</center><city>Brussel</city><state>Bruxelles</state><country>Belgium</country><postal-code>1090</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32006</center><city>Gent</city><country>Belgium</country><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15009</center><city>Edmonton</city><state>Alberta</state><country>Canada</country><postal-code>T6G 2B7</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15004</center><city>Halifax</city><state>Nova Scotia</state><country>Canada</country><postal-code>B3H 2Y9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15002</center><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 2M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15006</center><city>Montreal</city><state>Quebec</state><country>Canada</country><postal-code>H4A 3J1</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33002</center><city>Pessac</city><state>Gironde</state><country>France</country><postal-code>33604</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33015</center><city>Rouen</city><state>Haute-Normandie</state><country>France</country><postal-code>76038</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33016</center><city>Limoges</city><state>Haute-Vienne</state><country>France</country><postal-code>87042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33019</center><city>Montpellier Cedex 5</city><state>Herault</state><country>France</country><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33018</center><city>Rennes</city><state>Ille-et-Vilaine</state><country>France</country><postal-code>35033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33001</center><city>Nantes cedex 01</city><state>Loire-Atlantique</state><country>France</country><postal-code>44093</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33014</center><city>Vandoeuvre les Nancy</city><state>Meurthe-et-Moselle</state><country>France</country><postal-code>54500</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33013</center><city>Pierre-Benite</city><state>Rhone</state><country>France</country><postal-code>69310</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33017</center><city>Le Mans</city><state>Sarthe</state><country>France</country><postal-code>72037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33005</center><city>Amiens</city><state>Somme</state><country>France</country><postal-code>80054</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33012</center><city>Poitiers</city><state>Vienne</state><country>France</country><postal-code>86000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33009</center><city>Angers</city><country>France</country><postal-code>49033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33007</center><city>Le Chesnay Cedex</city><country>France</country><postal-code>78157</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33004</center><city>Lille cedex</city><country>France</country><postal-code>59020</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33006</center><city>Lille</city><country>France</country><postal-code>59037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49002</center><city>Tuebingen</city><state>Baden-Wurttemberg</state><country>Germany</country><postal-code>72076</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49007</center><city>Munchen</city><state>Bayern</state><country>Germany</country><postal-code>81737</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49012</center><city>Braunschweig</city><state>Niedersachsen</state><country>Germany</country><postal-code>38118</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49004</center><city>Hannover</city><state>Niedersachsen</state><country>Germany</country><postal-code>30625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49008</center><city>Bonn</city><state>Nordrhein-Westfalen</state><country>Germany</country><postal-code>53105</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49009</center><city>Halle (Saale)</city><state>Sachsen-Anhalt</state><country>Germany</country><postal-code>06120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49013</center><city>Heilbronn</city><country>Germany</country><postal-code>74078</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49011</center><city>Stuttgart</city><country>Germany</country><postal-code>70376</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81027</center><city>Matsuyama</city><state>Ehime</state><country>Japan</country><postal-code>790-0024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81024</center><city>Gifu</city><state>Gihu</state><country>Japan</country><postal-code>500-8513</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81010</center><city>Maebashi</city><state>Gunma</state><country>Japan</country><postal-code>371-0821</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81006</center><city>Sapporo</city><state>Hokkaido</state><country>Japan</country><postal-code>060-8648</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81014</center><city>Shinagawa-ku</city><state>Tokyo</state><country>Japan</country><postal-code>141-8625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81022</center><city>Tachikawa</city><state>Tokyo</state><country>Japan</country><postal-code>190-0014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81017</center><city>Nagasaki</city><country>Japan</country><postal-code>852-8511</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81019</center><city>Toyama</city><country>Japan</country><postal-code>930-8550</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82003</center><city>Namdong</city><state>Incheon Gwang'yeogsiv</state><country>Korea, Republic of</country><postal-code>405 760</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82010</center><city>Hwasungun</city><state>Jeonranamdo</state><country>Korea, Republic of</country><postal-code>58128</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82013</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>05505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82008</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>06351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82006</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>110-744</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82002</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>137-701</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82001</center><city>Ulsan</city><state>Ulsan Gwang'yeogsi</state><country>Korea, Republic of</country><postal-code>682-714</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82014</center><city>Busan</city><country>Korea, Republic of</country><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82012</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>156-707</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48003</center><city>Lublin</city><state>Lubelskie</state><country>Poland</country><postal-code>20-081</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48005</center><city>Krakow</city><state>Małopolskie</state><country>Poland</country><postal-code>31-501</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48002</center><city>Opole</city><state>Opolskie</state><country>Poland</country><postal-code>45-061</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48001</center><city>Olsztyn</city><state>Warmińsko-mazurskie</state><country>Poland</country><postal-code>10-228</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34011</center><city>Coruna</city><state>A Coruna</state><country>Spain</country><postal-code>15006</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34003</center><city>Oviedo</city><state>Asturias</state><country>Spain</country><postal-code>33011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34007</center><city>Palma de Mallorca</city><state>Baleares</state><country>Spain</country><postal-code>07010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34008</center><city>Barcelona</city><country>Spain</country><postal-code>08003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34004</center><city>Barcelona</city><country>Spain</country><postal-code>08035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34010</center><city>Barcelona</city><country>Spain</country><postal-code>08036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34009</center><city>Barcelona</city><country>Spain</country><postal-code>8041</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34002</center><city>Caceres</city><country>Spain</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34005</center><city>Valencia</city><country>Spain</country><postal-code>46026</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88605</center><city>Kweishan Hsiang</city><state>Taoyuan</state><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88604</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88607</center><city>Taichung</city><country>Taiwan</country><postal-code>40705</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88602</center><city>Tainan</city><country>Taiwan</country><postal-code>704</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88609</center><city>Tainan</city><country>Taiwan</country><postal-code>736</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88601</center><city>Taipei</city><country>Taiwan</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88608</center><city>Taipei</city><country>Taiwan</country><postal-code>10449</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88610</center><city>Taipei</city><country>Taiwan</country><postal-code>11217</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44004</center><city>London</city><state>London, City of</state><country>United Kingdom</country><postal-code>EC1A 7BE</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02920008</trial-id><title>Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia</title><phase>Phase 3</phase><targets><target>DNMT</target></targets><overall-contact>Overall contact: Laksmi Wilson, laksmi.wilson@astx.com, 925-560-2914</overall-contact><markers><marker>TET2</marker></markers><trial-sites><trial-site><center>University of Southern California</center><contact>Sondra Ortiz</contact><city>Los Angeles</city><state>California</state><country>United States</country><email>sondra.ortiz@med.usc.edu</email><postal-code>90033</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Chicago Medical Center</center><contact>Howard Weiner</contact><city>Chicago</city><state>Illinois</state><country>United States</country><email>hweiner@medicine.bsd.uchicago.edu</email><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Franciscan Research Center</center><contact>Isabella van der Merwe</contact><city>Indianapolis</city><state>Indiana</state><country>United States</country><email>isabella.vandermerwe@franciscanalliance.org</email><postal-code>46237</postal-code><status>Recruiting</status></trial-site><trial-site><center>John Theurer Cancer Center at Hackensack University Medical Center</center><contact>Gillian Velardi</contact><city>Hackensack</city><state>New Jersey</state><country>United States</country><email>Gillian.Velardi@hackensackmeridian.org</email><postal-code>07601-1915</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of New Mexico School of Medicine</center><contact>Daniel Weishampel</contact><city>Albuquerque</city><state>New Mexico</state><country>United States</country><email>dweishampel@salud.unm.edu</email><postal-code>87106</postal-code><status>Recruiting</status></trial-site><trial-site><center>Roswell Park Cancer Institute</center><contact>Heather Bashaw</contact><city>Buffalo</city><state>New York</state><country>United States</country><email>heather.bashaw@roswellpark.org</email><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Weill Cornell Medical College</center><contact>Latia Skerving</contact><city>New York</city><state>New York</state><country>United States</country><email>las2051@med.cornell.edu</email><postal-code>10021</postal-code><status>Recruiting</status></trial-site><trial-site><center>Stony Brook University Hospital</center><contact>Sebastian Munoz</contact><city>Stony Brook</city><state>New York</state><country>United States</country><email>sebastian.munoz@stonybrookmedicine.edu</email><postal-code>11794</postal-code><status>Recruiting</status></trial-site><trial-site><center>Duke Cancer Institute</center><contact>Rachel Stowe</contact><city>Durham</city><state>North Carolina</state><country>United States</country><email>rachel.stowe@dm.duke.edu</email><postal-code>27710</postal-code><status>Recruiting</status></trial-site><trial-site><center>Temple University Hospital</center><contact>Lilanee Chanyothi</contact><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><email>lilanee.chanyothi@fccc.edu</email><postal-code>19111-2433</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vanderbilt University Medical Center</center><contact>Channing Dudley</contact><city>Nashville</city><state>Tennessee</state><country>United States</country><email>channing.v.dudley@vanderbilt.edu</email><postal-code>37232</postal-code><status>Recruiting</status></trial-site><trial-site><center>MD Anderson Cancer Center</center><contact>Dana Wright</contact><city>Houston</city><state>Texas</state><country>United States</country><email>djwright@mdanderson.org</email><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Swedish Cancer Institute</center><contact>Erik Bailey</contact><city>Seattle</city><state>Washington</state><country>United States</country><email>erik.bailey@swedish.org</email><postal-code>98104</postal-code><status>Recruiting</status></trial-site><trial-site><center>West Virginia University Hospitals, Inc.</center><contact>Patricia Beal</contact><city>Morgantown</city><state>West Virginia</state><country>United States</country><email>pbeal@hsc.wvu.edu</email><postal-code>26506</postal-code><status>Recruiting</status></trial-site><trial-site><center>AZ Sint-Jan Brugge-Oostende AV</center><contact>Laura Salenbien</contact><city>Brugge</city><country>Belgium</country><email>laura.salenbien@azsintjan.be</email><postal-code>8000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitair Ziekenhuis Gent</center><contact>Jonas Segaert</contact><city>Gent</city><country>Belgium</country><email>jonas.segaert@uzgent.be</email><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tom Baker Cancer Centre</center><contact>Jeff Greenway</contact><city>Calgary</city><state>Alberta</state><country>Canada</country><email>jeff.greenway@ahs.ca</email><postal-code>T2N 4N2</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Alberta Hospital</center><contact>Lori Rackel</contact><city>Edmonton</city><state>Alberta</state><country>Canada</country><email>lori.rackel@albertahealthservices.ca</email><postal-code>T6G 2V2</postal-code><status>Recruiting</status></trial-site><trial-site><center>Princess Margaret Cancer Centre</center><contact>Jennifer Kim</contact><city>Toronto</city><state>Ontario</state><country>Canada</country><email>jennifer.kim@uhn.ca</email><postal-code>M5G 2C1</postal-code><status>Recruiting</status></trial-site><trial-site><center>CHRU Montpellier - Saint Eloi</center><contact>Vera Sabadash</contact><city>Montpellier</city><country>France</country><email>v-sabadash@chu-montpellier.fr</email><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Groupe Hospitalier de la Région de Mulhouse et Sud Alsace</center><contact>Céline Haby</contact><city>Mulhouse</city><country>France</country><email>habyc@ghrmsa.fr</email><postal-code>68100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Saint-Louis</center><contact>Blandine Beve</contact><city>Paris</city><country>France</country><email>blandine.beve@aphp.fr</email><postal-code>75475</postal-code><status>Recruiting</status></trial-site><trial-site><center>Institut Universitaire du Cancer de Toulouse - Oncopole</center><contact>Isabelle De Ponnat</contact><city>Toulouse</city><country>France</country><email>deponnat.isabelle@iuct-oncopole.fr</email><postal-code>31059</postal-code><status>Recruiting</status></trial-site><trial-site><center>Debreceni Egyetem Klinikai Központ</center><contact>Gabriella Mezei</contact><city>Debrecen</city><country>Hungary</country><email>gmezei@gmail.com</email><postal-code>4032</postal-code><status>Recruiting</status></trial-site><trial-site><center>Somogy Megyei Kaposi Mór Oktató Kórház</center><contact>Éva Meskuláné Szilágyi</contact><city>Kaposvar</city><country>Hungary</country><postal-code>7400</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pecsi Tudomanyegyetem Klinikai Központ</center><contact>Gábor Kollár</contact><city>Pécs</city><country>Hungary</country><email>gkollar32@gmail.com</email><status>Recruiting</status></trial-site><trial-site><center>Szegedi Tudományegyetem</center><contact>Agnes Nagyne</contact><city>Szeged</city><country>Hungary</country><email>nagyne.agi.szte@gmail.com</email><postal-code>6725</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Bundang Hospital</center><contact>Eun Jin Kim</contact><city>Seongnam-si</city><state>Gyeonggi-do</state><country>Korea, Republic of</country><email>r1598@snubh.org</email><postal-code>5505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pusan National University Hospital</center><contact>Jinyi Baek</contact><city>Busan</city><country>Korea, Republic of</country><email>forawayz@naver.com</email><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Hospital</center><contact>Ju-Hyun Lee</contact><city>Seoul</city><country>Korea, Republic of</country><email>lee-jh8368@daum.net</email><postal-code>3080</postal-code><status>Recruiting</status></trial-site><trial-site><center>Severance Hospital</center><contact>So-Young Choi</contact><city>Seoul</city><country>Korea, Republic of</country><email>so-youngchoi@yuhs.ac</email><postal-code>3722</postal-code><status>Recruiting</status></trial-site><trial-site><center>Samsung Medical Center</center><contact>Jayeon Kim</contact><city>Seoul</city><country>Korea, Republic of</country><email>jy0760.kim@samsung.com</email><postal-code>6351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ulsan University Hospital (UUH)</center><contact>Hae Jin Kang</contact><city>Ulsan</city><country>Korea, Republic of</country><email>uuhimpjina@naver.com</email><postal-code>44033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital San Pedro de Alcántara</center><contact>Carmen Alcaine</contact><city>Cáceres</city><country>Spain</country><email>mamenalca@gmail.com</email><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario Gregorio Marañón</center><contact>Marta Hernández Martín</contact><city>Madrid</city><country>Spain</country><email>martama.hernandez@gmail.com</email><postal-code>28007</postal-code><status>Recruiting</status></trial-site><trial-site><center>East Kent Hospitals University NHS Foundation Trust - Kent and Canterbury Hospital</center><contact>Lavina Davey</contact><city>Canterbury</city><country>United Kingdom</country><email>laviniadavey@nhs.net</email><postal-code>CT1 3NG</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02993523</trial-id><title>A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy</title><phase>Phase 3</phase><targets><target>BCL2</target><target>DNMT</target></targets><overall-contact>Overall contact: AbbVie_Call Center, abbvieclinicaltrials@abbvie.com, 847.283.8955</overall-contact><markers><marker>TET2</marker></markers><trial-sites><trial-site><center>City of Hope National Medical Center /ID# 154105</center><city>Duarte</city><state>California</state><country>United States</country><postal-code>91010</postal-code><status>Recruiting</status></trial-site><trial-site><center>UCLA /Id# 154107</center><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>University of California, Davis Comprehensive Cancer Center /ID# 162725</center><city>Sacramento</city><state>California</state><country>United States</country><postal-code>95817</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Chicago /ID# 154108</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Fort Wayne Medical Oncology and Hematology, Inc. /ID# 157190</center><city>Fort Wayne</city><state>Indiana</state><country>United States</country><postal-code>46804</postal-code><status>Recruiting</status></trial-site><trial-site><center>Cotton-O'Neil Clinical Research Center /ID# 155136</center><city>Topeka</city><state>Kansas</state><country>United States</country><postal-code>66606</postal-code><status>Recruiting</status></trial-site><trial-site><center>Norton Cancer Institute /ID# 154992</center><city>Louisville</city><state>Kentucky</state><country>United States</country><postal-code>40207</postal-code><status>Recruiting</status></trial-site><trial-site><center>EMMC Cancer Care /ID# 154991</center><city>Brewer</city><state>Maine</state><country>United States</country><postal-code>04412</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Sepctrum Health Medical Center /ID# 159522</center><city>Grand Rapids</city><state>Michigan</state><country>United States</country><postal-code>49503</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Columbia University Medical Center /ID# 154101</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10032</postal-code><status>Recruiting</status></trial-site><trial-site><center>Duke Univ Medical Center /ID# 154106</center><city>Durham</city><state>North Carolina</state><country>United States</country><postal-code>27710</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Pittsburgh /ID# 154102</center><city>Pittsburgh</city><state>Pennsylvania</state><country>United States</country><postal-code>15232</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Texas - MD Anderson Cancer Center /ID# 154100</center><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Scott &amp; White Memorial Hospital and Clinic /ID# 157191</center><city>Temple</city><state>Texas</state><country>United States</country><postal-code>76508</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Utah Huntsman Cancer Hospital /ID# 157192</center><city>Salt Lake City</city><state>Utah</state><country>United States</country><postal-code>84112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Royal Adelaide Hospital /ID# 154271</center><city>Adelaide</city><country>Australia</country><postal-code>5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Medical University Graz /ID# 157882</center><city>Graz</city><country>Austria</country><postal-code>8036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Krankenhaus der Elisabethinen Linz GmbH /ID# 154885</center><city>Linz</city><country>Austria</country><postal-code>4020</postal-code><status>Recruiting</status></trial-site><trial-site><center>Krankenhaus der Barmherzigen Schwestern /ID# 154888</center><city>Linz</city><country>Austria</country><postal-code>4070</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hanusch Krankenhaus der WGKK Wien /ID# 155676</center><city>Vienna</city><country>Austria</country><postal-code>1140</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital de Clinicas de Porto Alegre /ID# 157779</center><city>Porto Alegre</city><country>Brazil</country><postal-code>CEP 90430-160</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Hospital das Clinicas da Faculdade de Medicina de Ribeirao /ID# 153099</center><city>Ribeirao Preto</city><country>Brazil</country><postal-code>14048-900</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Hospital Albert Einstein /ID# 153098</center><city>Sao Paulo, Morumbi</city><country>Brazil</country><postal-code>05652-000</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Instituto de Ensino e Pesquisa Salo Lucas /ID# 157778</center><city>Sao Paulo</city><country>Brazil</country><postal-code>01236-030</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>ICESP Instituto do Cancer do Estado de Sao Paulo /ID# 153095</center><city>Sao Paulo</city><country>Brazil</country><postal-code>01246-000</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Tom Baker Cancer Centre /ID# 159645</center><city>Calgary</city><country>Canada</country><postal-code>T2N 2T9</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Juravinski Hospital &amp; Cancer Centre /ID# 153650</center><city>Hamilton</city><country>Canada</country><postal-code>L8V 1C3</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>The Ottawa Hospital Cancer Centre /ID# 153541</center><city>Ottawa</city><country>Canada</country><postal-code>K1H 8L6</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>St. Paul's Hospital /ID# 159644</center><city>Vancouver,BC</city><country>Canada</country><postal-code>V6E1M7</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Klinicki bolnicki centar Osijek /ID# 153623</center><city>Osijek</city><country>Croatia</country><postal-code>31000</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Klinicka bolnica Dubrava /ID# 153515</center><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Klinicki bolnicki Centar Zagreb /ID# 153383</center><city>Zagreb</city><country>Croatia</country><postal-code>10000</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Aalborg University Hospital /ID# 154047</center><city>Aalborg</city><country>Denmark</country><postal-code>9000</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Tampereen yliopistollinen sairaala /ID# 154963</center><city>Tampere</city><country>Finland</country><postal-code>33520</postal-code><status>Recruiting</status></trial-site><trial-site><center>Turku University Hospital /ID# 154964</center><city>Turku</city><country>Finland</country><postal-code>FI-20520</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>CHU d'Angers /ID# 153792</center><city>Angers Cedex</city><country>France</country><postal-code>49033</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>IUCT Oncopole /ID# 153788</center><city>Toulouse Cedex 9</city><country>France</country><postal-code>31059</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Universitatsklinikum Halle (Saale) /ID# 153058</center><city>Halle</city><country>Germany</country><postal-code>06120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitatsklinikum Munster /ID# 153059</center><city>Muenster</city><country>Germany</country><postal-code>D-48149</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitaetsklinikum Ulm /ID# 167253</center><city>Ulm</city><country>Germany</country><postal-code>89081</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Semmelweis Egyetem /ID# 153816</center><city>Budapest</city><country>Hungary</country><postal-code>1083</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Egyesitett Szent Istvan es Szent Laszlo Korhaz /ID# 158990</center><city>Budapest</city><country>Hungary</country><postal-code>1097</postal-code><status>Recruiting</status></trial-site><trial-site><center>Semmelweis Egyeteme III. sz Belgyogyaszati Klinika /ID# 153815</center><city>Budapest</city><country>Hungary</country><postal-code>1125</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Debreceni Egyetem /ID# 153814</center><city>Debrecen</city><country>Hungary</country><postal-code>4032</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Kaposi Mor Oktato Korhaz /ID# 153813</center><city>Kaposvar</city><country>Hungary</country><postal-code>7400</postal-code><status>Recruiting</status></trial-site><trial-site><center>Szegedi Tudomanyegyetem Szent-Gyorgyi /ID# 153812</center><city>Szeged</city><country>Hungary</country><postal-code>6725</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Hadassah /ID# 154172</center><city>Jerusalem</city><country>Israel</country><postal-code>91120</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Assaf Harofeh Medical Center /ID# 158063</center><city>Zerifin</city><country>Israel</country><postal-code>70300</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Papa Giovanni XXIII /ID# 152875</center><city>Bergamo</city><country>Italy</country><postal-code>24127</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>IRCCS AOU San Martino-IST Padiglione Maragliano /ID# 158104</center><city>Genoa</city><country>Italy</country><postal-code>16132</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 152879</center><city>Naples</city><country>Italy</country><postal-code>80131</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 152882</center><city>padiglione Marcora</city><country>Italy</country><postal-code>20122</postal-code><status>Recruiting</status></trial-site><trial-site><center>Azieda Ospedaliera "Bianchi Melacrino Morelli" /ID# 152877</center><city>Reggio Calabria</city><country>Italy</country><postal-code>89125</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Azienda Ospedaliera Sant' Andrea /ID# 152876</center><city>Roma</city><country>Italy</country><postal-code>00189</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Hospital /ID# 153675</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>03080</postal-code><status>Recruiting</status></trial-site><trial-site><center>Konkuk University Medical Center /ID# 153973</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>05030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Samsung Medical Center /ID# 153674</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>06351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Haukeland universitetssykehus /ID# 154281</center><city>Bergen</city><country>Norway</country><postal-code>5021</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Drammen Sykehus /ID# 154280</center><city>Drammen</city><country>Norway</country><postal-code>3004</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>SPZOZ Zespol Szpitali Miejskich w Chorzowie /ID# 153385</center><city>Chorzow</city><country>Poland</country><postal-code>41-500</postal-code><status>Recruiting</status></trial-site><trial-site><center>VA Caribbean Healthcare System (VACHS) /ID# 160507</center><city>San Juan</city><country>Puerto Rico</country><postal-code>00921</postal-code><status>Recruiting</status></trial-site><trial-site><center>Kemerovo Regional Clinical Hospital /ID# 157461</center><city>Kemerovo</city><country>Russian Federation</country><postal-code>650066</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>City Clinical Hospital n.a. S.P. Botkina /ID# 155738</center><city>Moscow</city><country>Russian Federation</country><postal-code>125284</postal-code><status>Recruiting</status></trial-site><trial-site><center>Nizhniy Novgorod Regional Clinical Hospital /ID# 153268</center><city>Nizhniy Novgorod</city><country>Russian Federation</country><postal-code>603126</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Ryazan Regional Clinical Hospital /ID# 157460</center><city>Ryazan</city><country>Russian Federation</country><postal-code>390039</postal-code><status>Recruiting</status></trial-site><trial-site><center>State Budgetary Educational Institution of Higher Profession /ID# 153267</center><city>Saratov</city><country>Russian Federation</country><postal-code>410012</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Tshwane District Hospital /ID# 153682</center><city>Pretoria</city><country>South Africa</country><postal-code>0001</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Netcare Pretoria East Hospital /ID# 153684</center><city>Pretoria</city><country>South Africa</country><postal-code>0044</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>VO Hematologi, onkologi och stralningsfysik /ID# 153174</center><city>Lund</city><country>Sweden</country><postal-code>221 85</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Changhua Christian Hospital /ID# 153899</center><city>Changhua</city><country>Taiwan</country><postal-code>500</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 153902</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>807</postal-code><status>Recruiting</status></trial-site><trial-site><center>China Medical University Hospital /ID# 153904</center><city>Taichung</city><country>Taiwan</country><postal-code>40447</postal-code><status>Not yet recruiting</status></trial-site><trial-site><center>National Taiwan University Hospital /ID# 153900</center><city>Taipei City</city><country>Taiwan</country><postal-code>10002</postal-code><status>Not yet recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02343939</trial-id><title>Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)</title><phase>Phase 1/Phase 2</phase><targets><target>DNMT</target><target>SYK</target></targets><overall-contact>Overall contact: Gilead Study Team, GS9973alerts@gilead.com</overall-contact><markers><marker>TET2</marker></markers><trial-sites><trial-site><center>UCLA</center><city>Los Angeles</city><state>California</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>University of Chicago</center><city>Chicago</city><state>Illinois</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Loyola University Medical Center</center><city>Maywood</city><state>Illinois</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Indiana University</center><city>Indianapolis</city><state>Indiana</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>University of Kansas Medical Center Research Institute, Inc</center><city>Fairway</city><state>Kansas</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Dana Farber Cancer Institute</center><city>Boston</city><state>Massachusetts</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Henry Ford Health System</center><city>Detroit</city><state>Michigan</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Karmanos Cancer Institute</center><city>Detroit</city><state>Michigan</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Weill Cornell Medical College - New York - Presbyterian Hospital</center><city>New York</city><state>New York</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Duke Cancer Center</center><city>Durham</city><state>North Carolina</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>University Hospitals Case Medical Center</center><city>Cleveland</city><state>Ohio</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Ohio State University</center><city>Columbus</city><state>Ohio</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Penn State Hershey Cancer Institute</center><city>Hershey</city><state>Pennsylvania</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>University of Pennsylvania, Abramson Cancer Center</center><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Saint Francis Cancer Center</center><city>Greenville</city><state>South Carolina</state><country>United States</country><status>Recruiting</status></trial-site><trial-site><center>Princess Margaret</center><city>Toronto</city><state>Ontario</state><country>Canada</country><status>Recruiting</status></trial-site><trial-site><center>Jewish General Hospital</center><city>Montreal</city><state>Quebec</state><country>Canada</country><status>Recruiting</status></trial-site><trial-site><center>Universitätsklinikum Frankfurt Medizinische Klinik II</center><city>Frankfurt</city><country>Germany</country><postal-code>60590</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT01926587</trial-id><title>Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine</title><phase>Phase 1/Phase 2</phase><targets><target>DNMT</target><target>PLK1</target></targets><overall-contact>Overall contact: Joseph Morgan, MD, jmorgan@onconova.us, (267) 759-3680</overall-contact><markers><marker>TET2</marker></markers><trial-sites><trial-site><center>City of Hope</center><city>Duarte</city><state>California</state><country>United States</country><investigator>Samer Khaled, MD</investigator><postal-code>91010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Rush University Medical Center</center><city>Chicago</city><state>Illinois</state><country>United States</country><investigator>Jamile Shammo, MD</investigator><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>Saint Louis University</center><city>Saint Louis</city><state>Missouri</state><country>United States</country><investigator>M. Nabeel Rajeh, MD</investigator><postal-code>63110</postal-code><status>Recruiting</status></trial-site><trial-site><center>Mount Sinai Medical Center</center><city>New York</city><state>New York</state><country>United States</country><investigator>Shyamala Navada, MD</investigator><postal-code>10029</postal-code><status>Recruiting</status></trial-site><trial-site><center>White Plains Hospital Center for Cancer Care</center><city>White Plains</city><state>New York</state><country>United States</country><investigator>Dan Costin, MD</investigator><postal-code>10601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Carolina Blood and Cancer Care Associates</center><city>Rock Hill</city><state>South Carolina</state><country>United States</country><investigator>Sashi Naidu, MD</investigator><postal-code>29732</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Texas MD Anderson Cancer Center</center><city>Houston</city><state>Texas</state><country>United States</country><investigator>Guillermo Garcia-Manero, MD</investigator><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Froedtert Hospital and the Medical College of Wisconsin</center><city>Milwaukee</city><state>Wisconsin</state><country>United States</country><investigator>Ehab Atallah, MD</investigator><postal-code>53226</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial></clinical-trials><clinical-trials prioritized-by="clinically"><clinical-trial><trial-id>NCT02752035</trial-id><title>A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy</title><phase>Phase 2/Phase 3</phase><targets><target>ALK</target><target>AXL</target><target>DNMT</target><target>FLT3</target></targets><overall-contact>Overall contact: Astellas Pharma Global Development, astellas.registration@astellas.com, 800-888-7704 x5473</overall-contact><markers><marker>TET2</marker><marker>FLT3</marker></markers><trial-sites><trial-site><center>Site US10007</center><city>Los Angeles</city><state>California</state><country>United States</country><postal-code>90095</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10004</center><city>New Haven</city><state>Connecticut</state><country>United States</country><postal-code>06510-3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10006</center><city>Gainesville</city><state>Florida</state><country>United States</country><postal-code>32610-0278</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10036</center><city>Augusta</city><state>Georgia</state><country>United States</country><postal-code>30912</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10010</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60611-5975</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10037</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60612</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10003</center><city>Chicago</city><state>Illinois</state><country>United States</country><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10023</center><city>Maywood</city><state>Illinois</state><country>United States</country><postal-code>60153</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10018</center><city>Louisville</city><state>Kentucky</state><country>United States</country><postal-code>40207</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10021</center><city>New Orleans</city><state>Louisiana</state><country>United States</country><postal-code>70112</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10035</center><city>Brewer</city><state>Maine</state><country>United States</country><postal-code>04412</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10005</center><city>Hackensack</city><state>New Jersey</state><country>United States</country><postal-code>7601</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10011</center><city>Morristown</city><state>New Jersey</state><country>United States</country><postal-code>07962</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10033</center><city>Buffalo</city><state>New York</state><country>United States</country><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10039</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10022</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10016</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10012</center><city>New York</city><state>New York</state><country>United States</country><postal-code>10065</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10009</center><city>Syracuse</city><state>New York</state><country>United States</country><postal-code>13210</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10015</center><city>Oklahoma City</city><state>Oklahoma</state><country>United States</country><postal-code>73104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10031</center><city>Hershey</city><state>Pennsylvania</state><country>United States</country><postal-code>17033-0850</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10034</center><city>Greenville</city><state>South Carolina</state><country>United States</country><postal-code>26615</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10028</center><city>Dallas</city><state>Texas</state><country>United States</country><postal-code>75246</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10002</center><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site US10026</center><city>Seattle</city><state>Washington</state><country>United States</country><postal-code>98104</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61012</center><city>Camperdown</city><state>New South Wales</state><country>Australia</country><postal-code>2050</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61004</center><city>Liverpool</city><state>New South Wales</state><country>Australia</country><postal-code>2170</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61008</center><city>Adelaide</city><state>South Australia</state><country>Australia</country><postal-code>SA 5000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site AU61007</center><city>Geelong</city><state>Victoria</state><country>Australia</country><postal-code>3220</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32003</center><city>Bruxelles</city><state>Bruxelles-Capitale, Region de</state><country>Belgium</country><postal-code>1200</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32007</center><city>Brussel</city><state>Bruxelles</state><country>Belgium</country><postal-code>1090</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site BE32006</center><city>Gent</city><country>Belgium</country><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15009</center><city>Edmonton</city><state>Alberta</state><country>Canada</country><postal-code>T6G 2B7</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15004</center><city>Halifax</city><state>Nova Scotia</state><country>Canada</country><postal-code>B3H 2Y9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15002</center><city>Toronto</city><state>Ontario</state><country>Canada</country><postal-code>M5G 2M9</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site CA15006</center><city>Montreal</city><state>Quebec</state><country>Canada</country><postal-code>H4A 3J1</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33002</center><city>Pessac</city><state>Gironde</state><country>France</country><postal-code>33604</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33015</center><city>Rouen</city><state>Haute-Normandie</state><country>France</country><postal-code>76038</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33016</center><city>Limoges</city><state>Haute-Vienne</state><country>France</country><postal-code>87042</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33019</center><city>Montpellier Cedex 5</city><state>Herault</state><country>France</country><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33018</center><city>Rennes</city><state>Ille-et-Vilaine</state><country>France</country><postal-code>35033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33001</center><city>Nantes cedex 01</city><state>Loire-Atlantique</state><country>France</country><postal-code>44093</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33014</center><city>Vandoeuvre les Nancy</city><state>Meurthe-et-Moselle</state><country>France</country><postal-code>54500</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33013</center><city>Pierre-Benite</city><state>Rhone</state><country>France</country><postal-code>69310</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33017</center><city>Le Mans</city><state>Sarthe</state><country>France</country><postal-code>72037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33005</center><city>Amiens</city><state>Somme</state><country>France</country><postal-code>80054</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33012</center><city>Poitiers</city><state>Vienne</state><country>France</country><postal-code>86000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33009</center><city>Angers</city><country>France</country><postal-code>49033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33007</center><city>Le Chesnay Cedex</city><country>France</country><postal-code>78157</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33004</center><city>Lille cedex</city><country>France</country><postal-code>59020</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site FR33006</center><city>Lille</city><country>France</country><postal-code>59037</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49002</center><city>Tuebingen</city><state>Baden-Wurttemberg</state><country>Germany</country><postal-code>72076</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49007</center><city>Munchen</city><state>Bayern</state><country>Germany</country><postal-code>81737</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49012</center><city>Braunschweig</city><state>Niedersachsen</state><country>Germany</country><postal-code>38118</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49004</center><city>Hannover</city><state>Niedersachsen</state><country>Germany</country><postal-code>30625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49008</center><city>Bonn</city><state>Nordrhein-Westfalen</state><country>Germany</country><postal-code>53105</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49009</center><city>Halle (Saale)</city><state>Sachsen-Anhalt</state><country>Germany</country><postal-code>06120</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49013</center><city>Heilbronn</city><country>Germany</country><postal-code>74078</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site DE49011</center><city>Stuttgart</city><country>Germany</country><postal-code>70376</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81027</center><city>Matsuyama</city><state>Ehime</state><country>Japan</country><postal-code>790-0024</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81024</center><city>Gifu</city><state>Gihu</state><country>Japan</country><postal-code>500-8513</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81010</center><city>Maebashi</city><state>Gunma</state><country>Japan</country><postal-code>371-0821</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81006</center><city>Sapporo</city><state>Hokkaido</state><country>Japan</country><postal-code>060-8648</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81014</center><city>Shinagawa-ku</city><state>Tokyo</state><country>Japan</country><postal-code>141-8625</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81022</center><city>Tachikawa</city><state>Tokyo</state><country>Japan</country><postal-code>190-0014</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81017</center><city>Nagasaki</city><country>Japan</country><postal-code>852-8511</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site JP81019</center><city>Toyama</city><country>Japan</country><postal-code>930-8550</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82003</center><city>Namdong</city><state>Incheon Gwang'yeogsiv</state><country>Korea, Republic of</country><postal-code>405 760</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82010</center><city>Hwasungun</city><state>Jeonranamdo</state><country>Korea, Republic of</country><postal-code>58128</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82013</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>05505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82008</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>06351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82006</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>110-744</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82002</center><city>Seoul</city><state>Seoul Teugbyeolsi</state><country>Korea, Republic of</country><postal-code>137-701</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82001</center><city>Ulsan</city><state>Ulsan Gwang'yeogsi</state><country>Korea, Republic of</country><postal-code>682-714</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82014</center><city>Busan</city><country>Korea, Republic of</country><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site KR82012</center><city>Seoul</city><country>Korea, Republic of</country><postal-code>156-707</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48003</center><city>Lublin</city><state>Lubelskie</state><country>Poland</country><postal-code>20-081</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48005</center><city>Krakow</city><state>Małopolskie</state><country>Poland</country><postal-code>31-501</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48002</center><city>Opole</city><state>Opolskie</state><country>Poland</country><postal-code>45-061</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site PL48001</center><city>Olsztyn</city><state>Warmińsko-mazurskie</state><country>Poland</country><postal-code>10-228</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34011</center><city>Coruna</city><state>A Coruna</state><country>Spain</country><postal-code>15006</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34003</center><city>Oviedo</city><state>Asturias</state><country>Spain</country><postal-code>33011</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34007</center><city>Palma de Mallorca</city><state>Baleares</state><country>Spain</country><postal-code>07010</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34008</center><city>Barcelona</city><country>Spain</country><postal-code>08003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34004</center><city>Barcelona</city><country>Spain</country><postal-code>08035</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34010</center><city>Barcelona</city><country>Spain</country><postal-code>08036</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34009</center><city>Barcelona</city><country>Spain</country><postal-code>8041</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34002</center><city>Caceres</city><country>Spain</country><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site ES34005</center><city>Valencia</city><country>Spain</country><postal-code>46026</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88605</center><city>Kweishan Hsiang</city><state>Taoyuan</state><country>Taiwan</country><postal-code>33305</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88604</center><city>Kaohsiung</city><country>Taiwan</country><postal-code>83301</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88607</center><city>Taichung</city><country>Taiwan</country><postal-code>40705</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88602</center><city>Tainan</city><country>Taiwan</country><postal-code>704</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88609</center><city>Tainan</city><country>Taiwan</country><postal-code>736</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88601</center><city>Taipei</city><country>Taiwan</country><postal-code>10002</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88608</center><city>Taipei</city><country>Taiwan</country><postal-code>10449</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site TW88610</center><city>Taipei</city><country>Taiwan</country><postal-code>11217</postal-code><status>Recruiting</status></trial-site><trial-site><center>Site GB44004</center><city>London</city><state>London, City of</state><country>United Kingdom</country><postal-code>EC1A 7BE</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02196857</trial-id><title>Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation</title><phase>Phase 2</phase><targets><target>BRAF</target><target>CSF1R</target><target>DNMT</target><target>FLT1</target><target>FLT3</target><target>FLT4</target><target>KIT</target><target>PDGFRB</target><target>RAF1</target><target>RET</target></targets><overall-contact>Overall contact: Farhad Ravandi-Kashani, MD, 713-792-7305</overall-contact><markers><marker>TET2</marker><marker>FLT3</marker></markers><trial-sites><trial-site><center>University of Texas MD Anderson Cancer Center</center><contact>MD Anderson Cancer Center</contact><city>Houston</city><state>Texas</state><country>United States</country><postal-code>77030</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02400281</trial-id><title>Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients</title><phase>Phase 1/Phase 2</phase><targets><target>DNMT</target><target>FLT3</target><target>PDGFR</target><target>TOP2A</target></targets><overall-contact>Overall contact: Abhijit Ramachandran, aramachandran@arogpharma.com, 214-593-0515</overall-contact><markers><marker>TET2</marker><marker>FLT3</marker></markers><trial-sites><trial-site><center>MD Anderson Cancer Center</center><contact>Jorge Cortes, MD</contact><city>Houston</city><state>Texas</state><country>United States</country><email>jcortes@mdanderson.edu</email><postal-code>77030</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02551718</trial-id><title>High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia</title><phase>N/A</phase><targets><target>abl kinase</target><target>ABL1</target><target>ALK</target><target>AXL</target><target>BRAF</target><target>BTK</target><target>CSF1R</target><target>DNMT</target><target>EGFR</target><target>EPHA2</target><target>EPHA3</target><target>ERBB2</target><target>ERBB3</target><target>ERBB4</target><target>FGFR1</target><target>FGFR2</target><target>FGFR3</target><target>FGFR4</target><target>FLT1</target><target>FLT3</target><target>FLT4</target><target>HDAC</target><target>HDAC1</target><target>HDAC2</target><target>JAK1</target><target>JAK2</target><target>KDR</target><target>KIT</target><target>MEK</target><target>MET</target><target>MTOR</target><target>NTRK1</target><target>PDGFR</target><target>PDGFRA</target><target>PDGFRB</target><target>proteasome</target><target>RAF1</target><target>RET</target><target>ROS1</target><target>RRM1</target><target>RXRA</target><target>RXRB</target><target>RXRG</target><target>SRC</target><target>TOP1</target><target>TOP2A</target><target>VEGFR1</target><target>VEGFR2</target><target>VEGFR3</target><target>YES1</target></targets><markers><marker>TET2</marker><marker>FLT3</marker></markers><trial-sites><trial-site><center>Fred Hutch/University of Washington Cancer Consortium</center><contact>Pamela S. Becker</contact><city>Seattle</city><state>Washington</state><country>United States</country><email>pbecker@u.washington.edu</email><investigator>Pamela S. Becker</investigator><postal-code>98109</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial><clinical-trial><trial-id>NCT02920008</trial-id><title>Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia</title><phase>Phase 3</phase><targets><target>DNMT</target></targets><overall-contact>Overall contact: Laksmi Wilson, laksmi.wilson@astx.com, 925-560-2914</overall-contact><markers><marker>TET2</marker></markers><trial-sites><trial-site><center>University of Southern California</center><contact>Sondra Ortiz</contact><city>Los Angeles</city><state>California</state><country>United States</country><email>sondra.ortiz@med.usc.edu</email><postal-code>90033</postal-code><status>Recruiting</status></trial-site><trial-site><center>The University of Chicago Medical Center</center><contact>Howard Weiner</contact><city>Chicago</city><state>Illinois</state><country>United States</country><email>hweiner@medicine.bsd.uchicago.edu</email><postal-code>60637</postal-code><status>Recruiting</status></trial-site><trial-site><center>Franciscan Research Center</center><contact>Isabella van der Merwe</contact><city>Indianapolis</city><state>Indiana</state><country>United States</country><email>isabella.vandermerwe@franciscanalliance.org</email><postal-code>46237</postal-code><status>Recruiting</status></trial-site><trial-site><center>John Theurer Cancer Center at Hackensack University Medical Center</center><contact>Gillian Velardi</contact><city>Hackensack</city><state>New Jersey</state><country>United States</country><email>Gillian.Velardi@hackensackmeridian.org</email><postal-code>07601-1915</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of New Mexico School of Medicine</center><contact>Daniel Weishampel</contact><city>Albuquerque</city><state>New Mexico</state><country>United States</country><email>dweishampel@salud.unm.edu</email><postal-code>87106</postal-code><status>Recruiting</status></trial-site><trial-site><center>Roswell Park Cancer Institute</center><contact>Heather Bashaw</contact><city>Buffalo</city><state>New York</state><country>United States</country><email>heather.bashaw@roswellpark.org</email><postal-code>14263</postal-code><status>Recruiting</status></trial-site><trial-site><center>Weill Cornell Medical College</center><contact>Latia Skerving</contact><city>New York</city><state>New York</state><country>United States</country><email>las2051@med.cornell.edu</email><postal-code>10021</postal-code><status>Recruiting</status></trial-site><trial-site><center>Stony Brook University Hospital</center><contact>Sebastian Munoz</contact><city>Stony Brook</city><state>New York</state><country>United States</country><email>sebastian.munoz@stonybrookmedicine.edu</email><postal-code>11794</postal-code><status>Recruiting</status></trial-site><trial-site><center>Duke Cancer Institute</center><contact>Rachel Stowe</contact><city>Durham</city><state>North Carolina</state><country>United States</country><email>rachel.stowe@dm.duke.edu</email><postal-code>27710</postal-code><status>Recruiting</status></trial-site><trial-site><center>Temple University Hospital</center><contact>Lilanee Chanyothi</contact><city>Philadelphia</city><state>Pennsylvania</state><country>United States</country><email>lilanee.chanyothi@fccc.edu</email><postal-code>19111-2433</postal-code><status>Recruiting</status></trial-site><trial-site><center>Vanderbilt University Medical Center</center><contact>Channing Dudley</contact><city>Nashville</city><state>Tennessee</state><country>United States</country><email>channing.v.dudley@vanderbilt.edu</email><postal-code>37232</postal-code><status>Recruiting</status></trial-site><trial-site><center>MD Anderson Cancer Center</center><contact>Dana Wright</contact><city>Houston</city><state>Texas</state><country>United States</country><email>djwright@mdanderson.org</email><postal-code>77030</postal-code><status>Recruiting</status></trial-site><trial-site><center>Swedish Cancer Institute</center><contact>Erik Bailey</contact><city>Seattle</city><state>Washington</state><country>United States</country><email>erik.bailey@swedish.org</email><postal-code>98104</postal-code><status>Recruiting</status></trial-site><trial-site><center>West Virginia University Hospitals, Inc.</center><contact>Patricia Beal</contact><city>Morgantown</city><state>West Virginia</state><country>United States</country><email>pbeal@hsc.wvu.edu</email><postal-code>26506</postal-code><status>Recruiting</status></trial-site><trial-site><center>AZ Sint-Jan Brugge-Oostende AV</center><contact>Laura Salenbien</contact><city>Brugge</city><country>Belgium</country><email>laura.salenbien@azsintjan.be</email><postal-code>8000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Universitair Ziekenhuis Gent</center><contact>Jonas Segaert</contact><city>Gent</city><country>Belgium</country><email>jonas.segaert@uzgent.be</email><postal-code>9000</postal-code><status>Recruiting</status></trial-site><trial-site><center>Tom Baker Cancer Centre</center><contact>Jeff Greenway</contact><city>Calgary</city><state>Alberta</state><country>Canada</country><email>jeff.greenway@ahs.ca</email><postal-code>T2N 4N2</postal-code><status>Recruiting</status></trial-site><trial-site><center>University of Alberta Hospital</center><contact>Lori Rackel</contact><city>Edmonton</city><state>Alberta</state><country>Canada</country><email>lori.rackel@albertahealthservices.ca</email><postal-code>T6G 2V2</postal-code><status>Recruiting</status></trial-site><trial-site><center>Princess Margaret Cancer Centre</center><contact>Jennifer Kim</contact><city>Toronto</city><state>Ontario</state><country>Canada</country><email>jennifer.kim@uhn.ca</email><postal-code>M5G 2C1</postal-code><status>Recruiting</status></trial-site><trial-site><center>CHRU Montpellier - Saint Eloi</center><contact>Vera Sabadash</contact><city>Montpellier</city><country>France</country><email>v-sabadash@chu-montpellier.fr</email><postal-code>34295</postal-code><status>Recruiting</status></trial-site><trial-site><center>Groupe Hospitalier de la Région de Mulhouse et Sud Alsace</center><contact>Céline Haby</contact><city>Mulhouse</city><country>France</country><email>habyc@ghrmsa.fr</email><postal-code>68100</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hôpital Saint-Louis</center><contact>Blandine Beve</contact><city>Paris</city><country>France</country><email>blandine.beve@aphp.fr</email><postal-code>75475</postal-code><status>Recruiting</status></trial-site><trial-site><center>Institut Universitaire du Cancer de Toulouse - Oncopole</center><contact>Isabelle De Ponnat</contact><city>Toulouse</city><country>France</country><email>deponnat.isabelle@iuct-oncopole.fr</email><postal-code>31059</postal-code><status>Recruiting</status></trial-site><trial-site><center>Debreceni Egyetem Klinikai Központ</center><contact>Gabriella Mezei</contact><city>Debrecen</city><country>Hungary</country><email>gmezei@gmail.com</email><postal-code>4032</postal-code><status>Recruiting</status></trial-site><trial-site><center>Somogy Megyei Kaposi Mór Oktató Kórház</center><contact>Éva Meskuláné Szilágyi</contact><city>Kaposvar</city><country>Hungary</country><postal-code>7400</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pecsi Tudomanyegyetem Klinikai Központ</center><contact>Gábor Kollár</contact><city>Pécs</city><country>Hungary</country><email>gkollar32@gmail.com</email><status>Recruiting</status></trial-site><trial-site><center>Szegedi Tudományegyetem</center><contact>Agnes Nagyne</contact><city>Szeged</city><country>Hungary</country><email>nagyne.agi.szte@gmail.com</email><postal-code>6725</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Bundang Hospital</center><contact>Eun Jin Kim</contact><city>Seongnam-si</city><state>Gyeonggi-do</state><country>Korea, Republic of</country><email>r1598@snubh.org</email><postal-code>5505</postal-code><status>Recruiting</status></trial-site><trial-site><center>Pusan National University Hospital</center><contact>Jinyi Baek</contact><city>Busan</city><country>Korea, Republic of</country><email>forawayz@naver.com</email><postal-code>49241</postal-code><status>Recruiting</status></trial-site><trial-site><center>Seoul National University Hospital</center><contact>Ju-Hyun Lee</contact><city>Seoul</city><country>Korea, Republic of</country><email>lee-jh8368@daum.net</email><postal-code>3080</postal-code><status>Recruiting</status></trial-site><trial-site><center>Severance Hospital</center><contact>So-Young Choi</contact><city>Seoul</city><country>Korea, Republic of</country><email>so-youngchoi@yuhs.ac</email><postal-code>3722</postal-code><status>Recruiting</status></trial-site><trial-site><center>Samsung Medical Center</center><contact>Jayeon Kim</contact><city>Seoul</city><country>Korea, Republic of</country><email>jy0760.kim@samsung.com</email><postal-code>6351</postal-code><status>Recruiting</status></trial-site><trial-site><center>Ulsan University Hospital (UUH)</center><contact>Hae Jin Kang</contact><city>Ulsan</city><country>Korea, Republic of</country><email>uuhimpjina@naver.com</email><postal-code>44033</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital San Pedro de Alcántara</center><contact>Carmen Alcaine</contact><city>Cáceres</city><country>Spain</country><email>mamenalca@gmail.com</email><postal-code>10003</postal-code><status>Recruiting</status></trial-site><trial-site><center>Hospital General Universitario Gregorio Marañón</center><contact>Marta Hernández Martín</contact><city>Madrid</city><country>Spain</country><email>martama.hernandez@gmail.com</email><postal-code>28007</postal-code><status>Recruiting</status></trial-site><trial-site><center>East Kent Hospitals University NHS Foundation Trust - Kent and Canterbury Hospital</center><contact>Lavina Davey</contact><city>Canterbury</city><country>United Kingdom</country><email>laviniadavey@nhs.net</email><postal-code>CT1 3NG</postal-code><status>Recruiting</status></trial-site></trial-sites></clinical-trial></clinical-trials></biomarker-content><biomarker-content Aa37df004-31ff-423b-9684-1992350c3be1="A9debe631-7b86-48f5-83ba-a00672f93720" alteration-name="K564E" marker="ASXL1" test-type="MUTN (seq)" user-alteration-name="K564E"><Ace3cfbce-329f-4c7b-8b0f-cf280c753d5d>A6270b0dd-9508-49b0-a3ae-d2e4c22a05d6</Ace3cfbce-329f-4c7b-8b0f-cf280c753d5d><biomarker-summary><content><item><text>The effect of ASXL1-K564E has not been determined by N-of-One.</text><references/></item></content><references/></biomarker-summary><biomarker-summary content-type="clinical-relevance"><content><item><text>Asxl1 is involved in the recruitment of chromatin remodeling and histone modifying enzymes to genetic loci, and thus may activate oncogenes or repress tumor suppressor expression. Currently, there are no therapies in clinical development targeted at ASXL1 alterations.</text><references><reference><reference-id>23736028</reference-id><title>Functional and cancer genomics of ASXL family members.</title><authors>Katoh M</authors><journal>British journal of cancer</journal><issue>2</issue><year>2013</year><page>299-306</page></reference></references></item><item><text>However, ASXL1-K564E has not been analyzed by N-of-One, and therefore the relevance of any therapeutic approaches is uncertain.</text><references/></item></content><references><reference><reference-id>23736028</reference-id><title>Functional and cancer genomics of ASXL family members.</title><authors>Katoh M</authors><journal>British journal of cancer</journal><issue>2</issue><year>2013</year><page>299-306</page></reference></references></biomarker-summary><biomarker-summary content-type="disease-summary"><content><item><text>ASXL1 mutations in AML have been associated with older patient age, male sex, secondary AML, decreased white blood cell (WBC) counts, and lower circulating and bone marrow blast counts; ASXL1 mutations have also been correlated with presence of RUNX1 mutations, but absence of NPM1, FLT3-ITD and DNMT3A mutations.</text><references><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>28063196</reference-id><title>ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.</title><authors>Yamato G, Shiba N, Yoshida K, Shiraishi Y, Hara Y, Ohki K, Okubo J, Okuno H, Chiba K, Tanaka H, Kinoshita A, Moritake H, Kiyokawa N, Tomizawa D, Park M, Sotomatsu M, Taga T, Adachi S, Tawa A, Horibe K, Arakawa H, Miyano S, Ogawa S, Hayashi Y</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>5</issue><year>2017</year><page>382-393</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference></references></item><item><text>Loss of Asxl1 function in mice, either by ASXL1 deletion or C-terminal truncation of the protein, has been shown to lead to hematopoietic dysplasia and features of myelodysplastic syndrome (MDS).</text><references><reference><reference-id>24255920</reference-id><title>Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.</title><authors>Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai C, Xu M, Yang F</authors><journal>Blood</journal><issue>4</issue><year>2014</year><page>541-53</page></reference><reference><reference-id>24216483</reference-id><title>Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.</title><authors>Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata K, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine R, Abdel-Wahab O, Kitamura T</authors><journal>The Journal of clinical investigation</journal><issue>11</issue><year>2013</year><page>4627-40</page></reference><reference><reference-id>24218140</reference-id><title>Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.</title><authors>Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R</authors><journal>The Journal of experimental medicine</journal><issue>12</issue><year>2013</year><page>2641-59</page></reference><reference><reference-id>19861679</reference-id><title>Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.</title><authors>Fisher C, Pineault N, Brookes C, Helgason C, Ohta H, Bodner C, Hess J, Humphries R, Brock H</authors><journal>Blood</journal><issue>1</issue><year>2010</year><page>38-46</page></reference></references></item><item><text>ASXL1 mutations have been associated with reduced event-free and overall survival in AML patients; however, several studies have reported that the negative effects of ASXL1 mutations may be limited to specific AML populations such as intermediate-risk patients or those with both ASXL1 and RUNX1 mutations.</text><references><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>23952244</reference-id><title>ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.</title><authors>El-Sharkawi D, Ali A, Evans C, Hills R, Burnett A, Linch D, Gale R</authors><journal>Leukemia &amp; lymphoma</journal><issue>6</issue><year>2014</year><page>1326-31</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>25860933</reference-id><title>Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.</title><authors>Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci M, Delabesse E, Birnbaum D</authors><journal>Oncotarget</journal><issue>10</issue><year>2015</year><page>8388-96</page></reference><reference><reference-id>25412851</reference-id><title>Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.</title><authors>Ohgami R, Ma L, Merker J, Gotlib J, Schrijver I, Zehnder J, Arber D</authors><journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal><issue>5</issue><year>2015</year><page>706-14</page></reference><reference><reference-id>27137476</reference-id><title>RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.</title><authors>Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne C, Horst H, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus J, Kestler H, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk R, Döhner K, Döhner H</authors><journal>Leukemia</journal><issue>11</issue><year>2016</year><page>2160-2168</page></reference><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>24402164</reference-id><title>High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.</title><authors>Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>7</issue><year>2014</year><page>1449-58</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></item></content><references><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>28063196</reference-id><title>ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.</title><authors>Yamato G, Shiba N, Yoshida K, Shiraishi Y, Hara Y, Ohki K, Okubo J, Okuno H, Chiba K, Tanaka H, Kinoshita A, Moritake H, Kiyokawa N, Tomizawa D, Park M, Sotomatsu M, Taga T, Adachi S, Tawa A, Horibe K, Arakawa H, Miyano S, Ogawa S, Hayashi Y</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>5</issue><year>2017</year><page>382-393</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference><reference><reference-id>24255920</reference-id><title>Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.</title><authors>Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai C, Xu M, Yang F</authors><journal>Blood</journal><issue>4</issue><year>2014</year><page>541-53</page></reference><reference><reference-id>24216483</reference-id><title>Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.</title><authors>Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata K, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine R, Abdel-Wahab O, Kitamura T</authors><journal>The Journal of clinical investigation</journal><issue>11</issue><year>2013</year><page>4627-40</page></reference><reference><reference-id>24218140</reference-id><title>Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.</title><authors>Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R</authors><journal>The Journal of experimental medicine</journal><issue>12</issue><year>2013</year><page>2641-59</page></reference><reference><reference-id>19861679</reference-id><title>Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.</title><authors>Fisher C, Pineault N, Brookes C, Helgason C, Ohta H, Bodner C, Hess J, Humphries R, Brock H</authors><journal>Blood</journal><issue>1</issue><year>2010</year><page>38-46</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>23952244</reference-id><title>ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.</title><authors>El-Sharkawi D, Ali A, Evans C, Hills R, Burnett A, Linch D, Gale R</authors><journal>Leukemia &amp; lymphoma</journal><issue>6</issue><year>2014</year><page>1326-31</page></reference><reference><reference-id>25860933</reference-id><title>Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.</title><authors>Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci M, Delabesse E, Birnbaum D</authors><journal>Oncotarget</journal><issue>10</issue><year>2015</year><page>8388-96</page></reference><reference><reference-id>25412851</reference-id><title>Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.</title><authors>Ohgami R, Ma L, Merker J, Gotlib J, Schrijver I, Zehnder J, Arber D</authors><journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal><issue>5</issue><year>2015</year><page>706-14</page></reference><reference><reference-id>27137476</reference-id><title>RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.</title><authors>Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne C, Horst H, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus J, Kestler H, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk R, Döhner K, Döhner H</authors><journal>Leukemia</journal><issue>11</issue><year>2016</year><page>2160-2168</page></reference><reference><reference-id>24402164</reference-id><title>High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.</title><authors>Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>7</issue><year>2014</year><page>1449-58</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></biomarker-summary><molecular-function><content><item><text>ASXL1-K564E has not been analyzed by N-of-One; therefore its effect on protein function cannot be described.</text><references/></item></content><references/></molecular-function><incidence><content><item><text>ASXL1 mutations have been reported in 8.1% (586/7260) of Acute myelocytic leukemia (AML) samples analyzed in COSMIC (Apr 2017).</text><references/></item><item><text>ASXL1 mutations have been reported in 2.5% of Acute myelocytic leukemia (AML) samples (cBioPortal for Cancer Genomics, Apr 2017).</text><references/></item><item><text>ASXL1 mutations have been reported in 3-17% of AML patients, with some studies reporting increased frequencies in specific AML populations including 21% (26/125) of AML with myelodysplasia-related changes, and 32% (30/93) of secondary AML patients.</text><references><reference><reference-id>25022553</reference-id><title>Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.</title><authors>Kao H, Liang D, Wu J, Kuo M, Wang P, Yang C, Shih Y, Lin T, Huang Y, Shih L</authors><journal>Neoplasia (New York, N.Y.)</journal><issue>6</issue><year>2014</year><page>481-8</page></reference><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>25412851</reference-id><title>Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.</title><authors>Ohgami R, Ma L, Merker J, Gotlib J, Schrijver I, Zehnder J, Arber D</authors><journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal><issue>5</issue><year>2015</year><page>706-14</page></reference><reference><reference-id>25550361</reference-id><title>Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.</title><authors>Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S, Pigneux A, Wetzler M, Stuart R, Erba H, Damon L, Powell B, Lindeman N, Steensma D, Wadleigh M, DeAngelo D, Neuberg D, Stone R, Ebert B</authors><journal>Blood</journal><issue>9</issue><year>2015</year><page>1367-76</page></reference><reference><reference-id>24859829</reference-id><title>TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.</title><authors>Tian X, Xu Y, Yin J, Tian H, Chen S, Wu D, Sun A</authors><journal>International journal of hematology</journal><issue>1</issue><year>2014</year><page>96-104</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>24402164</reference-id><title>High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.</title><authors>Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>7</issue><year>2014</year><page>1449-58</page></reference><reference><reference-id>25860933</reference-id><title>Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.</title><authors>Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci M, Delabesse E, Birnbaum D</authors><journal>Oncotarget</journal><issue>10</issue><year>2015</year><page>8388-96</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference></references></item></content><references><reference><reference-id>25022553</reference-id><title>Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.</title><authors>Kao H, Liang D, Wu J, Kuo M, Wang P, Yang C, Shih Y, Lin T, Huang Y, Shih L</authors><journal>Neoplasia (New York, N.Y.)</journal><issue>6</issue><year>2014</year><page>481-8</page></reference><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>25412851</reference-id><title>Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.</title><authors>Ohgami R, Ma L, Merker J, Gotlib J, Schrijver I, Zehnder J, Arber D</authors><journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal><issue>5</issue><year>2015</year><page>706-14</page></reference><reference><reference-id>25550361</reference-id><title>Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.</title><authors>Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S, Pigneux A, Wetzler M, Stuart R, Erba H, Damon L, Powell B, Lindeman N, Steensma D, Wadleigh M, DeAngelo D, Neuberg D, Stone R, Ebert B</authors><journal>Blood</journal><issue>9</issue><year>2015</year><page>1367-76</page></reference><reference><reference-id>24859829</reference-id><title>TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.</title><authors>Tian X, Xu Y, Yin J, Tian H, Chen S, Wu D, Sun A</authors><journal>International journal of hematology</journal><issue>1</issue><year>2014</year><page>96-104</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>24402164</reference-id><title>High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.</title><authors>Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>7</issue><year>2014</year><page>1449-58</page></reference><reference><reference-id>25860933</reference-id><title>Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.</title><authors>Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci M, Delabesse E, Birnbaum D</authors><journal>Oncotarget</journal><issue>10</issue><year>2015</year><page>8388-96</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference></references></incidence><role-in-disease><content><item><text>Truncating mutations in ASXL1 are frequent in hematologic malignancies and in colorectal cancer cell lines with microsatellite instability, although ASXL1 knockout mice do not develop cancers.</text><references><reference><reference-id>23736028</reference-id><title>Functional and cancer genomics of ASXL family members.</title><authors>Katoh M</authors><journal>British journal of cancer</journal><issue>2</issue><year>2013</year><page>299-306</page></reference><reference><reference-id>19861679</reference-id><title>Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.</title><authors>Fisher C, Pineault N, Brookes C, Helgason C, Ohta H, Bodner C, Hess J, Humphries R, Brock H</authors><journal>Blood</journal><issue>1</issue><year>2010</year><page>38-46</page></reference><reference><reference-id>21209843</reference-id><title>Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability.</title><authors>Williams D, Bird M, Jorissen R, Yu Y, Walker F, Walker F, Zhang H, Nice E, Burgess A</authors><journal>PloS one</journal><issue>12</issue><year>2010</year><page>e16012</page></reference><reference><reference-id>24218140</reference-id><title>Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.</title><authors>Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R</authors><journal>The Journal of experimental medicine</journal><issue>12</issue><year>2013</year><page>2641-59</page></reference></references></item><item><text>Asxl1 may be found as a member of various transcriptional complexes, and its function has been shown to be context-dependent; Asxl1 may activate oncogenes or repress tumor suppressor expression.</text><references><reference><reference-id>23736028</reference-id><title>Functional and cancer genomics of ASXL family members.</title><authors>Katoh M</authors><journal>British journal of cancer</journal><issue>2</issue><year>2013</year><page>299-306</page></reference></references></item><item><text>ASXL1 mutations in AML have been associated with older patient age, male sex, secondary AML, decreased white blood cell (WBC) counts, and lower circulating and bone marrow blast counts; ASXL1 mutations have also been correlated with presence of RUNX1 mutations, but absence of NPM1, FLT3-ITD and DNMT3A mutations.</text><references><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>28063196</reference-id><title>ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.</title><authors>Yamato G, Shiba N, Yoshida K, Shiraishi Y, Hara Y, Ohki K, Okubo J, Okuno H, Chiba K, Tanaka H, Kinoshita A, Moritake H, Kiyokawa N, Tomizawa D, Park M, Sotomatsu M, Taga T, Adachi S, Tawa A, Horibe K, Arakawa H, Miyano S, Ogawa S, Hayashi Y</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>5</issue><year>2017</year><page>382-393</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference></references></item><item><text>Loss of Asxl1 function in mice, either by ASXL1 deletion or C-terminal truncation of the protein, has been shown to lead to hematopoietic dysplasia and features of myelodysplastic syndrome (MDS).</text><references><reference><reference-id>24255920</reference-id><title>Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.</title><authors>Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai C, Xu M, Yang F</authors><journal>Blood</journal><issue>4</issue><year>2014</year><page>541-53</page></reference><reference><reference-id>24216483</reference-id><title>Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.</title><authors>Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata K, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine R, Abdel-Wahab O, Kitamura T</authors><journal>The Journal of clinical investigation</journal><issue>11</issue><year>2013</year><page>4627-40</page></reference><reference><reference-id>24218140</reference-id><title>Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.</title><authors>Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R</authors><journal>The Journal of experimental medicine</journal><issue>12</issue><year>2013</year><page>2641-59</page></reference><reference><reference-id>19861679</reference-id><title>Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.</title><authors>Fisher C, Pineault N, Brookes C, Helgason C, Ohta H, Bodner C, Hess J, Humphries R, Brock H</authors><journal>Blood</journal><issue>1</issue><year>2010</year><page>38-46</page></reference></references></item></content><references><reference><reference-id>23736028</reference-id><title>Functional and cancer genomics of ASXL family members.</title><authors>Katoh M</authors><journal>British journal of cancer</journal><issue>2</issue><year>2013</year><page>299-306</page></reference><reference><reference-id>19861679</reference-id><title>Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.</title><authors>Fisher C, Pineault N, Brookes C, Helgason C, Ohta H, Bodner C, Hess J, Humphries R, Brock H</authors><journal>Blood</journal><issue>1</issue><year>2010</year><page>38-46</page></reference><reference><reference-id>21209843</reference-id><title>Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability.</title><authors>Williams D, Bird M, Jorissen R, Yu Y, Walker F, Walker F, Zhang H, Nice E, Burgess A</authors><journal>PloS one</journal><issue>12</issue><year>2010</year><page>e16012</page></reference><reference><reference-id>24218140</reference-id><title>Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.</title><authors>Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R</authors><journal>The Journal of experimental medicine</journal><issue>12</issue><year>2013</year><page>2641-59</page></reference><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>28063196</reference-id><title>ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.</title><authors>Yamato G, Shiba N, Yoshida K, Shiraishi Y, Hara Y, Ohki K, Okubo J, Okuno H, Chiba K, Tanaka H, Kinoshita A, Moritake H, Kiyokawa N, Tomizawa D, Park M, Sotomatsu M, Taga T, Adachi S, Tawa A, Horibe K, Arakawa H, Miyano S, Ogawa S, Hayashi Y</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>5</issue><year>2017</year><page>382-393</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference><reference><reference-id>24255920</reference-id><title>Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.</title><authors>Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai C, Xu M, Yang F</authors><journal>Blood</journal><issue>4</issue><year>2014</year><page>541-53</page></reference><reference><reference-id>24216483</reference-id><title>Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.</title><authors>Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata K, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine R, Abdel-Wahab O, Kitamura T</authors><journal>The Journal of clinical investigation</journal><issue>11</issue><year>2013</year><page>4627-40</page></reference></references></role-in-disease><diagnostic-significance><variant diagnostic-level-of-evidence="None found"><content><item empty-type="Unknown"><text>Unknown.</text><references/></item></content><references/></variant></diagnostic-significance><prognostic-significance><variant prognostic-level-of-evidence="Not determined"><content><item><text>ASXL1 mutations have been associated with reduced event-free and overall survival in AML patients; however, several studies have reported that the negative effects of ASXL1 mutations may be limited to specific AML populations such as intermediate-risk patients or those with both ASXL1 and RUNX1 mutations.</text><references><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>23952244</reference-id><title>ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.</title><authors>El-Sharkawi D, Ali A, Evans C, Hills R, Burnett A, Linch D, Gale R</authors><journal>Leukemia &amp; lymphoma</journal><issue>6</issue><year>2014</year><page>1326-31</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>25860933</reference-id><title>Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.</title><authors>Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci M, Delabesse E, Birnbaum D</authors><journal>Oncotarget</journal><issue>10</issue><year>2015</year><page>8388-96</page></reference><reference><reference-id>25412851</reference-id><title>Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.</title><authors>Ohgami R, Ma L, Merker J, Gotlib J, Schrijver I, Zehnder J, Arber D</authors><journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal><issue>5</issue><year>2015</year><page>706-14</page></reference><reference><reference-id>27137476</reference-id><title>RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.</title><authors>Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne C, Horst H, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus J, Kestler H, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk R, Döhner K, Döhner H</authors><journal>Leukemia</journal><issue>11</issue><year>2016</year><page>2160-2168</page></reference><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>24402164</reference-id><title>High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.</title><authors>Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>7</issue><year>2014</year><page>1449-58</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></item></content><references><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>23952244</reference-id><title>ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.</title><authors>El-Sharkawi D, Ali A, Evans C, Hills R, Burnett A, Linch D, Gale R</authors><journal>Leukemia &amp; lymphoma</journal><issue>6</issue><year>2014</year><page>1326-31</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>25860933</reference-id><title>Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.</title><authors>Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci M, Delabesse E, Birnbaum D</authors><journal>Oncotarget</journal><issue>10</issue><year>2015</year><page>8388-96</page></reference><reference><reference-id>25412851</reference-id><title>Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.</title><authors>Ohgami R, Ma L, Merker J, Gotlib J, Schrijver I, Zehnder J, Arber D</authors><journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal><issue>5</issue><year>2015</year><page>706-14</page></reference><reference><reference-id>27137476</reference-id><title>RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.</title><authors>Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne C, Horst H, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus J, Kestler H, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk R, Döhner K, Döhner H</authors><journal>Leukemia</journal><issue>11</issue><year>2016</year><page>2160-2168</page></reference><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>24402164</reference-id><title>High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.</title><authors>Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>7</issue><year>2014</year><page>1449-58</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></variant></prognostic-significance><drug-sensitivity><content><item><text>However, the functional consequences of ASXL1-K564E have not been analyzed by N-of-One. Therefore, the relevance of any available therapies and clinical trials targeting this alteration is uncertain.</text><references/></item></content><references/></drug-sensitivity><drug-resistance><content><item><text>ASXL1 mutation has been significantly correlated with primary chemoresistance and failure to achieve remission after induction therapy within a cohort of 107 AML cases.</text><references><reference><reference-id>27766616</reference-id><title>Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.</title><authors>Brown F, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp K, Alonzo T, Meshinchi S, Stone R, Kornblau S, Marcucci G, Gamis A, Byrd J, Gonen M, Levine R, Kentsis A</authors><journal>British journal of haematology</journal><issue>1</issue><year>2017</year><page>86-91</page></reference></references></item></content><references><reference><reference-id>27766616</reference-id><title>Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.</title><authors>Brown F, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp K, Alonzo T, Meshinchi S, Stone R, Kornblau S, Marcucci G, Gamis A, Byrd J, Gonen M, Levine R, Kentsis A</authors><journal>British journal of haematology</journal><issue>1</issue><year>2017</year><page>86-91</page></reference></references></drug-resistance><fda-approved><content><item empty-type="None"><text>None.</text><references/></item></content><references/></fda-approved><phase-3><content><item empty-type="None"><text>None.</text><references/></item></content><references/></phase-3><phase-2><content><item empty-type="None"><text>None.</text><references/></item></content><references/></phase-2><phase-1><content><item empty-type="None"><text>None.</text><references/></item></content><references/></phase-1><preclinical><content><item empty-type="None"><text>None.</text><references/></item></content><references/></preclinical><therapies><curation-notes><curation-note>The functional consequences of ASXL1-K564E have not been analyzed by N-of-One. Therefore, the relevance of any available therapies and clinical trials targeting this alteration is uncertain.</curation-note></curation-notes></therapies><clinical-trials prioritized-by="regionally"><curation-notes><curation-note>The functional consequences of ASXL1-K564E have not been analyzed by N-of-One. Therefore, the relevance of any available therapies and clinical trials targeting this alteration is uncertain.</curation-note></curation-notes></clinical-trials><clinical-trials prioritized-by="clinically"><curation-notes><curation-note>The functional consequences of ASXL1-K564E have not been analyzed by N-of-One. Therefore, the relevance of any available therapies and clinical trials targeting this alteration is uncertain.</curation-note></curation-notes></clinical-trials></biomarker-content><biomarker-content A72abdfe4-8233-41b5-b0bf-61a96d24dd9f="A0dfb0dcd-57d5-4201-a651-4bb054d2c171" alteration-name="K292_S293insI" marker="NPM1" test-type="MUTN (seq)" user-alteration-name="K292_S293insI"><A328ef799-fc5a-4c9a-94ea-25dbe5061336>A7d1a861f-24b7-4aa8-9e66-cb4593103253</A328ef799-fc5a-4c9a-94ea-25dbe5061336><biomarker-summary><content><item><text>The functional consequences of NPM1-K292_S293insI are unknown.</text><references/></item></content><references/></biomarker-summary><biomarker-summary content-type="clinical-relevance"><content><item><text>NPM1 encodes nucleophosmin (Npm1), a multifunctional protein that regulates the ARF/p53 pathway and enhances Myc oncogenic activities.</text><references><reference><reference-id>16794633</reference-id><title>Nucleophosmin and cancer.</title><authors>Grisendi S, Mecucci C, Falini B, Pandolfi P</authors><journal>Nature reviews. Cancer</journal><issue>7</issue><year>2006</year><page>493-505</page></reference><reference><reference-id>19652540</reference-id><title>The Myc-nucleophosmin-ARF network: a complex web unveiled.</title><authors>Li Z, Hann S</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>17</issue><year>2009</year><page>2703-7</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>22631075</reference-id><title>Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.</title><authors>Liu Y, Zhang F, Zhang X, Qi L, Yang L, Guo H, Zhang N</authors><journal>Journal of biomedical science</journal><year>2012</year><page>53</page></reference></references></item><item><text>NPM1 mutations, particularly C-terminal truncations, have been reported frequently in myeloid malignancies, and although mutation has not been commonly found in solid tumors, overexpression of the Npm1 protein has been reported.</text><references><reference><reference-id>23436734</reference-id><title>Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.</title><authors>Federici L, Falini B</authors><journal>Protein science : a publication of the Protein Society</journal><issue>5</issue><year>2013</year><page>545-56</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>21258971</reference-id><title>Nucleophosmin delocalization in thyroid tumour cells.</title><authors>Pianta A, Puppin C, Passon N, Franzoni A, Romanello M, Tell G, Di Loreto C, Bulotta S, Russo D, Damante G</authors><journal>Endocrine pathology</journal><issue>1</issue><year>2011</year><page>18-23</page></reference><reference><reference-id>17504301</reference-id><title>Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.</title><authors>Jeong E, Lee S, Yoo N, Lee S</authors><journal>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</journal><issue>4</issue><year>2007</year><page>341-6</page></reference></references></item><item><text>There are currently no therapeutic approaches targeting alterations in NPM1 or changes in Npm1 protein expression.</text><references/></item><item><text>However, as this alteration has not been functionally characterized, the relevance of these therapeutic approaches is unknown in this case.</text><references/></item></content><references><reference><reference-id>16794633</reference-id><title>Nucleophosmin and cancer.</title><authors>Grisendi S, Mecucci C, Falini B, Pandolfi P</authors><journal>Nature reviews. Cancer</journal><issue>7</issue><year>2006</year><page>493-505</page></reference><reference><reference-id>19652540</reference-id><title>The Myc-nucleophosmin-ARF network: a complex web unveiled.</title><authors>Li Z, Hann S</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>17</issue><year>2009</year><page>2703-7</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>22631075</reference-id><title>Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.</title><authors>Liu Y, Zhang F, Zhang X, Qi L, Yang L, Guo H, Zhang N</authors><journal>Journal of biomedical science</journal><year>2012</year><page>53</page></reference><reference><reference-id>23436734</reference-id><title>Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.</title><authors>Federici L, Falini B</authors><journal>Protein science : a publication of the Protein Society</journal><issue>5</issue><year>2013</year><page>545-56</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>21258971</reference-id><title>Nucleophosmin delocalization in thyroid tumour cells.</title><authors>Pianta A, Puppin C, Passon N, Franzoni A, Romanello M, Tell G, Di Loreto C, Bulotta S, Russo D, Damante G</authors><journal>Endocrine pathology</journal><issue>1</issue><year>2011</year><page>18-23</page></reference><reference><reference-id>17504301</reference-id><title>Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.</title><authors>Jeong E, Lee S, Yoo N, Lee S</authors><journal>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</journal><issue>4</issue><year>2007</year><page>341-6</page></reference></references></biomarker-summary><biomarker-summary content-type="disease-summary"><content><item><text>NPM1 mutation in AML has been shown to result in the aberrant cytoplasmic localization of Npm1, in contrast to its normal nucleolar localization, and has been reported to play a role in the development of AML through the mislocalization and inhibition of Npm1 binding partners, including the tumor suppressor ARF.</text><references><reference><reference-id>16455950</reference-id><title>Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.</title><authors>Falini B, Bolli N, Shan J, Martelli M, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli M, Gu W, Mecucci C, Nicoletti I</authors><journal>Blood</journal><issue>11</issue><year>2006</year><page>4514-23</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>16205118</reference-id><title>Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.</title><authors>den Besten W, Kuo M, Williams R, Sherr C</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>11</issue><year>2005</year><page>1593-8</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference></references></item><item><text>NPM1 mutations in AML have been associated with M4 and M5 morphology, increased leukocyte and bone marrow blast counts, female sex, and decreased expression of CD34; NPM1 mutations have been reported more frequently in cytogenetically normal AML (CN-AML) and often occur in combination with FLT3, IDH1/2, NRAS, and DMNT3A mutations.</text><references><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>27276561</reference-id><title>Genomic Classification and Prognosis in Acute Myeloid Leukemia.</title><authors>Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones D, Teague J, Butler A, Greaves M, Ganser A, Döhner K, Schlenk R, Döhner H, Campbell P</authors><journal>The New England journal of medicine</journal><issue>23</issue><year>2016</year><page>2209-2221</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference></references></item><item><text>AML with mutant NPM1 is recognized as a subtype of AML with recurrent genetic abnormalities in the WHO classification of myeloid neoplasms and acute leukemia.</text><references><reference><reference-id>27069254</reference-id><title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</title><authors>Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M, Bloomfield C, Cazzola M, Vardiman J</authors><journal>Blood</journal><issue>20</issue><year>2016</year><page>2391-405</page></reference></references></item><item><text>NPM1 mutations in the absence of FLT3-ITD have been associated with favorable outcomes in AML, especially in cytogenetically normal AML (CN-AML), while NPM1 mutations in the presence of FLT3-ITD have been associated with an intermediate prognosis.</text><references><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference></references></item><item><text>Additionally, monitoring of mutant NPM1 transcript levels has been reported to be useful in the detection of minimal residual disease (MRD) and prediction of disease relapse.</text><references><reference><reference-id>19587375</reference-id><title>Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.</title><authors>Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T</authors><journal>Blood</journal><issue>11</issue><year>2009</year><page>2220-31</page></reference><reference><reference-id>21555683</reference-id><title>Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.</title><authors>Krönke J, Schlenk R, Jensen K, Tschürtz F, Corbacioglu A, Gaidzik V, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>19</issue><year>2011</year><page>2709-16</page></reference><reference><reference-id>23656730</reference-id><title>The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.</title><authors>Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C</authors><journal>Blood</journal><issue>1</issue><year>2013</year><page>83-92</page></reference><reference><reference-id>24816240</reference-id><title>Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.</title><authors>Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander S, Subklewe M, Sauerland M, Berdel W, Büchner T, Wörmann B, Hiddemann W, Spiekermann K</authors><journal>Haematologica</journal><issue>8</issue><year>2014</year><page>1317-25</page></reference><reference><reference-id>26789727</reference-id><title>Assessment of Minimal Residual Disease in Standard-Risk AML.</title><authors>Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett A, Grimwade D</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2016</year><page>422-33</page></reference></references></item></content><references><reference><reference-id>16455950</reference-id><title>Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.</title><authors>Falini B, Bolli N, Shan J, Martelli M, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli M, Gu W, Mecucci C, Nicoletti I</authors><journal>Blood</journal><issue>11</issue><year>2006</year><page>4514-23</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>16205118</reference-id><title>Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.</title><authors>den Besten W, Kuo M, Williams R, Sherr C</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>11</issue><year>2005</year><page>1593-8</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>27276561</reference-id><title>Genomic Classification and Prognosis in Acute Myeloid Leukemia.</title><authors>Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones D, Teague J, Butler A, Greaves M, Ganser A, Döhner K, Schlenk R, Döhner H, Campbell P</authors><journal>The New England journal of medicine</journal><issue>23</issue><year>2016</year><page>2209-2221</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference><reference><reference-id>27069254</reference-id><title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</title><authors>Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M, Bloomfield C, Cazzola M, Vardiman J</authors><journal>Blood</journal><issue>20</issue><year>2016</year><page>2391-405</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference><reference><reference-id>19587375</reference-id><title>Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.</title><authors>Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T</authors><journal>Blood</journal><issue>11</issue><year>2009</year><page>2220-31</page></reference><reference><reference-id>21555683</reference-id><title>Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.</title><authors>Krönke J, Schlenk R, Jensen K, Tschürtz F, Corbacioglu A, Gaidzik V, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>19</issue><year>2011</year><page>2709-16</page></reference><reference><reference-id>23656730</reference-id><title>The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.</title><authors>Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C</authors><journal>Blood</journal><issue>1</issue><year>2013</year><page>83-92</page></reference><reference><reference-id>24816240</reference-id><title>Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.</title><authors>Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander S, Subklewe M, Sauerland M, Berdel W, Büchner T, Wörmann B, Hiddemann W, Spiekermann K</authors><journal>Haematologica</journal><issue>8</issue><year>2014</year><page>1317-25</page></reference><reference><reference-id>26789727</reference-id><title>Assessment of Minimal Residual Disease in Standard-Risk AML.</title><authors>Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett A, Grimwade D</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2016</year><page>422-33</page></reference></references></biomarker-summary><molecular-function><content><item><text>NPM1 K292_S293insI is a deletion of two amino acids and an insertion of one amino acid within the nucleolar localization region of the Npm1 protein (UniProt).</text><references/></item><item><text>This alteration has not been reported (COSMIC, Aug 2017) or functionally characterized (PubMed, Aug 2017), and its effect on protein function is unknown.</text><references/></item></content><references/></molecular-function><incidence><content><item><text>NPM1 mutations have been reported in 32% (5959/18460) of Acute myelocytic leukemia (AML) samples analyzed in COSMIC (Apr 2017).</text><references/></item><item><text>NPM1 mutations have been reported in 27% of Acute myelocytic leukemia (AML) samples (cBioPortal for Cancer Genomics, Apr 2017).</text><references/></item><item><text>NPM1 mutations, predominately resulting in C-terminal truncations, have been reported in 27-35% of AML samples and in 46-53% of cytogenetically normal AML (CN-AML) samples analyzed in scientific studies.</text><references><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference></references></item></content><references><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference></references></incidence></biomarker-content><biomarker-content A26b099b1-2215-4c1a-a36e-80d43937de18="A99166d5c-7af6-4db8-959d-2c0cfaeddd53" alteration-name="H195_P196dup" marker="CEBPA" test-type="MUTN (seq)" user-alteration-name="H195_P196dup"><Af2ecb169-aa5c-4cdb-8fef-943cb0e47f57>Adbc2a1ae-0cb1-41f4-8beb-78e01b5fe46f</Af2ecb169-aa5c-4cdb-8fef-943cb0e47f57><biomarker-summary><content><item><text>CEBPA-H195_P196dup is predicted to have no effect on the protein function.</text><references/></item></content><references/></biomarker-summary><biomarker-summary content-type="clinical-relevance"><content><item><text>CEBPA encodes the transcription factor C/EBPalpha, which has been reported to function as a tumor suppressor in several types of cancer.</text><references><reference><reference-id>11809705</reference-id><title>Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.</title><authors>Halmos B, Huettner C, Kocher O, Ferenczi K, Karp D, Tenen D</authors><journal>Cancer research</journal><issue>2</issue><year>2002</year><page>528-34</page></reference><reference><reference-id>23437297</reference-id><title>CCAAT/enhancer-binding protein-α suppresses lung tumor development in mice through the p38α MAP kinase pathway.</title><authors>Sato A, Yamada N, Ogawa Y, Ikegami M</authors><journal>PloS one</journal><issue>2</issue><year>2013</year><page>e57013</page></reference><reference><reference-id>20386538</reference-id><title>C/EBP alpha expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis.</title><authors>Regalo G, Resende C, Wen X, Gomes B, Durães C, Seruca R, Carneiro F, Machado J</authors><journal>Laboratory investigation; a journal of technical methods and pathology</journal><issue>8</issue><year>2010</year><page>1132-9</page></reference><reference><reference-id>11242107</reference-id><title>Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.</title><authors>Pabst T, Mueller B, Zhang P, Radomska H, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen D</authors><journal>Nature genetics</journal><issue>3</issue><year>2001</year><page>263-70</page></reference></references></item><item><text>There are currently no therapies directed toward CEBPA inactivating mutation or loss.</text><references/></item><item><text>However, as the alteration reported here has been characterized as a germline polymorphism, these therapeutic approaches are not likely to be relevant.</text><references/></item></content><references><reference><reference-id>11809705</reference-id><title>Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.</title><authors>Halmos B, Huettner C, Kocher O, Ferenczi K, Karp D, Tenen D</authors><journal>Cancer research</journal><issue>2</issue><year>2002</year><page>528-34</page></reference><reference><reference-id>23437297</reference-id><title>CCAAT/enhancer-binding protein-α suppresses lung tumor development in mice through the p38α MAP kinase pathway.</title><authors>Sato A, Yamada N, Ogawa Y, Ikegami M</authors><journal>PloS one</journal><issue>2</issue><year>2013</year><page>e57013</page></reference><reference><reference-id>20386538</reference-id><title>C/EBP alpha expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis.</title><authors>Regalo G, Resende C, Wen X, Gomes B, Durães C, Seruca R, Carneiro F, Machado J</authors><journal>Laboratory investigation; a journal of technical methods and pathology</journal><issue>8</issue><year>2010</year><page>1132-9</page></reference><reference><reference-id>11242107</reference-id><title>Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.</title><authors>Pabst T, Mueller B, Zhang P, Radomska H, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen D</authors><journal>Nature genetics</journal><issue>3</issue><year>2001</year><page>263-70</page></reference></references></biomarker-summary><biomarker-summary content-type="disease-summary"><content><item><text>Bi-allelic mutations of CEBPA, with one allele harboring an N-terminal mutation and the other allele containing a C-terminal mutation, have been reported to synergistically drive AML formation in preclinical studies.</text><references><reference><reference-id>11242107</reference-id><title>Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.</title><authors>Pabst T, Mueller B, Zhang P, Radomska H, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen D</authors><journal>Nature genetics</journal><issue>3</issue><year>2001</year><page>263-70</page></reference><reference><reference-id>19878871</reference-id><title>Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML.</title><authors>Bereshchenko O, Mancini E, Moore S, Bilbao D, Månsson R, Luc S, Grover A, Jacobsen S, Bryder D, Nerlov C</authors><journal>Cancer cell</journal><issue>5</issue><year>2009</year><page>390-400</page></reference><reference><reference-id>22150310</reference-id><title>C/EBPα dysregulation in AML and ALL.</title><authors>Paz-Priel I, Friedman A</authors><journal>Critical reviews in oncogenesis</journal><issue>1-2</issue><year>2011</year><page>93-102</page></reference><reference><reference-id>18394553</reference-id><title>Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.</title><authors>Kirstetter P, Schuster M, Bereshchenko O, Moore S, Dvinge H, Kurz E, Theilgaard-Mönch K, Månsson R, Pedersen T, Pabst T, Schrock E, Porse B, Jacobsen S, Bertone P, Tenen D, Nerlov C</authors><journal>Cancer cell</journal><issue>4</issue><year>2008</year><page>299-310</page></reference></references></item><item><text>Additionally, bi-allelic CEBPA mutations have been associated with normal cytogenetics and M1 or M2 morphology in studies of AML.</text><references><reference><reference-id>20439648</reference-id><title>Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.</title><authors>Green C, Koo K, Hills R, Burnett A, Linch D, Gale R</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>16</issue><year>2010</year><page>2739-47</page></reference><reference><reference-id>20038735</reference-id><title>Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.</title><authors>Dufour A, Schneider F, Metzeler K, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland M, Berdel W, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander S, Spiekermann K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>570-7</page></reference><reference><reference-id>25400766</reference-id><title>Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.</title><authors>Wen X, Lin J, Yang J, Yao D, Deng Z, Tang C, Xiao G, Yang L, Ma J, Hu J, Qian W, Qian J</authors><journal>International journal of clinical and experimental pathology</journal><issue>10</issue><year>2014</year><page>6832-40</page></reference><reference><reference-id>24056881</reference-id><title>The role of different genetic subtypes of CEBPA mutated AML.</title><authors>Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>4</issue><year>2014</year><page>794-803</page></reference></references></item><item><text>CEBPA mutation has been associated with improved outcome in acute myeloid leukemia (AML) patients, including studies specifically analyzing cytogenetically normal (CN)-AML patients.</text><references><reference><reference-id>24801015</reference-id><title>Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.</title><authors>Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1279-86</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference></references></item><item><text>In addition, separate studies have reported that improved outcomes are associated with AML patients harboring bi-allelic or double CEBPA mutations as compared with patients harboring a single CEBPA mutation.</text><references><reference><reference-id>25227715</reference-id><title>Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.</title><authors>Li H, Deng D, Huang Y, Ye F, Huang L, Xiao Q, Zhang B, Ye B, Lai Y, Mo Z, Liu Z</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>439-48</page></reference><reference><reference-id>25400766</reference-id><title>Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.</title><authors>Wen X, Lin J, Yang J, Yao D, Deng Z, Tang C, Xiao G, Yang L, Ma J, Hu J, Qian W, Qian J</authors><journal>International journal of clinical and experimental pathology</journal><issue>10</issue><year>2014</year><page>6832-40</page></reference><reference><reference-id>20038735</reference-id><title>Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.</title><authors>Dufour A, Schneider F, Metzeler K, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland M, Berdel W, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander S, Spiekermann K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>570-7</page></reference><reference><reference-id>20439648</reference-id><title>Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.</title><authors>Green C, Koo K, Hills R, Burnett A, Linch D, Gale R</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>16</issue><year>2010</year><page>2739-47</page></reference></references></item></content><references><reference><reference-id>11242107</reference-id><title>Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.</title><authors>Pabst T, Mueller B, Zhang P, Radomska H, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen D</authors><journal>Nature genetics</journal><issue>3</issue><year>2001</year><page>263-70</page></reference><reference><reference-id>19878871</reference-id><title>Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML.</title><authors>Bereshchenko O, Mancini E, Moore S, Bilbao D, Månsson R, Luc S, Grover A, Jacobsen S, Bryder D, Nerlov C</authors><journal>Cancer cell</journal><issue>5</issue><year>2009</year><page>390-400</page></reference><reference><reference-id>22150310</reference-id><title>C/EBPα dysregulation in AML and ALL.</title><authors>Paz-Priel I, Friedman A</authors><journal>Critical reviews in oncogenesis</journal><issue>1-2</issue><year>2011</year><page>93-102</page></reference><reference><reference-id>18394553</reference-id><title>Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.</title><authors>Kirstetter P, Schuster M, Bereshchenko O, Moore S, Dvinge H, Kurz E, Theilgaard-Mönch K, Månsson R, Pedersen T, Pabst T, Schrock E, Porse B, Jacobsen S, Bertone P, Tenen D, Nerlov C</authors><journal>Cancer cell</journal><issue>4</issue><year>2008</year><page>299-310</page></reference><reference><reference-id>20439648</reference-id><title>Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.</title><authors>Green C, Koo K, Hills R, Burnett A, Linch D, Gale R</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>16</issue><year>2010</year><page>2739-47</page></reference><reference><reference-id>20038735</reference-id><title>Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.</title><authors>Dufour A, Schneider F, Metzeler K, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland M, Berdel W, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander S, Spiekermann K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>570-7</page></reference><reference><reference-id>25400766</reference-id><title>Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.</title><authors>Wen X, Lin J, Yang J, Yao D, Deng Z, Tang C, Xiao G, Yang L, Ma J, Hu J, Qian W, Qian J</authors><journal>International journal of clinical and experimental pathology</journal><issue>10</issue><year>2014</year><page>6832-40</page></reference><reference><reference-id>24056881</reference-id><title>The role of different genetic subtypes of CEBPA mutated AML.</title><authors>Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>4</issue><year>2014</year><page>794-803</page></reference><reference><reference-id>24801015</reference-id><title>Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.</title><authors>Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1279-86</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>25227715</reference-id><title>Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.</title><authors>Li H, Deng D, Huang Y, Ye F, Huang L, Xiao Q, Zhang B, Ye B, Lai Y, Mo Z, Liu Z</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>439-48</page></reference></references></biomarker-summary><molecular-function><content><item><text>CEBPA H195_P196dup, also known as P194_H195dup, HP196_197ins, or  P197delinsHPP, results in the insertion and tandem duplication of two amino acids within the second transactivation domain of the C/EBPalpha protein (UniProt).</text><references><reference><reference-id>22150310</reference-id><title>C/EBPα dysregulation in AML and ALL.</title><authors>Paz-Priel I, Friedman A</authors><journal>Critical reviews in oncogenesis</journal><issue>1-2</issue><year>2011</year><page>93-102</page></reference><reference><reference-id>2227417</reference-id><title>Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene.</title><authors>Friedman A, McKnight S</authors><journal>Genes &amp; development</journal><issue>8</issue><year>1990</year><page>1416-26</page></reference></references></item><item><text>This alteration has been reported as a germline polymorphism; one study reported this alteration in 5.4% (61/1135) of acute myeloid leukemia (AML) cases and 5.3% (10/187) of healthy controls.</text><references><reference><reference-id>17190859</reference-id><title>A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.</title><authors>Wouters B, Louwers I, Valk P, Löwenberg B, Delwel R</authors><journal>Blood</journal><issue>1</issue><year>2007</year><page>389-90</page></reference><reference><reference-id>14726504</reference-id><title>CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.</title><authors>Fröhling S, Schlenk R, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2004</year><page>624-33</page></reference><reference><reference-id>20888888</reference-id><title>A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.</title><authors>Schnittger S, Bacher U, Eder C, Lohse P, Haferlach C, Kern W, Haferlach T</authors><journal>Experimental hematology</journal><issue>1</issue><year>2011</year><page>87-94</page></reference><reference><reference-id>15746035</reference-id><title>Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.</title><authors>Lin L, Chen C, Lin D, Tsay W, Tang J, Yeh Y, Shen H, Su F, Yao M, Huang S, Tien H</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>4</issue><year>2005</year><page>1372-9</page></reference><reference><reference-id>22389883</reference-id><title>Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.</title><authors>Kim S, Kim D, Jang J, Jung C, Jang M, Ki C, Kim J, Kim S, Kim H</authors><journal>Annals of laboratory medicine</journal><issue>2</issue><year>2012</year><page>153-7</page></reference><reference><reference-id>17851556</reference-id><title>Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.</title><authors>Biggio V, Renneville A, Nibourel O, Philippe N, Terriou L, Roumier C, Amouyel P, Cottel D, Castaigne S, Dombret H, Thomas X, Fenaux P, Preudhomme C</authors><journal>Leukemia</journal><issue>3</issue><year>2008</year><page>655-7</page></reference></references></item></content><references><reference><reference-id>22150310</reference-id><title>C/EBPα dysregulation in AML and ALL.</title><authors>Paz-Priel I, Friedman A</authors><journal>Critical reviews in oncogenesis</journal><issue>1-2</issue><year>2011</year><page>93-102</page></reference><reference><reference-id>2227417</reference-id><title>Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene.</title><authors>Friedman A, McKnight S</authors><journal>Genes &amp; development</journal><issue>8</issue><year>1990</year><page>1416-26</page></reference><reference><reference-id>17190859</reference-id><title>A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.</title><authors>Wouters B, Louwers I, Valk P, Löwenberg B, Delwel R</authors><journal>Blood</journal><issue>1</issue><year>2007</year><page>389-90</page></reference><reference><reference-id>14726504</reference-id><title>CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.</title><authors>Fröhling S, Schlenk R, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2004</year><page>624-33</page></reference><reference><reference-id>20888888</reference-id><title>A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.</title><authors>Schnittger S, Bacher U, Eder C, Lohse P, Haferlach C, Kern W, Haferlach T</authors><journal>Experimental hematology</journal><issue>1</issue><year>2011</year><page>87-94</page></reference><reference><reference-id>15746035</reference-id><title>Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.</title><authors>Lin L, Chen C, Lin D, Tsay W, Tang J, Yeh Y, Shen H, Su F, Yao M, Huang S, Tien H</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>4</issue><year>2005</year><page>1372-9</page></reference><reference><reference-id>22389883</reference-id><title>Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.</title><authors>Kim S, Kim D, Jang J, Jung C, Jang M, Ki C, Kim J, Kim S, Kim H</authors><journal>Annals of laboratory medicine</journal><issue>2</issue><year>2012</year><page>153-7</page></reference><reference><reference-id>17851556</reference-id><title>Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.</title><authors>Biggio V, Renneville A, Nibourel O, Philippe N, Terriou L, Roumier C, Amouyel P, Cottel D, Castaigne S, Dombret H, Thomas X, Fenaux P, Preudhomme C</authors><journal>Leukemia</journal><issue>3</issue><year>2008</year><page>655-7</page></reference></references></molecular-function><incidence><content><item><text>CEBPA mutations have been reported in 9.2% (1221/13256) of Acute myelocytic leukemia (AML) samples analyzed in COSMIC (Apr 2017).</text><references/></item><item><text>CEBPA mutations have been reported in 6.5-6.6% of Acute myelocytic leukemia (AML) samples (cBioPortal for Cancer Genomics, Apr 2017).</text><references/></item><item><text>Literature studies have reported CEBPA mutations in 7-13% of analyzed AML samples, including studies citing single or monoallelic mutation in 3-6% of cases and double or biallelic mutations in approximately 4% of cases.</text><references><reference><reference-id>24056881</reference-id><title>The role of different genetic subtypes of CEBPA mutated AML.</title><authors>Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>4</issue><year>2014</year><page>794-803</page></reference><reference><reference-id>20439648</reference-id><title>Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.</title><authors>Green C, Koo K, Hills R, Burnett A, Linch D, Gale R</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>16</issue><year>2010</year><page>2739-47</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>20038735</reference-id><title>Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.</title><authors>Dufour A, Schneider F, Metzeler K, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland M, Berdel W, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander S, Spiekermann K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>570-7</page></reference></references></item></content><references><reference><reference-id>24056881</reference-id><title>The role of different genetic subtypes of CEBPA mutated AML.</title><authors>Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>4</issue><year>2014</year><page>794-803</page></reference><reference><reference-id>20439648</reference-id><title>Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.</title><authors>Green C, Koo K, Hills R, Burnett A, Linch D, Gale R</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>16</issue><year>2010</year><page>2739-47</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>20038735</reference-id><title>Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.</title><authors>Dufour A, Schneider F, Metzeler K, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland M, Berdel W, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander S, Spiekermann K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>570-7</page></reference></references></incidence></biomarker-content></detailed-biomarker-information><glossary><glossary-item><biomarker>ASXL1</biomarker><description>Asxl1 is a member of the Asxl family of proteins involved in recruitment of epigenetic and transcriptional regulators at genomic loci. Asxl1 interacts directly with Bap-1 and several hormone receptors, and is involved in the recruitment of the PRC2 repressive complex.</description></glossary-item><glossary-item><biomarker>CEBPA</biomarker><description>CEBPA encodes the CCAAT/enhancer-binding protein alpha (C/EBPalpha), a member of the basic leucine zipper family of transcription factors, and is considered to be a tumor suppressor.</description></glossary-item><glossary-item><biomarker>FLT3</biomarker><description>FLT3 encodes FMS-like tyrosine kinase 3 (Flt3), a receptor tyrosine kinase activated by Flt3 ligand, which functions upstream of PI3K/Akt/mTOR, MAPK, and STAT5 signaling pathways to promote the proliferation, survival, and differentiation of hematopoietic progenitor cells.</description></glossary-item><glossary-item><biomarker>IGH</biomarker><description>IGH encodes the immunoglobulin heavy chain (IgH), a gene that undergoes a number of modifications, including recombination of its V, D, and J segments, somatic hypermutation, and class-switch recombination, during the course of normal B-cell maturation to form a functional antigen receptor.</description></glossary-item><glossary-item><biomarker>NPM1</biomarker><description>NPM1 encodes nucleophosmin (Npm1), a nuclear phosphoprotein involved in numerous critical cellular processes including ribosome biogenesis and export, centrosome duplication, chromatin remodeling, and DNA repair. Npm1 regulates the ARF/p53 pathway and enhances the oncogenic activities of Myc.</description></glossary-item><glossary-item><biomarker>TET2</biomarker><description>The TET2 gene encodes Tet2, a methylcytosine dioxygenase that converts methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), a crucial component in the DNA methylation process. It is a tumor suppressor gene that is widely expressed in hematopoietic cells and plays a role in the progression of myeloid neoplasms.</description></glossary-item></glossary><references A9ab39301-e297-40b8-9d31-44dadac355fc="A740f360f-ef6f-487f-a657-61b0a699cd25"><Af23b5b67-d962-405a-931a-90ed0222b6f2>Ae8486650-c4f5-4855-bf4f-9f71d27c1978</Af23b5b67-d962-405a-931a-90ed0222b6f2><reference><reference-id>24218140</reference-id><title>Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.</title><authors>Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R</authors><journal>The Journal of experimental medicine</journal><issue>12</issue><year>2013</year><page>2641-59</page></reference><reference><reference-id>20068184</reference-id><title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.</title><authors>Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine R, Verstovsek S</authors><journal>Cancer research</journal><issue>2</issue><year>2010</year><page>447-52</page></reference><reference><reference-id>19420352</reference-id><title>Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.</title><authors>Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau M, Beran M, Tallman M, Ebert B, Kantarjian H, Stone R, Gilliland D, Crispino J, Levine R</authors><journal>Blood</journal><issue>1</issue><year>2009</year><page>144-7</page></reference><reference><reference-id>ASH 2016, Abstract 1642</reference-id><title>The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial</title><authors>Abdelall W, Kantarjian HM, Borthakur G, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 1642</page></reference><reference><reference-id>26045292</reference-id><title>Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.</title><authors>Ahn J, Kim H, Kim Y, Jung S, Yang D, Lee J, Lee I, Kim N, Minden M, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim N, Yoshida K, Ogawa S, Kim D</authors><journal>Haematologica</journal><issue>9</issue><year>2015</year><page>e351-3</page></reference><reference><reference-id>28039446</reference-id><title>5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Ahn S, Jung S, Yang D, Lee J, Park H, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Michael S, Minden M, Kim D</authors><journal>Oncotarget</journal><issue>5</issue><year>2017</year><page>8305-8314</page></reference><reference><reference-id>26234722</reference-id><title>DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.</title><authors>Ahn J, Kim H, Kim Y, Lee S, Jung S, Yang D, Lee J, Kim N, Choi S, Jung C, Jang J, Kim H, Moon J, Sohn S, Won J, Kim S, Kim D</authors><journal>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</journal><issue>1</issue><year>2016</year><page>61-70</page></reference><reference><reference-id>26607761</reference-id><title>Acute loss of TET function results in aggressive myeloid cancer in mice.</title><authors>An J, González-Avalos E, Chawla A, Jeong M, López-Moyado I, Li W, Goodell M, Chavez L, Ko M, Rao A</authors><journal>Nature communications</journal><year>2015</year><page>10071</page></reference><reference><reference-id>27069254</reference-id><title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</title><authors>Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M, Bloomfield C, Cazzola M, Vardiman J</authors><journal>Blood</journal><issue>20</issue><year>2016</year><page>2391-405</page></reference><reference><reference-id>24994606</reference-id><title>Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.</title><authors>Aslanyan M, Kroeze L, Langemeijer S, Koorenhof-Scheele T, Massop M, van Hoogen P, Stevens-Linders E, van de Locht L, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie J, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt E, de Witte T, van der Reijden B, Suciu S, Jansen J</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1401-12</page></reference><reference><reference-id>17965322</reference-id><title>Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.</title><authors>Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S</authors><journal>Blood</journal><issue>5</issue><year>2008</year><page>2527-37</page></reference><reference><reference-id>16266897</reference-id><title>Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.</title><authors>Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C</authors><journal>Haematologica</journal><issue>11</issue><year>2005</year><page>1502-10</page></reference><reference><reference-id>17268528</reference-id><title>Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.</title><authors>Baldwin B, Li L, Tse K, Small S, Collector M, Whartenby K, Sharkis S, Racke F, Huso D, Small D</authors><journal>Leukemia</journal><issue>4</issue><year>2007</year><page>764-71</page></reference><reference><reference-id>25224413</reference-id><title>TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.</title><authors>Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone R, Neuberg D, Steensma D, Ebert B</authors><journal>Blood</journal><issue>17</issue><year>2014</year><page>2705-12</page></reference><reference><reference-id>19878871</reference-id><title>Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML.</title><authors>Bereshchenko O, Mancini E, Moore S, Bilbao D, Månsson R, Luc S, Grover A, Jacobsen S, Bryder D, Nerlov C</authors><journal>Cancer cell</journal><issue>5</issue><year>2009</year><page>390-400</page></reference><reference><reference-id>17851556</reference-id><title>Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.</title><authors>Biggio V, Renneville A, Nibourel O, Philippe N, Terriou L, Roumier C, Amouyel P, Cottel D, Castaigne S, Dombret H, Thomas X, Fenaux P, Preudhomme C</authors><journal>Leukemia</journal><issue>3</issue><year>2008</year><page>655-7</page></reference><reference><reference-id>20368434</reference-id><title>Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.</title><authors>Blum W, Garzon R, Klisovic R, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine S, Chan K, Heerema N, Bloomfield C, Grever M, Byrd J, Villalona-Calero M, Croce C, Marcucci G</authors><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><issue>16</issue><year>2010</year><page>7473-8</page></reference><reference><reference-id>18625840</reference-id><title>Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma.</title><authors>Bonetti P, Davoli T, Sironi C, Amati B, Pelicci P, Colombo E</authors><journal>The Journal of cell biology</journal><issue>1</issue><year>2008</year><page>19-26</page></reference><reference><reference-id>ASH 2014, Abstract 388</reference-id><title>388 The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
</title><authors>Borthakur G, Kantarjian HM, O'Brien S et al.</authors><journal>Blood</journal><year>2014</year></reference><reference><reference-id>16266983</reference-id><title>Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.</title><authors>Brandts C, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel W, Serve H</authors><journal>Cancer research</journal><issue>21</issue><year>2005</year><page>9643-50</page></reference><reference><reference-id>27766616</reference-id><title>Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.</title><authors>Brown F, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp K, Alonzo T, Meshinchi S, Stone R, Kornblau S, Marcucci G, Gamis A, Byrd J, Gonen M, Levine R, Kentsis A</authors><journal>British journal of haematology</journal><issue>1</issue><year>2017</year><page>86-91</page></reference><reference><reference-id>20026803</reference-id><title>Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.</title><authors>Cashen A, Schiller G, O'Donnell M, DiPersio J</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>556-61</page></reference><reference><reference-id>16540653</reference-id><title>Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.</title><authors>Colombo E, Martinelli P, Zamponi R, Shing D, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci P</authors><journal>Cancer research</journal><issue>6</issue><year>2006</year><page>3044-50</page></reference><reference><reference-id>24778653</reference-id><title>The epigenetic landscape of acute myeloid leukemia.</title><authors>Conway O'Brien E, Prideaux S, Chevassut T</authors><journal>Advances in hematology</journal><year>2014</year><page>103175</page></reference><reference><reference-id>24002496</reference-id><title>Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.</title><authors>Cortes J, Kantarjian H, Foran J, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong R, James J, Levis M</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>29</issue><year>2013</year><page>3681-7</page></reference><reference><reference-id>ASCO 2016, Abstract 7008</reference-id><title>Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.</title><authors>Cortes JE, Kantarjian HM, Kadia TM, et al. </authors><journal>J Clin Oncol</journal><year>2016</year><page>Abstract 7008</page></reference><reference><reference-id>22122748</reference-id><title>Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.</title><authors>Cowan L, Talwar S, Yang A</authors><journal>Epigenomics</journal><issue>1</issue><year>2010</year><page>71-86</page></reference><reference><reference-id>24898826</reference-id><title>TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.</title><authors>Damm F, Markus B, Thol F, Morgan M, Göhring G, Schlegelberger B, Krauter J, Heuser M, Bernard O, Ganser A</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>10</issue><year>2014</year><page>824-32</page></reference><reference><reference-id>ASH 2016, Abstract 904</reference-id><title>Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies</title><authors>Daver N, Kantarjian HM, Roboz GJ, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 904</page></reference><reference><reference-id>19474426</reference-id><title>Mutation in TET2 in myeloid cancers.</title><authors>Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic J, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus F, Marzac C, Casadevall N, Lacombe C, Romana S, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard O</authors><journal>The New England journal of medicine</journal><issue>22</issue><year>2009</year><page>2289-301</page></reference><reference><reference-id>27315441</reference-id><title>Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.</title><authors>Deol A, Sengsayadeth S, Ahn K, Wang H, Aljurf M, Antin J, Battiwalla M, Bornhauser M, Cahn J, Camitta B, Chen Y, Cutler C, Gale R, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus H, Liesveld J, Litzow M, Marks D, Nishihori T, Olsson R, Reshef R, Rowe J, Saad A, Sabloff M, Schouten H, Shea T, Soiffer R, Uy G, Waller E, Wiernik P, Wirk B, Woolfrey A, Bunjes D, Devine S, de Lima M, Sandmaier B, Weisdorf D, Khoury H, Saber W</authors><journal>Cancer</journal><issue>19</issue><year>2016</year><page>3005-3014</page></reference><reference><reference-id>25860933</reference-id><title>Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.</title><authors>Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci M, Delabesse E, Birnbaum D</authors><journal>Oncotarget</journal><issue>10</issue><year>2015</year><page>8388-96</page></reference><reference><reference-id>25987659</reference-id><title>International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts.</title><authors>Dombret H, Seymour J, Butrym A, Wierzbowska A, Selleslag D, Jang J, Kumar R, Cavenagh J, Schuh A, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, Al-Ali H, Martinelli G, Falantes J, Noppeney R, Stone R, Minden M, McIntyre H, Songer S, Lucy L, Beach C, Döhner H</authors><journal>Blood</journal><issue>3</issue><year>2015</year><page>291-9</page></reference><reference><reference-id>20038735</reference-id><title>Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.</title><authors>Dufour A, Schneider F, Metzeler K, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland M, Berdel W, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander S, Spiekermann K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2010</year><page>570-7</page></reference><reference><reference-id>16051734</reference-id><title>Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.</title><authors>Döhner K, Schlenk R, Habdank M, Scholl C, Rücker F, Corbacioglu A, Bullinger L, Fröhling S, Döhner H</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3740-6</page></reference><reference><reference-id>23952244</reference-id><title>ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.</title><authors>El-Sharkawi D, Ali A, Evans C, Hills R, Burnett A, Linch D, Gale R</authors><journal>Leukemia &amp; lymphoma</journal><issue>6</issue><year>2014</year><page>1326-31</page></reference><reference><reference-id>16455950</reference-id><title>Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.</title><authors>Falini B, Bolli N, Shan J, Martelli M, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli M, Gu W, Mecucci C, Nicoletti I</authors><journal>Blood</journal><issue>11</issue><year>2006</year><page>4514-23</page></reference><reference><reference-id>15659725</reference-id><title>Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.</title><authors>Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci P, Martelli M</authors><journal>The New England journal of medicine</journal><issue>3</issue><year>2005</year><page>254-66</page></reference><reference><reference-id>17488663</reference-id><title>Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.</title><authors>Falini B, Nicoletti I, Bolli N, Martelli M, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli M</authors><journal>Haematologica</journal><issue>4</issue><year>2007</year><page>519-32</page></reference><reference><reference-id>17008539</reference-id><title>Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.</title><authors>Falini B, Nicoletti I, Martelli M, Mecucci C</authors><journal>Blood</journal><issue>3</issue><year>2007</year><page>874-85</page></reference><reference><reference-id>24056881</reference-id><title>The role of different genetic subtypes of CEBPA mutated AML.</title><authors>Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>4</issue><year>2014</year><page>794-803</page></reference><reference><reference-id>Blood 2016, Abstract 5218</reference-id><title>A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia</title><authors>Fathi AT, Blonquist TM, Levis MJ</authors><journal>Blood</journal><issue>22</issue><year>2016</year><page>Abstract 5218</page></reference><reference><reference-id>23436734</reference-id><title>Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.</title><authors>Federici L, Falini B</authors><journal>Protein science : a publication of the Protein Society</journal><issue>5</issue><year>2013</year><page>545-56</page></reference><reference><reference-id>22912701</reference-id><title>Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.</title><authors>Fernandez-Mercado M, Yip B, Pellagatti A, Davies C, Larrayoz M, Kondo T, Pérez C, Killick S, McDonald E, Odero M, Agirre X, Prósper F, Calasanz M, Wainscoat J, Boultwood J</authors><journal>PloS one</journal><issue>8</issue><year>2012</year><page>e42334</page></reference><reference><reference-id>25818407</reference-id><title>A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.</title><authors>Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk R</authors><journal>British journal of haematology</journal><issue>5</issue><year>2015</year><page>694-700</page></reference><reference><reference-id>15459012</reference-id><title>A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.</title><authors>Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann O, O'Farrell A, Bello C, Allred R, Manning W, Cherrington J, Louie S, Hong W, Brega N, Massimini G, Scigalla P, Berdel W, Hossfeld D</authors><journal>Blood</journal><issue>3</issue><year>2005</year><page>986-93</page></reference><reference><reference-id>19861679</reference-id><title>Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.</title><authors>Fisher C, Pineault N, Brookes C, Helgason C, Ohta H, Bodner C, Hess J, Humphries R, Brock H</authors><journal>Blood</journal><issue>1</issue><year>2010</year><page>38-46</page></reference><reference><reference-id>2227417</reference-id><title>Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene.</title><authors>Friedman A, McKnight S</authors><journal>Genes &amp; development</journal><issue>8</issue><year>1990</year><page>1416-26</page></reference><reference><reference-id>14726504</reference-id><title>CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.</title><authors>Fröhling S, Schlenk R, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>4</issue><year>2004</year><page>624-33</page></reference><reference><reference-id>22430270</reference-id><title>TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.</title><authors>Gaidzik V, Paschka P, Späth D, Habdank M, Köhne C, Germing U, von Lilienfeld-Toal M, Held G, Horst H, Haase D, Bentz M, Götze K, Döhner H, Schlenk R, Bullinger L, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>12</issue><year>2012</year><page>1350-7</page></reference><reference><reference-id>27137476</reference-id><title>RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.</title><authors>Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne C, Horst H, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus J, Kestler H, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk R, Döhner K, Döhner H</authors><journal>Leukemia</journal><issue>11</issue><year>2016</year><page>2160-2168</page></reference><reference><reference-id>24227820</reference-id><title>Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.</title><authors>Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M</authors><journal>Blood</journal><issue>1</issue><year>2014</year><page>94-100</page></reference><reference><reference-id>20439648</reference-id><title>Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.</title><authors>Green C, Koo K, Hills R, Burnett A, Linch D, Gale R</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>16</issue><year>2010</year><page>2739-47</page></reference><reference><reference-id>16794633</reference-id><title>Nucleophosmin and cancer.</title><authors>Grisendi S, Mecucci C, Falini B, Pandolfi P</authors><journal>Nature reviews. Cancer</journal><issue>7</issue><year>2006</year><page>493-505</page></reference><reference><reference-id>23521373</reference-id><title>CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.</title><authors>Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S</authors><journal>British journal of haematology</journal><issue>5</issue><year>2013</year><page>649-58</page></reference><reference><reference-id>11809705</reference-id><title>Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.</title><authors>Halmos B, Huettner C, Kocher O, Ferenczi K, Karp D, Tenen D</authors><journal>Cancer research</journal><issue>2</issue><year>2002</year><page>528-34</page></reference><reference><reference-id>10698507</reference-id><title>Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.</title><authors>Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T</authors><journal>Oncogene</journal><issue>5</issue><year>2000</year><page>624-31</page></reference><reference><reference-id>26559910</reference-id><title>NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape.</title><authors>Holmberg Olausson K, Elsir T, Moazemi Goudarzi K, Nistér M, Lindström M</authors><journal>Scientific reports</journal><year>2015</year><page>16495</page></reference><reference><reference-id>25349213</reference-id><title>Loss of nucleolar histone chaperone NPM1 triggers rearrangement of heterochromatin and synergizes with a deficiency in DNA methyltransferase DNMT3A to drive ribosomal DNA transcription.</title><authors>Holmberg Olausson K, Nistér M, Lindström M</authors><journal>The Journal of biological chemistry</journal><issue>50</issue><year>2014</year><page>34601-19</page></reference><reference><reference-id>24816240</reference-id><title>Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.</title><authors>Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander S, Subklewe M, Sauerland M, Berdel W, Büchner T, Wörmann B, Hiddemann W, Spiekermann K</authors><journal>Haematologica</journal><issue>8</issue><year>2014</year><page>1317-25</page></reference><reference><reference-id>24216483</reference-id><title>Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.</title><authors>Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata K, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine R, Abdel-Wahab O, Kitamura T</authors><journal>The Journal of clinical investigation</journal><issue>11</issue><year>2013</year><page>4627-40</page></reference><reference><reference-id>26296954</reference-id><title>Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.</title><authors>Issa J, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths E, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder J, Azab M, Kantarjian H</authors><journal>The Lancet. Oncology</journal><issue>9</issue><year>2015</year><page>1099-1110</page></reference><reference><reference-id>20639862</reference-id><title>Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.</title><authors>Ito S, D'Alessio A, Taranova O, Hong K, Sowers L, Zhang Y</authors><journal>Nature</journal><issue>7310</issue><year>2010</year><page>1129-33</page></reference><reference><reference-id>21494260</reference-id><title>Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.</title><authors>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M</authors><journal>Leukemia</journal><issue>7</issue><year>2011</year><page>1147-52</page></reference><reference><reference-id>26789727</reference-id><title>Assessment of Minimal Residual Disease in Standard-Risk AML.</title><authors>Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch D, Gale R, Vyas P, Freeman S, Russell N, Burnett A, Grimwade D</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2016</year><page>422-33</page></reference><reference><reference-id>19372255</reference-id><title>Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.</title><authors>Jankowska A, Szpurka H, Tiu R, Makishima H, Afable M, Huh J, O'Keefe C, Ganetzky R, McDevitt M, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2009</year><page>6403-10</page></reference><reference><reference-id>17504301</reference-id><title>Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers.</title><authors>Jeong E, Lee S, Yoo N, Lee S</authors><journal>APMIS : acta pathologica, microbiologica, et immunologica Scandinavica</journal><issue>4</issue><year>2007</year><page>341-6</page></reference><reference><reference-id>19734942</reference-id><title>RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells.</title><authors>Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y, Yang C</authors><journal>Oncogene</journal><issue>47</issue><year>2009</year><page>4201-11</page></reference><reference><reference-id>9988266</reference-id><title>Cancer epigenetics comes of age.</title><authors>Jones P, Laird P</authors><journal>Nature genetics</journal><issue>2</issue><year>1999</year><page>163-7</page></reference><reference><reference-id>24122999</reference-id><title>Loss of 5-hydroxymethylcytosine and TET2 in oral squamous cell carcinoma.</title><authors>Jäwert F, Hasséus B, Kjeller G, Magnusson B, Sand L, Larsson L</authors><journal>Anticancer research</journal><issue>10</issue><year>2013</year><page>4325-8</page></reference><reference><reference-id>15897554</reference-id><title>Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.</title><authors>Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh L, Lee S, Leighton J, Patel H, Rahman A, Sridhara R, Wang Y, Pazdur R</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>10</issue><year>2005</year><page>3604-8</page></reference><reference><reference-id>22689805</reference-id><title>Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.</title><authors>Kantarjian H, Thomas X, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau J, Chou W, Buckstein R, Cermak J, Kuo C, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>21</issue><year>2012</year><page>2670-7</page></reference><reference><reference-id>ASH 2015, Abstract 458</reference-id><title>Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)</title><authors>Kantarjian HM, Roboz GJ, Kropf PL et al.</authors><journal>Blood</journal><year>2015</year><page>Abstract 458</page></reference><reference><reference-id>25022553</reference-id><title>Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.</title><authors>Kao H, Liang D, Wu J, Kuo M, Wang P, Yang C, Shih Y, Lin T, Huang Y, Shih L</authors><journal>Neoplasia (New York, N.Y.)</journal><issue>6</issue><year>2014</year><page>481-8</page></reference><reference><reference-id>21689627</reference-id><title>An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.</title><authors>Karhemo P, Rivinoja A, Lundin J, Hyvönen M, Chernenko A, Lammi J, Sihto H, Lundin M, Heikkilä P, Joensuu H, Bono P, Laakkonen P</authors><journal>The American journal of pathology</journal><issue>2</issue><year>2011</year><page>1004-14</page></reference><reference><reference-id>23736028</reference-id><title>Functional and cancer genomics of ASXL family members.</title><authors>Katoh M</authors><journal>British journal of cancer</journal><issue>2</issue><year>2013</year><page>299-306</page></reference><reference><reference-id>11756186</reference-id><title>FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.</title><authors>Kelly L, Liu Q, Kutok J, Williams I, Boulton C, Gilliland D</authors><journal>Blood</journal><issue>1</issue><year>2002</year><page>310-8</page></reference><reference><reference-id>22389883</reference-id><title>Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.</title><authors>Kim S, Kim D, Jang J, Jung C, Jang M, Ki C, Kim J, Kim S, Kim H</authors><journal>Annals of laboratory medicine</journal><issue>2</issue><year>2012</year><page>153-7</page></reference><reference><reference-id>18394553</reference-id><title>Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells.</title><authors>Kirstetter P, Schuster M, Bereshchenko O, Moore S, Dvinge H, Kurz E, Theilgaard-Mönch K, Månsson R, Pedersen T, Pabst T, Schrock E, Porse B, Jacobsen S, Bertone P, Tenen D, Nerlov C</authors><journal>Cancer cell</journal><issue>4</issue><year>2008</year><page>299-310</page></reference><reference><reference-id>12400596</reference-id><title>FLT3 in human hematologic malignancies.</title><authors>Kiyoi H, Naoe T</authors><journal>Leukemia &amp; lymphoma</journal><issue>8</issue><year>2002</year><page>1541-7</page></reference><reference><reference-id>25231999</reference-id><title>Targeting FLT3 to treat leukemia.</title><authors>Konig H, Levis M</authors><journal>Expert opinion on therapeutic targets</journal><issue>1</issue><year>2015</year><page>37-54</page></reference><reference><reference-id>15684379</reference-id><title>Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.</title><authors>Korgaonkar C, Hagen J, Tompkins V, Frazier A, Allamargot C, Quelle F, Quelle D</authors><journal>Molecular and cellular biology</journal><issue>4</issue><year>2005</year><page>1258-71</page></reference><reference><reference-id>24402164</reference-id><title>High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.</title><authors>Krauth M, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S</authors><journal>Leukemia</journal><issue>7</issue><year>2014</year><page>1449-58</page></reference><reference><reference-id>21555683</reference-id><title>Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.</title><authors>Krönke J, Schlenk R, Jensen K, Tschürtz F, Corbacioglu A, Gaidzik V, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih H, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler H, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>19</issue><year>2011</year><page>2709-16</page></reference><reference><reference-id>19483684</reference-id><title>Acquired mutations in TET2 are common in myelodysplastic syndromes.</title><authors>Langemeijer S, Kuiper R, Berends M, Knops R, Aslanyan M, Massop M, Stevens-Linders E, van Hoogen P, van Kessel A, Raymakers R, Kamping E, Verhoef G, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden B, Jansen J</authors><journal>Nature genetics</journal><issue>7</issue><year>2009</year><page>838-42</page></reference><reference><reference-id>17936561</reference-id><title>FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.</title><authors>Lee B, Tothova Z, Levine R, Anderson K, Buza-Vidas N, Cullen D, McDowell E, Adelsperger J, Fröhling S, Huntly B, Beran M, Jacobsen S, Gilliland D</authors><journal>Cancer cell</journal><issue>4</issue><year>2007</year><page>367-80</page></reference><reference><reference-id>16116483</reference-id><title>FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.</title><authors>Lee B, Williams I, Anastasiadou E, Boulton C, Joseph S, Amaral S, Curley D, Duclos N, Huntly B, Fabbro D, Griffin J, Gilliland D</authors><journal>Oncogene</journal><issue>53</issue><year>2005</year><page>7882-92</page></reference><reference><reference-id>25227715</reference-id><title>Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.</title><authors>Li H, Deng D, Huang Y, Ye F, Huang L, Xiao Q, Zhang B, Ye B, Lai Y, Mo Z, Liu Z</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>439-48</page></reference><reference><reference-id>21803851</reference-id><title>Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.</title><authors>Li Z, Cai X, Cai C, Wang J, Zhang W, Petersen B, Yang F, Xu M</authors><journal>Blood</journal><issue>17</issue><year>2011</year><page>4509-18</page></reference><reference><reference-id>19652540</reference-id><title>The Myc-nucleophosmin-ARF network: a complex web unveiled.</title><authors>Li Z, Hann S</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>17</issue><year>2009</year><page>2703-7</page></reference><reference><reference-id>26062848</reference-id><title>Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.</title><authors>Lim Y, Gondek L, Li L, Wang Q, Ma H, Ma H, Chang E, Huso D, Foerster S, Marchionni L, McGovern K, Watkins D, Peacock C, Levis M, Smith B, Merchant A, Small D, Matsui W</authors><journal>Science translational medicine</journal><issue>291</issue><year>2015</year><page>291ra96</page></reference><reference><reference-id>15746035</reference-id><title>Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.</title><authors>Lin L, Chen C, Lin D, Tsay W, Tang J, Yeh Y, Shen H, Su F, Yao M, Huang S, Tien H</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>4</issue><year>2005</year><page>1372-9</page></reference><reference><reference-id>28070990</reference-id><title>A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.</title><authors>Lin P, Li H, Fan S, Yuan T, Chen M, Hsu Y, Yang Y, Li L, Yeh S, Bai L, Liao Y, Lin C, Hsieh C, Lin C, Lin C, Lien M, Chen T, Ni Y, Chiu C</authors><journal>Cancer medicine</journal><issue>2</issue><year>2017</year><page>349-360</page></reference><reference><reference-id>23996483</reference-id><title>Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.</title><authors>Lin T, Nagata Y, Kao H, Sanada M, Okuno Y, Huang C, Liang D, Kuo M, Lai C, Lee E, Shih Y, Tanaka H, Shiraishi Y, Chiba K, Lin T, Wu J, Miyano S, Ogawa S, Shih L</authors><journal>Haematologica</journal><issue>1</issue><year>2014</year><page>28-36</page></reference><reference><reference-id>25550361</reference-id><title>Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.</title><authors>Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S, Pigneux A, Wetzler M, Stuart R, Erba H, Damon L, Powell B, Lindeman N, Steensma D, Wadleigh M, DeAngelo D, Neuberg D, Stone R, Ebert B</authors><journal>Blood</journal><issue>9</issue><year>2015</year><page>1367-76</page></reference><reference><reference-id>24524305</reference-id><title>Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.</title><authors>Liu W, Tan X, Luo X, Guo B, Wei Z, Ke Q, He S, Cen H</authors><journal>Leukemia &amp; lymphoma</journal><issue>12</issue><year>2014</year><page>2691-8</page></reference><reference><reference-id>22631075</reference-id><title>Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells.</title><authors>Liu Y, Zhang F, Zhang X, Qi L, Yang L, Guo H, Zhang N</authors><journal>Journal of biomedical science</journal><year>2012</year><page>53</page></reference><reference><reference-id>27060207</reference-id><title>Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).</title><authors>Lu J, Wang A, Liao H, Chen C, Hou H, Hu C, Tien H, Ou D, Lin L</authors><journal>Cancer letters</journal><issue>2</issue><year>2016</year><page>218-25</page></reference><reference><reference-id>22058219</reference-id><title>A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.</title><authors>Lübbert M, Rüter B, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans P, Döhner H</authors><journal>Haematologica</journal><issue>3</issue><year>2012</year><page>393-401</page></reference><reference><reference-id>22240200</reference-id><title>TET2, a tumor suppressor in hematological disorders.</title><authors>Mercher T, Quivoron C, Couronné L, Bastard C, Vainchenker W, Bernard O</authors><journal>Biochimica et biophysica acta</journal><issue>2</issue><year>2012</year><page>173-7</page></reference><reference><reference-id>19549778</reference-id><title>Structural and functional alterations of FLT3 in acute myeloid leukemia.</title><authors>Meshinchi S, Appelbaum F</authors><journal>Clinical cancer research : an official journal of the American Association for Cancer Research</journal><issue>13</issue><year>2009</year><page>4263-9</page></reference><reference><reference-id>22031865</reference-id><title>ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.</title><authors>Metzeler K, Becker H, Maharry K, Radmacher M, Kohlschmidt J, Mrózek K, Nicolet D, Whitman S, Wu Y, Schwind S, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Blood</journal><issue>26</issue><year>2011</year><page>6920-9</page></reference><reference><reference-id>27288520</reference-id><title>Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.</title><authors>Metzeler K, Herold T, Rothenberg-Thurley M, Amler S, Sauerland M, Görlich D, Schneider S, Konstandin N, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif P, Fiegl M, Subklewe M, Bohlander S, Krug U, Faldum A, Berdel W, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K</authors><journal>Blood</journal><issue>5</issue><year>2016</year><page>686-98</page></reference><reference><reference-id>21343549</reference-id><title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.</title><authors>Metzeler K, Maharry K, Radmacher M, Mrózek K, Margeson D, Becker H, Curfman J, Holland K, Schwind S, Whitman S, Wu Y, Blum W, Powell B, Carter T, Wetzler M, Moore J, Kolitz J, Baer M, Carroll A, Larson R, Caligiuri M, Marcucci G, Bloomfield C</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>10</issue><year>2011</year><page>1373-81</page></reference><reference><reference-id>11090077</reference-id><title>Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.</title><authors>Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel W, Serve H</authors><journal>Blood</journal><issue>12</issue><year>2000</year><page>3907-14</page></reference><reference><reference-id>21723200</reference-id><title>Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.</title><authors>Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa M, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer S, Melnick A, Godley L, Aifantis I, Levine R</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>11-24</page></reference><reference><reference-id>26093090</reference-id><title>TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.</title><authors>Murata A, Baba Y, Ishimoto T, Miyake K, Kosumi K, Harada K, Kurashige J, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Yamamoto M, Oda S, Watanabe M, Nakao M, Baba H</authors><journal>Oncotarget</journal><issue>27</issue><year>2015</year><page>23372-82</page></reference><reference><reference-id>25912052</reference-id><title>Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.</title><authors>Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak W, Kyrcz-Krzemien S, Komarnicki M, Warzocha K</authors><journal>European journal of haematology</journal><issue>3</issue><year>2016</year><page>236-44</page></reference><reference><reference-id>27983727</reference-id><title>The complexity of interpreting genomic data in patients with acute myeloid leukemia.</title><authors>Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway H, Hirsch C, Przychodzen B, Patel B, Clemente M, Sanikommu S, Kalaycio M, Maciejewski J, Sekeres M</authors><journal>Blood cancer journal</journal><issue>12</issue><year>2016</year><page>e510</page></reference><reference><reference-id>25567350</reference-id><title>A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.</title><authors>Newman E, Morgan R, Kummar S, Beumer J, Blanchard M, Ruel C, El-Khoueiry A, Carroll M, Hou J, Li C, Lenz H, Eiseman J, Doroshow J</authors><journal>Cancer chemotherapy and pharmacology</journal><issue>3</issue><year>2015</year><page>537-46</page></reference><reference><reference-id>12450141</reference-id><title>Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization.</title><authors>Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H</authors><journal>Bioscience, biotechnology, and biochemistry</journal><issue>10</issue><year>2002</year><page>2239-42</page></reference><reference><reference-id>25412851</reference-id><title>Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.</title><authors>Ohgami R, Ma L, Merker J, Gotlib J, Schrijver I, Zehnder J, Arber D</authors><journal>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal><issue>5</issue><year>2015</year><page>706-14</page></reference><reference><reference-id>11242107</reference-id><title>Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.</title><authors>Pabst T, Mueller B, Zhang P, Radomska H, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen D</authors><journal>Nature genetics</journal><issue>3</issue><year>2001</year><page>263-70</page></reference><reference><reference-id>27276561</reference-id><title>Genomic Classification and Prognosis in Acute Myeloid Leukemia.</title><authors>Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N, Potter N, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones D, Teague J, Butler A, Greaves M, Ganser A, Döhner K, Schlenk R, Döhner H, Campbell P</authors><journal>The New England journal of medicine</journal><issue>23</issue><year>2016</year><page>2209-2221</page></reference><reference><reference-id>25596267</reference-id><title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.</title><authors>Paschka P, Schlenk R, Gaidzik V, Herzig J, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne C, Brossart P, Held G, Horst H, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K</authors><journal>Haematologica</journal><issue>3</issue><year>2015</year><page>324-30</page></reference><reference><reference-id>22417203</reference-id><title>Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.</title><authors>Patel J, Gönen M, Figueroa M, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci N, Heguy A, Cherry A, Vance G, Higgins R, Ketterling R, Gallagher R, Litzow M, van den Brink M, Lazarus H, Rowe J, Luger S, Ferrando A, Paietta E, Tallman M, Melnick A, Abdel-Wahab O, Levine R</authors><journal>The New England journal of medicine</journal><issue>12</issue><year>2012</year><page>1079-89</page></reference><reference><reference-id>22150310</reference-id><title>C/EBPα dysregulation in AML and ALL.</title><authors>Paz-Priel I, Friedman A</authors><journal>Critical reviews in oncogenesis</journal><issue>1-2</issue><year>2011</year><page>93-102</page></reference><reference><reference-id>24749672</reference-id><title>Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.</title><authors>Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F</authors><journal>Expert opinion on investigational drugs</journal><issue>7</issue><year>2014</year><page>943-54</page></reference><reference><reference-id>ASCO 2013, Abstract 7023</reference-id><title>Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).</title><authors>Perl AE, Dohner H, Rousselot PH, et al. </authors><journal>J Clin Onc</journal><year>2013</year><page>Abstract 7023</page></reference><reference><reference-id>21258971</reference-id><title>Nucleophosmin delocalization in thyroid tumour cells.</title><authors>Pianta A, Puppin C, Passon N, Franzoni A, Romanello M, Tell G, Di Loreto C, Bulotta S, Russo D, Damante G</authors><journal>Endocrine pathology</journal><issue>1</issue><year>2011</year><page>18-23</page></reference><reference><reference-id>24951123</reference-id><title>Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.</title><authors>Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, Schreder M, Tinchon C, Sliwa T, Lang A, Sperr W, Krippl P, Geissler D, Voskova D, Schlick K, Thaler J, Machherndl-Spandl S, Theiler G, Eckmüllner O, Greil R</authors><journal>Annals of hematology</journal><issue>11</issue><year>2014</year><page>1825-38</page></reference><reference><reference-id>27636998</reference-id><title>Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.</title><authors>Poitras J, Heiser D, Li L, Nguyen B, Nagai K, Duffield A, Gamper C, Small D</authors><journal>Oncotarget</journal><issue>43</issue><year>2016</year><page>69124-69135</page></reference><reference><reference-id>24801015</reference-id><title>Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.</title><authors>Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L</authors><journal>Annals of hematology</journal><issue>8</issue><year>2014</year><page>1279-86</page></reference><reference><reference-id>18345031</reference-id><title>NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.</title><authors>Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D</authors><journal>Oncogene</journal><issue>30</issue><year>2008</year><page>4210-20</page></reference><reference><reference-id>21723201</reference-id><title>TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.</title><authors>Quivoron C, Couronné L, Della Valle V, Lopez C, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern M, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard O</authors><journal>Cancer cell</journal><issue>1</issue><year>2011</year><page>25-38</page></reference><reference><reference-id>25886910</reference-id><title>Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.</title><authors>Rasmussen K, Jia G, Johansen J, Pedersen M, Rapin N, Bagger F, Porse B, Bernard O, Christensen J, Helin K</authors><journal>Genes &amp; development</journal><issue>9</issue><year>2015</year><page>910-22</page></reference><reference><reference-id>19569254</reference-id><title>Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.</title><authors>Rau R, Brown P</authors><journal>Hematological oncology</journal><issue>4</issue><year>2009</year><page>171-81</page></reference><reference><reference-id>20212254</reference-id><title>Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.</title><authors>Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Byrd A, Bekele B, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian H</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>11</issue><year>2010</year><page>1856-62</page></reference><reference><reference-id>20386538</reference-id><title>C/EBP alpha expression is associated with homeostasis of the gastric epithelium and with gastric carcinogenesis.</title><authors>Regalo G, Resende C, Wen X, Gomes B, Durães C, Seruca R, Carneiro F, Machado J</authors><journal>Laboratory investigation; a journal of technical methods and pathology</journal><issue>8</issue><year>2010</year><page>1132-9</page></reference><reference><reference-id>ASH 2014, Abstract 6</reference-id><title>Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial</title><authors>Rollig C, Muller-Tidow C, Huttmann A et al.</authors><journal>Blood</journal><year>2014</year><page>Abstract 6</page></reference><reference><reference-id>27285584</reference-id><title>Subtype-specific patterns of molecular mutations in acute myeloid leukemia.</title><authors>Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C</authors><journal>Leukemia</journal><issue>1</issue><year>2017</year><page>11-17</page></reference><reference><reference-id>26549589</reference-id><title>Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.</title><authors>Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus C, Brandts C, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause S, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut I, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel W, Ehninger G</authors><journal>The Lancet. Oncology</journal><issue>16</issue><year>2015</year><page>1691-9</page></reference><reference><reference-id>23437297</reference-id><title>CCAAT/enhancer-binding protein-α suppresses lung tumor development in mice through the p38α MAP kinase pathway.</title><authors>Sato A, Yamada N, Ogawa Y, Ikegami M</authors><journal>PloS one</journal><issue>2</issue><year>2013</year><page>e57013</page></reference><reference><reference-id>22289496</reference-id><title>p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.</title><authors>Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B</authors><journal>Seminars in oncology</journal><issue>1</issue><year>2012</year><page>97-108</page></reference><reference><reference-id>16990784</reference-id><title>FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).</title><authors>Schittenhelm M, Yee K, Tyner J, McGreevey L, Haley A, Town A, Griffith D, Bainbridge T, Braziel R, O'Farrell A, Cherrington J, Heinrich M</authors><journal>Leukemia</journal><issue>11</issue><year>2006</year><page>2008-14</page></reference><reference><reference-id>18450602</reference-id><title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</title><authors>Schlenk R, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H</authors><journal>The New England journal of medicine</journal><issue>18</issue><year>2008</year><page>1909-18</page></reference><reference><reference-id>27716819</reference-id><title>A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.</title><authors>Schliemann C, Gerss J, Wiebe S, Mikesch J, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Müller-Tidow C, Berdel W, Krug U</authors><journal>PloS one</journal><issue>10</issue><year>2016</year><page>e0164499</page></reference><reference><reference-id>20888888</reference-id><title>A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.</title><authors>Schnittger S, Bacher U, Eder C, Lohse P, Haferlach C, Kern W, Haferlach T</authors><journal>Experimental hematology</journal><issue>1</issue><year>2011</year><page>87-94</page></reference><reference><reference-id>23018865</reference-id><title>ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.</title><authors>Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann H, Kreuzer K, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T</authors><journal>Leukemia</journal><issue>1</issue><year>2013</year><page>82-91</page></reference><reference><reference-id>19587375</reference-id><title>Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.</title><authors>Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T</authors><journal>Blood</journal><issue>11</issue><year>2009</year><page>2220-31</page></reference><reference><reference-id>16076867</reference-id><title>Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.</title><authors>Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M, Haferlach T, Hiddemann W, Falini B</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3733-9</page></reference><reference><reference-id>25200248</reference-id><title>Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.</title><authors>Scopim-Ribeiro R, Machado-Neto J, Campos P, Silva C, Favaro P, Lorand-Metze I, Costa F, Saad S, Traina F</authors><journal>European journal of haematology</journal><issue>5</issue><year>2015</year><page>413-8</page></reference><reference><reference-id>26876596</reference-id><title>DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.</title><authors>Scourzic L, Couronné L, Pedersen M, Della Valle V, Diop M, Mylonas E, Calvo J, Mouly E, Lopez C, Martin N, Fontenay M, Bender A, Guibert S, Dubreuil P, Dessen P, Droin N, Pflumio F, Weber M, Gaulard P, Helin K, Mercher T, Bernard O</authors><journal>Leukemia</journal><issue>6</issue><year>2016</year><page>1388-98</page></reference><reference><reference-id>22915641</reference-id><title>Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.</title><authors>Sekeres M, Tiu R, Komrokji R, Lancet J, Advani A, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List A, Maciejewski J</authors><journal>Blood</journal><issue>25</issue><year>2012</year><page>4945-51</page></reference><reference><reference-id>23897964</reference-id><title>Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.</title><authors>Serve H, Krug U, Wagner R, Sauerland M, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer K, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel W</authors><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><issue>25</issue><year>2013</year><page>3110-8</page></reference><reference><reference-id>23656730</reference-id><title>The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.</title><authors>Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C</authors><journal>Blood</journal><issue>1</issue><year>2013</year><page>83-92</page></reference><reference><reference-id>25873173</reference-id><title>Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.</title><authors>Shih A, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer S, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine R</authors><journal>Cancer cell</journal><issue>4</issue><year>2015</year><page>502-15</page></reference><reference><reference-id>28193779</reference-id><title>Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.</title><authors>Shih A, Meydan C, Shank K, Garrett-Bakelman F, Ward P, Intlekofer A, Nazir A, Stein E, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason C, Yen K, Thompson C, Melnick A, Levine R</authors><journal>Cancer discovery</journal><issue>5</issue><year>2017</year><page>494-505</page></reference><reference><reference-id>ASH 2011, Abstract 764</reference-id><title>764 PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro</title><authors>Smith CC, Perl AE, Lasater E et al.</authors><journal>Blood</journal><year>2011</year><page>Abstract 764</page></reference><reference><reference-id>26191952</reference-id><title>FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.</title><authors>Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer D, Chughtai K, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi S</authors><journal>Bone marrow transplantation</journal><issue>4</issue><year>2016</year><page>511-520</page></reference><reference><reference-id>22053282</reference-id><title>How does the NPM1 mutant induce leukemia?</title><authors>Sportoletti P</authors><journal>Pediatric reports</journal><year>2011</year><page>e6</page></reference><reference><reference-id>28644114</reference-id><title>Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.</title><authors>Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C, Thiede C, Prior T, Döhner K, Marcucci G, Lo-Coco F, Klisovic R, Wei A, Sierra J, Sanz M, Brandwein J, de Witte T, Niederwieser D, Appelbaum F, Medeiros B, Tallman M, Krauter J, Schlenk R, Ganser A, Serve H, Ehninger G, Amadori S, Larson R, Döhner H</authors><journal>The New England journal of medicine</journal><issue>5</issue><year>2017</year><page>454-464</page></reference><reference><reference-id>ASH 2015, Abstract 6</reference-id><title>The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand)�P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])</title><authors>Stone RM, Mandrekar S, Sanford BL, et al. </authors><journal>Blood</journal><year>2015</year><page>Abstract 6</page></reference><reference><reference-id>15994285</reference-id><title>Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.</title><authors>Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2005</year><page>2854-61</page></reference><reference><reference-id>16107701</reference-id><title>Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription.</title><authors>Swaminathan V, Kishore A, Febitha K, Kundu T</authors><journal>Molecular and cellular biology</journal><issue>17</issue><year>2005</year><page>7534-45</page></reference><reference><reference-id>ASCO 2011, Abstract 6518</reference-id><title>Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.</title><authors>Talpaz M, Shah NP, Deininger MW et al.</authors><journal>J Clin Oncol</journal><year>2011</year><page>Abstract 6518</page></reference><reference><reference-id>27911276</reference-id><title>The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.</title><authors>Tan P, Soo Tiong I, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A</authors><journal>Oncotarget</journal><year>2016</year><page>[Epub ahead of print]</page></reference><reference><reference-id>25534201</reference-id><title>Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.</title><authors>Taylor S, Thien C, Dagger S, Duyvestyn J, Grove C, Lee B, Gilliland D, Langdon W</authors><journal>Experimental hematology</journal><issue>3</issue><year>2015</year><page>191-206.e1</page></reference><reference><reference-id>16455956</reference-id><title>Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).</title><authors>Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G</authors><journal>Blood</journal><issue>10</issue><year>2006</year><page>4011-20</page></reference><reference><reference-id>12036858</reference-id><title>Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.</title><authors>Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T</authors><journal>Blood</journal><issue>12</issue><year>2002</year><page>4326-35</page></reference><reference><reference-id>24859829</reference-id><title>TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.</title><authors>Tian X, Xu Y, Yin J, Tian H, Chen S, Wu D, Sun A</authors><journal>International journal of hematology</journal><issue>1</issue><year>2014</year><page>96-104</page></reference><reference><reference-id>24045501</reference-id><title>Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.</title><authors>Traina F, Visconte V, Elson P, Tabarroki A, Jankowska A, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe C, Sekeres M, Advani A, Kalaycio M, Copelan E, Saunthararajah Y, Olalla Saad S, Maciejewski J, Tiu R</authors><journal>Leukemia</journal><issue>1</issue><year>2014</year><page>78-87</page></reference><reference><reference-id>27055875</reference-id><title>Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.</title><authors>Tsai C, Hou H, Tang J, Liu C, Lin C, Chou W, Tseng M, Chiang Y, Kuo Y, Liu M, Liu C, Lin L, Tsay W, Yao M, Li C, Huang S, Ko B, Hsu S, Chen C, Lin C, Wu S, Tien H</authors><journal>Leukemia</journal><issue>7</issue><year>2016</year><page>1485-92</page></reference><reference><reference-id>26233683</reference-id><title>Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.</title><authors>Tschan-Plessl A, Halter J, Heim D, Medinger M, Passweg J, Gerull S</authors><journal>Annals of hematology</journal><issue>11</issue><year>2015</year><page>1899-905</page></reference><reference><reference-id>ASH 2015, Abstract 319</reference-id><title>Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)</title><authors>Uy GL, Mandrekar S, Laumann K et al. </authors><year>2015</year><page>Abstract 319</page></reference><reference><reference-id>16109776</reference-id><title>Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.</title><authors>Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W, Uitterlinden A, Erpelinck C, Delwel R, Löwenberg B, Valk P</authors><journal>Blood</journal><issue>12</issue><year>2005</year><page>3747-54</page></reference><reference><reference-id>21242187</reference-id><title>FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.</title><authors>Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, Schäfer I, Schlegelberger B, Heil G, Ganser A, Krauter J</authors><journal>Haematologica</journal><issue>5</issue><year>2011</year><page>681-6</page></reference><reference><reference-id>24883179</reference-id><title>The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.</title><authors>Wander S, Levis M, Fathi A</authors><journal>Therapeutic advances in hematology</journal><issue>3</issue><year>2014</year><page>65-77</page></reference><reference><reference-id>ASH 2016, Abstract 1071</reference-id><title>Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)</title><authors>Wang ES, Stone RM, Tallman MS, et al.</authors><journal>Blood</journal><year>2016</year><page>Abstract 2071</page></reference><reference><reference-id>24255920</reference-id><title>Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.</title><authors>Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai C, Xu M, Yang F</authors><journal>Blood</journal><issue>4</issue><year>2014</year><page>541-53</page></reference><reference><reference-id>25601757</reference-id><title>WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.</title><authors>Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, Wang P, Yang H, Ma S, Lin H, Jiao B, Ren R, Ye D, Guan K, Xiong Y</authors><journal>Molecular cell</journal><issue>4</issue><year>2015</year><page>662-73</page></reference><reference><reference-id>22116554</reference-id><title>Landscape of TET2 mutations in acute myeloid leukemia.</title><authors>Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A</authors><journal>Leukemia</journal><issue>5</issue><year>2012</year><page>934-42</page></reference><reference><reference-id>25400766</reference-id><title>Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.</title><authors>Wen X, Lin J, Yang J, Yao D, Deng Z, Tang C, Xiao G, Yang L, Ma J, Hu J, Qian W, Qian J</authors><journal>International journal of clinical and experimental pathology</journal><issue>10</issue><year>2014</year><page>6832-40</page></reference><reference><reference-id>21209843</reference-id><title>Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability.</title><authors>Williams D, Bird M, Jorissen R, Yu Y, Walker F, Walker F, Zhang H, Nice E, Burgess A</authors><journal>PloS one</journal><issue>12</issue><year>2010</year><page>e16012</page></reference><reference><reference-id>17190859</reference-id><title>A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.</title><authors>Wouters B, Louwers I, Valk P, Löwenberg B, Delwel R</authors><journal>Blood</journal><issue>1</issue><year>2007</year><page>389-90</page></reference><reference><reference-id>28130413</reference-id><title>The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36.</title><authors>Yamagata K, Kobayashi A</authors><journal>Journal of biochemistry</journal><issue>4</issue><year>2017</year><page>327-330</page></reference><reference><reference-id>11290608</reference-id><title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.</title><authors>Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T</authors><journal>Blood</journal><issue>8</issue><year>2001</year><page>2434-9</page></reference><reference><reference-id>28063196</reference-id><title>ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.</title><authors>Yamato G, Shiba N, Yoshida K, Shiraishi Y, Hara Y, Ohki K, Okubo J, Okuno H, Chiba K, Tanaka H, Kinoshita A, Moritake H, Kiyokawa N, Tomizawa D, Park M, Sotomatsu M, Taga T, Adachi S, Tawa A, Horibe K, Arakawa H, Miyano S, Ogawa S, Hayashi Y</authors><journal>Genes, chromosomes &amp; cancer</journal><issue>5</issue><year>2017</year><page>382-393</page></reference><reference><reference-id>22391558</reference-id><title>Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.</title><authors>Yang H, Liu Y, Bai F, Zhang J, Ma S, Liu J, Xu Z, Zhu H, Ling Z, Ye D, Guan K, Xiong Y</authors><journal>Oncogene</journal><issue>5</issue><year>2013</year><page>663-9</page></reference><reference><reference-id>25242579</reference-id><title>Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.</title><authors>Yi S, Wen L, He J, Wang Y, Zhao F, Zhao J, Zhao Z, Cui G, Chen Y</authors><journal>Annals of hematology</journal><issue>2</issue><year>2015</year><page>201-10</page></reference><reference><reference-id>16205118</reference-id><title>Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein.</title><authors>den Besten W, Kuo M, Williams R, Sherr C</authors><journal>Cell cycle (Georgetown, Tex.)</journal><issue>11</issue><year>2005</year><page>1593-8</page></reference><reference><reference-id>19318574</reference-id><title>FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.</title><authors>von Bubnoff N, Engh R, Aberg E, Sänger J, Peschel C, Duyster J</authors><journal>Cancer research</journal><issue>7</issue><year>2009</year><page>3032-41</page></reference><reference><reference-id>NCCNGuidelines</reference-id><title>NCCN Guidelines® are referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.1.2016, Breast Cancer V.1.2016, Central Nervous System Cancers V.1.2015, Gastric Cancer V.3.2015, Non-Small Cell Lung Cancer V.4.2016, Colon Cancer V.2.2016, Rectal Cancer V.1.2016, Melanoma V.2.2016, Neuroendocrine Tumors V.1.2015, Ovarian Cancer V.2.2015, Pancreatic Adenocarcinoma V.1.2016, Prostate Cancer V.2.2016, and Uterine Neoplasms V.2.2016. © 2016 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org</title><authors>NCCN</authors></reference></references><patient patient-id="AMP"><age>27</age><gender>male</gender><state-province>California</state-province><country-code>US</country-code></patient></report>